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Summary 
 
Recent studies into the molecular, pharmacological and behavioral basis of psychotomimetics such as 
the glutamate N-methyl- D -aspartate receptor (NMDAR) antagonist ketamine and the mixed 5- 
hydroxytryptamine (5-HT) receptor agonist psilocybin in healthy human subjects suggest that both the 
glutamatergic and serotonergic system are implicated in the pathophysiolology of psychotic disorders 
such as schizophrenia. Specifically, administration of ketamine to healthy humans reproduces positive 
and negative symptoms as well as cognitive impairments that are seen in acute and chronic 
schizophrenia, while the mixed 5-HT2A/1A receptor agonist psilocybin engenders positive symptoms 
and cognitive deficits that resemble the symptoms seen in incipient or acute phases of schizophrenia. 
Moreover, the observation that both ketamine and psilocybin also disrupt sensory gating (e.g. PPI, 
P50) in healthy subjects comparable to that seen in schizophrenia has led to the widespread use of 
these drugs to provide models for identifying neurobiological factors that are crucial to the 
pathophysiology of schizophrenia and to the development of novel treatments. Along this line, it has 
repeatedly been demonstrated that schizophrenia patients also show a reduced mismatch-negativity 
(MMN) event-related potential (ERP). The MMN is interpreted as a prediction error signal during 
implicit perceptual learning. The processing of prediction errors is of considerable importance in 
regard to psychosis, because recent theories posit that aberrant encoding of prediction errors may 
underlie the expression of psychotic symptoms. Furthermore, the MMN (i.e. prediction error 
processing) depends critically on NMDAR-dependent synaptic plasticity. In fact ketamine disrupts 
MMN responses in healthy humans comparable to those observed in schizophrenia. Given that 
neuromodulatory transmitters like 5-HT are thought to be implicated in the regulation of NMDAR-
dependent synaptic plasticity during prediction error processing, it is conceivable that psilocybin may 
also, though via a differential mechanism, affect the MMN expression in humans. 
Based on this background, we investigated in the present thesis (chapter 2) whether the encoding of 
prediction error (via the assessment of the MMN expression) is affected by S-ketamine or psilocybin 
and whether the encoding of prediction errors under placebo can be used to predict drug-induced 
symptoms. In brief, we found that S-ketamine, but not psilocybin, disrupted the processing of 
prediction errors as expressed by a disrupted MMN expression over fronto-central brain regions. 
Although both drugs produced positive-like symptoms, we found that only S-ketamine produced 
severe cognitive impairments, the extent of which significantly correlated with the processing of 
prediction errors under placebo. Our results suggest that the NMDAR, but not the 5-HT receptor 
system, is critically implicated in the processing of prediction errors during MMN generation as a form 
of implicit perceptual learning and that aberrant prediction error signaling contributes to the formation 
of cognitive impairment in this pharmacological model. Our results provide further insights into the 
pathophysiology of key cognitive symptoms of psychotic disorders and suggest that the assessment of 
the MMN expression in schizophrenia may allow detecting early phases of the illness and might also 
serve to assess the efficacy of novel pharmacological treatments, in particular of cognitive 
impairments. Moreover, in chapter 3 of this thesis we used a computational model-based approach to 
examine whether the known NMDAR-mediated reduction of MMN expression can explain the changes 
in the plasticity of glutamatergic long-range connections among hierarchically related auditory areas. 
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In other words, we have conducted a quantitative connectivity analysis to determine the coupling 
parameters, which significantly distinguished between placebo and S-ketamine conditions and also 
predicted changes in psychotic symptoms following S-ketamine administration. Summarized, 
quantitative connectivity analysis using dynamic causal modeling (DCM) revealed a significant 
reduction in bottom-up effective connectivity following S-ketamine administration. Moreover, this 
model-based estimate of ketamine effects on synaptic plasticity correlates significantly with subjects’ 
introspective ratings of ketamine-induced impairments in cognition and control. Our findings suggest a 
concrete mechanism for ketamine effects on MMN expression that correlates with drug-induced 
psychopathology and demonstrate the potential of model-based approaches for inferring synaptic 
mechanisms of brain responses, and their pharmacological modulation, from non-invasive EEG data. 
 
Apart from the experimental use of psychotomimetic compounds to model psychosis, previous work in 
the sixties and more recent studies into the clinical effects of psilocybin and ketamine showed that 
both compounds reveal mood enhancing properties and an antidepressant potential. Specifically, 
recent studies reported that acute ketamine administration ameliorates depressive symptoms in 
treatment- resistant depression within a few hours persisting for several days, while acute psilocybin 
was reported to enhance mood and reduce anxiety in terminal cancer patients. Imaging studies of 
ketamine and psilocybin in healthy subjects suggest that both drugs may modulate emotional 
processing by targeting a prefrontal-limbic-occipital network in a similar way. However, the neuronal 
basis of the effect of psilocybin and ketamine on emotional processing has not yet been investigated 
in an operationalized manner. To investigate further the neuronal underpinnings of the effect of 
psilocybin and S-ketamine on emotional processing, in chapter 4 of this thesis we examined for the 
first time whether psilocybin and S-ketamine affect visually evoked ERP responses (i.e. P100 and 
N170 ERP) to facial expressions in a valence specific manner, and second whether these effects vary 
as a function of visual awareness. Notably, emotional face processing is fundamental to social 
interaction and behavior and its critical importance in human social functioning is shown by the fact 
that emotional faces increase neuronal activity relative to neutral faces in visual face-selective areas of 
the brain, even in the absence of conscious awareness. Thus, modulation of face-selective responses 
in the visual cortex by emotional expression might correspond to a fundamental regulatory role of 
basic emotional signals associated with social appraisal and cognition. Our results revealed that the 
effects of psilocybin and S-ketamine on the early visual N170 ERP depended on the extent of visual 
awareness. Furthermore, both psilocybin and S-ketamine reduced early visual N170 ERP response to 
fearful faces, whereas S-ketamine, but not psilocybin, also reduced the N170 ERP response to happy 
faces. Our findings suggest that psilocybin and S-ketamine differentially contribute to the modulation 
of visual responses to emotional facial expressions. The present study shall provide a better 
understanding of the mood enhancing properties of psilocybin and ketamine and shall also allow us to 
lay the ground for further investigations on the clinical potential of ketamine and psilocybin to treat 
symptoms of affective disorders. Along this line, the assessment of early visual responses to 
emotional expressions may provide a useful framework to detect pharmacologically induced changes 
in emotional processing and might also lead to a greater understanding of pharmacological 
mechanisms underlying emotional processing and its dysfunction in affective disorders.	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Zusammenfassung 
 
In den vergangen Jahren haben molekulare, pharmakologische und verhaltensbezogene Studien zu 
den Grundlagen von psychotomimetischen Substanzen bei gesunden Probanden – wie der N-Methyl-
D-Aspartat Rezeptor (NMDAR) Antagonisten Ketamin oder der gemischte 5-Hydroxytryptamin (5-HT) 
Rezeptor Agonist Psilocybin – darauf hingewiesen, dass sowohl das glutamaterge als auch das 
serotonerge System zur Manifestation schizophrener Psychosen beitragen. Genauer gesagt führt die 
Verabreichung von Ketamin bei gesunden Probanden vorübergehend zu Positivsymptomen (z.B. 
Wahn), Negativsymptomen (z.B. Affektverflachung) und kognitiven Störungen, wie sie in der akuten 
und chronischen Schizophrenie zu beobachten sind. Die Verabreichung von Psilocybin hingegen führt 
bei Gesunden vor allem zu Positivsymptomen und kognitiven Störungen, die entsprechend und häufig 
in frühen Phasen der Schizophrenie auftreten. Weiter konnte gezeigt werden, dass Ketamin und 
Psilocybin zudem die sensorische Filterleistung des Gehirns bei gesunden Probanden reduziert (z.B 
PPI und P50), was vergleichbar mit dem Defizit bei schizophrenen Patienten ist. Diese Erkenntnis hat 
zu einer zunehmenden experimentellen Anwendung von psychotomimetischen Substanzen geführt 
(Modellpsychosen), welche dazu dienen, neurobiologische Korrelate (Grundlagen) schizophrener 
Psychosen aufzudecken. Des Weiteren konnten zahlreiche Untersuchungen zeigen, dass 
schizophrene Patienten auch ein Defizit in der Ausprägung des Ereignis-korrelierten Potentials (EKP) 
der „mismatch negativity“ (MMN) aufweisen. Die MMN ist eine negative EKP Komponente, welche 
implizit während perzeptuellen Lernprozessen aufgebaut wird und als „prediction error“ (PE) Signal 
verstanden werden kann. Die einwandfreie Generierung und Verarbeitung des PEs ist hinsichtlich 
psychotischer Episoden von entscheidender Bedeutung, da theoretische Modelle eine fehlerhafte 
Verarbeitung des PEs als einen möglichen Mechanismus für die Entstehung psychotischer Symptome 
postulieren. Des Weiteren wissen wir, dass die MMN Expression (d.h. die Verarbeitung des PEs) von 
einer NMDAR abhängigen synaptischen Plastizität vermittelt wird. Diesbezüglich ist von Bedeutung, 
dass Ketamin bei Gesunden die MMN Expression signifikant reduziert, ähnlich wie es bei 
schizophrenen Patienten zu sehen ist. Da angenommen wird, dass modulierende Neurotransmitter 
wie 5-HT zudem die NMDAR vermittelte Plastizität während der Verarbeitung des PEs regulieren, ist 
es denkbar, dass Psilocybin über einen differenzierten Mechanismus die Expression der MMN 
beeinflussen könnte. 
 
Basierend auf diesem Hintergrund haben wir im Kapitel 2 dieser Arbeit untersucht, wie die 
Verarbeitung von PEs (via der Erfassung der MMN Expression) durch die Verabreichung von S-
Ketamin und Psiloybin beeinflusst wird. Zudem untersuchten wir, ob die Verarbeitung von PEs unter 
Placebo, d.h. ohne Substanzeinfluss, prädiktiv für gewisse Substanz induzierte Symptome ist. Unsere 
Resultate zeigen, dass beide Modellsubstanzen vorübergehend moderate psychotische Symptome 
auslösen, jedoch nur S-Ketamin ausgeprägte kognitive Defizite induziert. Des Weiteren führt die 
Hemmung der NMDAR – nicht aber die Aktivierung von 5-HT Rezeptoren – zu einer Reduktion der 
MMN Expression, was auf eine beeinträchtigte PE Verarbeitung hinweist. Interessanterweise zeigte 
sich, dass die MMN Expression unter Placebo prädiktiv und selektiv für das Ausmass der S-Ketamin-
induzierten kognitiven Symptome ist. Unsere Ergebnisse weisen darauf hin, dass der glutamaterge 
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NMDA Rezeptor bei der Verarbeitung von PEs eine zentrale Stellung einnimmt und die Erfassung der 
MMN Expression einen wichtigen Beitrag zur Aufdeckung der Pathophysiologie kognitiver Störungen 
der Schizophrenie leisten kann. Dementsprechend könnte die Untersuchung der MMN Expression als 
Biomarker zur Früherkennung psychotischer Erkrankungen dienen und eine vielversprechende 
Grundlage zur Beurteilung neuer pharmakologischer Ansätze bei der Behandlung kognitiver 
Störungen schaffen. 
Im Kapitel 3 haben wir zudem einen computergestützten Modellierungsansatz verwendet, um zu 
prüfen, ob die gefundene NMDAR induzierte Reduktion der MMN Expression durch Veränderungen 
der effektiven Konnektivität innerhalb hierarchisch verbundenen auditiven Arealen erklärt werden 
kann. Das heisst, wir haben eine quantitative Konnektivitätsanalyse durchgeführt, um diejenigen 
Kopplungsparameter zu bestimmen, welche sich signifikant zwischen der Placebo- und der S-
Ketamin-Bedingung unterscheiden und zudem prädiktiv für die Veränderungen von S-Ketamin 
induzierten Symptomen sind. Die Konnektivitätsanalyse ergab eine signifikante Reduktion der 
„bottom-up“ Konnektivität infolge der S-Ketamin Verabreichung. Weiter konnte gezeigt werden, dass 
die reduzierte „bottom-up“ Konnektivität signifikant die S-Ketamin induzierten kognitiven Defizite 
vorhersagt. Unsere Resultate suggerieren einen konkreten Mechanismus für die NMDAR induzierte 
Reduktion der MMN Expression, welcher mit der Psychopathologie unter Substanzeinfluss korreliert. 
Im Generellen weist diese Studie auf das Potential Model basierter Ansätze hin, um aus nicht-
invasiven EEG-Daten den Beitrag der synaptischen Plastizität zur Generierung verschiedener 
Hirnaktivitäten zu quantifizieren. 
 
Neben der experimentellen Verwendung psychotomimetischer Substanzen als pharmakalogische 
Modellpsychosen haben Studien in den 60ziger Jahren und neuere klinische Arbeiten gezeigt, dass 
Psilocybin und Ketamin stimmungsaufhellende und antidepressive Eigenschaften aufweisen. Genauer 
gesagt konnte gezeigt werden, dass Ketamin bei ansonsten therapieresistenten depressiven 
Patienten die Symptome innert Stunden verbessern kann, während Psilocybin bei Krebspatienten im 
Endstadium zu einer Stimmungsaufhellung führt und die Angst reduziert. Einige bildgebende Studien 
lassen vermuten, dass Ketamin und Psilocybin die Verarbeitung von emotionalen Reizen 
beeinflussen, indem sie die Informationsverarbeitung zwischen präfrontalen, limbischen und visuellen 
Hirnstrukturen modulieren. Allerdings ist die neuronale Grundlage der Ketamin- und Psilocybin-
Wirkung auf die emotionale Informationsverarbeitung bislang noch nicht operationalisiert untersucht 
worden. 
Zur weiteren Aufklärung der neuronalen Grundlagen der Ketamin und Psilocybin Wirkung auf die 
emotionale Reizverarbeitung haben wir im Kapitel 4 dieser Arbeit untersucht, ob S-Ketamin und 
Psilocybin die visuell evozierten Ereignis-korrelierten Potentiale (EKP) P100 und N170 beeinflussen, 
wenn den Probanden unbewusst und bewusst emotionale Gesichter präsentiert wurden. Dabei 
scheint das Erkennen und die Verarbeitung von emotionalen Gesichtern nicht nur bei Gesunden für 
eine (optimale) soziale Interaktion von grundlegender Bedeutung zu sein, sondern dürfte auch, wie 
klinische Befunde vermuten lassen, in der Pathophysiologie der Depression eine wichtige Rolle 
spielen. Diese Ansicht wiederspielgelt sich auch in der Tatsache, dass emotionale Gesichter im 
Vergleich zu neutralen Gesichtern bei Gesunden im visuellen Kortex eine verstärkte neuronale 
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Aktivität hervorrufen. Dies ist auch zu beobachten, wenn die Gesichter unbewusst präsentiert und 
verarbeitet werden. Dementsprechend kann die Modulation visueller Aktivität durch emotionale 
Ausdrücke als eine grundlegende Regulation elementarer emotionaler Signale verstanden werden, 
welche in enger Verbindung mit unserer sozialen Kognition steht. Interessanterweise zeigen einige 
klinische Studien, dass depressive Patienten im Vergleich zu Gesunden vermehrt auf negative 
emotionale Reize fokussieren und auch verstärkt auf solche reagieren. Die Ergebnisse unserer Studie 
zeigen , dass beide Psilocybin und S-Ketamin die Reaktion auf emotionale visuelle Reize reduzieren, 
was sich in einer Abnahme der frühen visuellen N170 EKP ausdrückt, und dass diese Abnahme 
davon abhängt, ob das Gesicht unbewusst oder bewusst präsentiert wird. Desweitern hat unsere 
Auswertung ergeben, dass beide Substanzen das durch ängstliche Gesichter ausgelöste N170 EKP 
vergleichbar reduzieren. Hingegen scheint S-Ketamin, nicht aber Psilocybin, auch das durch 
glückliche Gesichter ausgelöste N170 EKP signifikant abzuschwächen. Unsere Resultate zeigen, dass 
die Aktivierung serotonerger Rezeptoren (5-HT2A/1A) und die Hemmung glutamaterger NMDA 
Rezeptoren durch Psilocybin respektive S-Ketamin zu einer differentiellen Modulation der frühen 
emotionalen Gesichtsverarbeitung im visuellen Cortex führen. In Anbetracht dessen, dass depressive 
Patienten einen negativen emotionalen Bias zeigen, weist diese Studie auf das Potential von 
Psilocybin und Ketamin hin, um solchen negativen emotionalen Verarbeitungsneigungen 
entgegenzuwirken und im Falle von Psilocybin zudem die Verarbeitung von positiven Reizen nicht 
beeinträchtigt. In diesem Sinne kann die Erfassung von frühen visuell evozierten Potentialen eine 
physiologische Grundlage bietet, um pharmakologisch induzierte Veränderungen der emotionalen 
Verarbeitung zu erkennen und möglicherweise auch zu einem besseren Verständnis der 
pharmakologischen Mechanismen führt, welche der emotionalen Verarbeitung und deren 
Pathophysiologie unterliegen. Schlussendlich ermöglicht uns diese Studie eine Grundlage, um das 
klinische Potential beider Substanzen zur Behandlung affektiver Störungen weiter zu untersuchen. 
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1. General Introduction 
 
Both the serotonergic (5-hydroxytryptamine, 5-HT) and glutamatergic (Glu) system have been 
implicated in the pathophysiology of different psychiatric disorders such as schizophrenia spectrum 
disorders, autism, addictive and obsessive compulsive disorders (OCD) as well as affective disorders 
(Elliott et al., 2011; Fontenelle et al., 2011; González-Maeso and Sealfon, 2009; McDougle et al., 
2005; Ross and Peselow, 2009; Sanacora et al., 2008). Despite the large public health impact of 
schizophrenia (Casey et al., 2011; Saha et al., 2007) and depression (Andrade et al., 2003; Insel and 
Charney, 2003; Kessler et al., 2003), the specific contributions of 5-HT and glu to pathophysiological 
processes underlying both diseases remain poorly understood. Consequently, pharmacological 
treatments of depression and schizophrenia are often unsatisfactory and leave much to be desired. 
The majority of pharmacological treatments of depression contain the administration of selective 
serotonin re-uptake inhibitors (SSRI), however, response rates for these treatments are only modest 
and the participants who respond show an antidepressant effect not until eight weeks after the initial 
administration (Rush et al., 2006; Trivedi et al., 2006). Similarly, pharmacological treatments including 
the administration of antipsychotic drugs have been widely used for nearly half a century to treat 
schizophrenia, but there is little evidence that these treatments have substantially improved outcomes 
for most people with schizophrenia (Insel, 2010) and a precise relationship between the 
pharmacological mechanism of action and specific symptom formation has not been established. 
 
The experimental research on psychedelic compounds might offer a suitable framework to gain more 
insights into the pathophysiology mechanisms underlying both diseases. Under this perspective, 
research on the pharmacological profile of serotonergic and glutamatergic psychedelics crucially 
contributed to several chemical hypotheses of schizophrenia. In particular, defining findings for these 
pharmacological models of schizophrenia were the discoveries of the psychosis-like symptoms 
induced by lysergic acid diethylamide (LSD), which predominantly activates 5-HT2A receptors (5-
HT2AR) and by phencyclidine (PCP), a non-competitive N-methyl-D-aspartate receptor (NMDAR) 
antagonist (Geyer and Vollenweider, 2008; Javitt, 2010). Thus, NMDAR antagonists and 5-HT2AR 
agonists constitute two classes of pharmacological models of psychosis that are used to study the 
neurobiology of psychotic symptom formation in schizophrenia. 
Aside the established application of NMDAR antagonists and 5-HT2AR agonists to model psychoses, 
research also carried out the use of psychotomimetics compounds as medical agents to treat mood 
and anxiety disorders (Vollenweider and Kometer, 2010). For example, studies in the late 1960s have 
been reported that NMDAR antagonists and 5-HT2AR agonists provoke therapeutic effects in patients 
with anxiety and obsessive-compulsive disorders (OCD), depression and with terminal cancer (Geert-
Jörgensen, 1968; Khorramzadeh and Lotfy, 1973; Pahnke et al., 1969). Recent evidence confirmed 
these findings by showing that the NMDAR antagonist ketamine produces rapid antidepressant effects 
in treatment-resistant depression (Diazgranados et al., 2010; Zarate et al., 2006), while the mixed 5-
HT receptor agonist psilocybin enhances mood and decreases anxiety in terminal cancer patients 
within a month (Grob et al. 2011). Figure 1 shows a rough temporal overview of psychedelic research. 
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Figure 1 Benchmark data in psychedelic research referring to glutamatergic and serotonergic agents. 
Abbreviations: LSD: lysergic acid diethylamide; NMDA: N-methyl-D-aspartate; PCP: phencyclidine. 
Discoveries relating to classical hallucinogens and to dissociative anaesthetics are shown by black 
and red boxes, respectively. Adapted from Vollenweider and Kometer (2010). 
 
Broadly speaking, exploring the effects of NMDAR antagonists and 5-HT2AR agonists offer two 
perspectives in psychiatric research; on the one hand to produce psychosis-like symptoms in healthy 
volunteers, i.e. to model psychosis, and on the other hand to study further the role of serotonin and 
glutamate in emotional processing. In this thesis, I aim to outline two different frameworks i) to 
investigate further the neurophysiological mechanisms of psychotic symptom formation in these two 
pharmacological models of psychosis, which may be relevant for detecting early phases of the illness 
and might also serve as biomarker to assess the efficacy of novel pharmacological treatments, and ii) 
to investigate further the effect of psilocybin and ketamine on emotional processing and to identify its 
underlying neurophysiological basis, which may lead to the detection of pharmacologically induced 
changes in emotional processing and might also help to better understand the pharmacological 
mechanisms underlying emotional processing and its dysfunction in affective disorders. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1  André Schmidt 2012 
8 
1.1. The Role of Glutamate and Serotonin in Models of Psychosis and 
Schizophrenia 
 
Recent research on schizophrenia has largely focused on neurobiological components of the disorder 
(Funk et al., 2011; Heckers, 2011; Smieskova et al., 2010). Although a huge amount of biological 
evidence could be found, schizophrenia lacks still robust relationships between neuronal correlates 
and psychopathological symptoms to specifically target pharmacological interventions. 
Several pharmacological hypothesis and models of schizophrenia are inspired by the remarkable 
concordance of research on psychotomimetic compounds and their pharmacological profiles such as 
NMDAR antagonists and 5-HT2AR agonists. Moreover, research on certain psychedelics has also 
contributed partly to the development of antipsychotic drugs. For example, the potential of ritanserin as 
an atypical antipsychotic has been revealed, inter alia, by its ability to block the LSD activity at 5-
HT2ARs (Colpaert, 2003). Thus, understanding the pharmacological mechanisms of psychedelics and 
their contributions to the formation of psychotic symptoms provides important insight about the base 
for psychosis and might further facilitate the development of better pharmacological therapies for 
schizophrenia (González-Maeso and Sealfon, 2009). In more detail, NMDAR antagonists such as 
ketamine and classical hallucinogens like psilocybin, which predominantly activate 5-HT2AR, constitute 
two pharmacological models of psychosis that are used to study the neurobiology of psychotic 
symptom formation in schizophrenia because they induce symptoms in healthy humans subjects that 
are highly reminiscent of those observed in schizophrenia (Geyer and Vollenweider, 2008; Javitt and 
Zukin, 1991; Kornhuber, 1990; Corlett et al., 2011). Table 1 depicts an overview of symptoms induced 
by NMDAR antagonists and 5-HT2AR agonists in accordance with the symptomatology of 
schizophrenia. Although administration of ketamine to healthy humans reproduces positive and 
negative symptoms of schizophrenia including depersonalization phenomena (ego-disturbances and 
passivity phenomena), affective blunting and different aspects of disordered thoughts and cognition 
(Adler et al., 1999; Gouzoulis-Mayfrank et al., 2005; Krystal et al., 1994; Malhotra et al., 1996; 
Vollenweider et al., 1997a), psilocybin elicits more positive symptoms comparable to those in 
schizophrenia like profound changes in mood states, thought, intuition and experience of self (Geyer 
and Vollenweider, 2008; Gouzoulis-Mayfrank et al., 1998). During such states, perceptual 
hypersensitivity, illusion and visual hallucinations are common. 
Despite this specific dissociation in symptoms induced by NMDAR antagonists and 5-HT2AR agonists, 
they also share some common symptoms including positive symptoms. Both classes of drugs increase 
extracellular glutamate in PFC (Moghaddam et al, 1997; Muschamp et al, 2004), which may explain 
some of the common psychotic symptoms. However, while the pharmacological properties of these 
psychotomimetic compounts are well documented (Fantegrossi et al, 2008; Nichols, 2004), the 
neuronal and cognitive mechanisms underlying ketamine- and psilocybin-induced symptoms are less 
well understood. Based on theoretical concepts (Corlett et al., 2011; Friston, 2005a; Stephan et al., 
2006; Stephan et al., 2009), in the following I outline a conceivable approach to study ketamine- and 
psilocybin-induced symptoms by embedding the drug-induced psychosis-like symptoms in a cognitive 
model referring to learning and inference. 
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Table 1 Comparison of effects of serotonergic hallucinogens (psilocybin), NMDAR antagonists 
(ketamine), and symptoms in schizophrenia. 
 
 
 
Abbreviations: 5-HT: 5-hydroxytryptamine; NMDA: N-methyl-D-aspartate; DA: dopamine; GABA: 
gamma-Aminobutyric acid. Adapted from Vollenweider et al. (2001). 
 
According to associative learning theories, it has repeatedly been proposed that both natural and 
drug-induced psychosis can be explained by the concept of predictive coding (Corlett et al., 2009; 
Corlett et al., 2011; Fletcher and Frith, 2009; Gray et al., 1991; Hemsley, 1993). This concept refers to 
predictive coding models of learning and inference, which rest on empirical Bayes (Friston, 2005a). In 
that article, the author provides a model how cortical responses can be understood as expressions of 
prediction errors (PE), which indexes learning and inference processes in the brain. Within this general 
framework, the brain’s architecture is hierarchically organized, so that the formed PE in lower-level 
systems passes forward to higher-level systems. Simultaneously, the lower-level systems receive 
feedbacks from higher-level systems to predict further sensory input. In other words, each neuronal 
system within the task-related hierarchy receives bottom-up input about the state of the level below 
and top-down predictions from the level above. A PE emerges when the actual input does not match 
with the prediction about it, i.e. when the existing model has not fully accounted for the input (Fletcher 
and Frith, 2009). PE represents an alert system, which suggests that the current model is wrong. 
During learning and inference, predictions and PE are adjusted in order to minimize PE at all levels of 
the hierarchy. This assumes updates of our internal models of the environment so that potentially 
surprising events can be predicted. Such a scheme has been used to explain the genesis of evoked 
brain responses like early visual cortical responses (Murray et al., 2002; Rao and Ballard, 1999) and 
auditory mismatch responses (Baldeweg, 2006; Baldeweg et al., 2004; Garrido et al., 2009a). 
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Therefore, PE constitutes a driving force for learning, because they signal the need for learning in 
order to update predictions (Schultz et al., 1997). Defining for this thesis, it has been posited that the 
Bayesian passing scheme of PE processing is aberrant in schizophrenia patients (Fletcher and Frith, 
2009; Stephan et al., 2006; Stephan et al., 2009), and specifically leads to the formation of positive 
symptoms such as delusions or hallucinations (Fletcher and Frith 2009). Recent studies began to 
elucidate the precise location of PE signals in the brain associated with positive symptom formation in 
drug-induced and naturally occuring psychosis. In a first work, Corlett and colleagues (2006) 
demonstrated that low-dose of ketamine disrupted the PE-dependent learning activity in the right 
prefrontal cortex (rPFC). Notably, the activity in the rPFC to PE under placebo i.e. without any drug 
intake was positively correlated with ideas of references under ketamine (Figure 2A). Along this line, 
the same procedure was translated into a patient study. This study revealed, analogue to the ketamine 
study, that PFC responses in the patient group were suggestive of disrupted PE processing, and that 
the extent of PE disruption was significantly related to an individual’s propensity to delusion formation 
(Corlett et al., 2007) (Figure 2B). Shortly speaking, NMDAR-mediated aberrant PE processing in the 
PFC may reflect a mechanism for the emergence of psychotic symptoms in schizophrenia in general 
and in particular of positive symptoms. 
 
 
 
Figure 2 A) The left panel shows brain regions in which the level of error-dependent response 
predicted the score for simple ideas of reference under ketamine. The right panel shows a plot of this 
relationship, with rPFC activity summarized as a box plot for each of the ratings on the Present State 
Examination. Adapted from Corlett et al. (2006). B) Relating brain response to prediction error with 
delusion formation in schizophrenia patients. The rendered image highlights a region of right lateral 
prefrontal cortex, the activity of which correlates across patients with their delusion severity at the time 
of scanning. Adapted from Corlett et al. (2007). 
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As already mentioned, predictions and PE are adjusted during learning and inference in order to 
minimize PE at all levels of the hierarchy. Critically, this adjustment is conveyed via synaptic 
connections (plasticity) among all levels of the neuronal hierarchy. In consequence, aberrant coupling 
or interactions within a task-related network could be due to impairments in synaptic transmission and 
plasticity, which is thought to be a key pathophysiological hallmark of schizophrenia (Friston, 1998; 
Stephan et al., 2006; Stephan et al., 2009). Recent studies examined the hypothesis of disconnection 
by investigating temporally coherent brain activity from functional magnetic resonance imaging (fMRI) 
data. In particular, they reported aberrant fronto-temporal connectivity in schizophrenia patients 
relative to healthy subjects (Allen et al., 2010; Diaconescu et al., 2011; Lawrie et al., 2002; Winder et 
al., 2007), what could be expressed at a cognitive level as a failure to integrate perception and action 
(Friston and Frith, 1995). This corresponds nicely with previous evidence showing that administration 
of both ketamine and psilocybin alters the fronto-temporal circuitry associated with depersonalization 
and thought disorder (Nagels et al., 2011a; Nagels et al., 2011b; Vollenweider et al., 1997a; 
Vollenweider et al., 1997b). Along this line, it is assumed that disrupted NMDAR-mediated synaptic 
plasticity due to abnormal regulation of NMDARs by neuromodulatory transmitters like 5-HT may 
underlie disordered brain connectivity, which leads to the manifestation of psychotic symptoms in 
schizophrenia patients (Stephan et al., 2006). Indirect support for NMDAR-mediated abnormal 
synaptic plasticity in schizophrenia is further provided by genetic studies. Specifically, it has been 
shown that six of the seven candidate genes for schizophrenia are intimately related to NMDAR-
dependent signaling (Harrison and Weinberger, 2005). However, the disconnection hypothesis of 
schizophrenia suggests that it is not NMDAR-mediated synaptic plasticity per se that is abnormal, but 
its modulation during reinforcement and perceptual learning, reflected in the inability to form new 
stimulus-stimulus associations, leading to a disruption of perceptual learning and inference (i.e., 
perceptual dysmetria) (Friston, 2005b). Put simply, psychotic symptom formation in schizophrenia may 
result from disrupted learning performances due to abnormal NMDAR-mediated synaptic plasticity 
within a task-related network, which is linked with the vulnerability to the formation of psychotic 
symptom. 
 
One of the most attractive paradigms for studying synaptic plasticity during implicit perceptual learning 
is the mismatch negativity (MMN) event-related potential (ERP) (Friston, 2005a; Garrido et al., 2009b; 
Todd and Robinson, 2010). The MMN is an electrophysiological event-related change (or regularity-
violation) detection to auditory stimuli (deviants) that differ in a physical stimulus dimension from a 
sequence of preceding identical standards (Näätänen et al., 1978). The maximum peak difference 
between the standard and the deviating tone occurs over temporal and frontal areas at approximately 
180 ms (Figure 3). The MMN is elicited in the absence of subject’s attention, providing a reliable 
paradigm in clinical populations. Indeed, the MMN is of particular interest in schizophrenia research, 
because deficits in the MMN amplitude have repeatedly been reported in schizophrenic patients 
(Umbricht and Krljes, 2005), making the MMN to one of the most strongly replicated biomarker of 
cognitive dysfunction in schizophrenia (Javitt et al., 2008). Moreover, the MMN appears to detect the 
transition of ‘ultra-high risk’ to first-episode psychosis (Atkinson et al., 2011; Bodatsch et al., 2010; 
Orosz et al., 2011; Shin et al., 2009), suggesting the potential of the MMN in predicting psychosis risk. 
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Figure 3 A) Significant effects between the standard and the deviating tone were found over temporal 
and frontal areas in the time range of 110 to 200 ms, peaking at 180 ms. B) Grand mean (averaged 
over all subjects) ERP responses to the sixth tone presentation, the established “standard” (t6 in black) 
and deviant tone (t1 in gray) at fronto-central electrodes where the MMN response peaks at about 180 
ms from change onset. Adapted from Garrido et al. (2008). 
 
The neuronal mechanism underlying the MMN generation is controversially discussed. In accordance 
with classical theories (Näätänen, 1992), the MMN potential arises whenever there is a break of 
regularity in a structured auditory sequence, generated by a fronto-temporal network comparing the 
actual sensory input with the already established memory trace of preceding standard stimuli (Doeller 
et al., 2003; Opitz et al., 2002; Rinne et al., 2000). This is the so-called model-adjustment hypothesis 
(Winkler et al., 1996). However, this notion has been challenged previously by proposing that the 
MMN emerges exclusively from local neuronal adaptation in the auditory cortex (Jääskeläinen et al., 
2004), the so-called adaptation hypothesis. A more recent study used Dynamic Causal Modeling 
(DCM) to estimate plausible connectivity graphs underlying the MMN and suggests that the model 
explaining the MMN amplitude best was a model that accommodates intra-areal (local) adaptation 
within the primary auditory cortex combined with plasticity of inter-areal connections between temporal 
and frontal regions (Garrido et al., 2008). The authors explicitly interpreted their findings within the 
predictive coding framework, emphasizing that this theory includes both adaptation and model 
adjustment in the sense that “model adjustment” corresponds to the adjustment of a generative model 
for future stimuli and “adaptation” corresponds to local changes in post-synaptic gain (Garrido et al., 
2008). Furthermore, there is strong evidence that the MMN depends critically on synaptic plasticity 
(Baldeweg, 2006; Stephan et al., 2006). In particular, schizophrenia patients show impairments at 
frontal but not temporal components of the MMN (Baldeweg et al., 2002; Sato et al., 2003), which may 
reflect aberrant coupling between temporal and frontal areas. Consistent with the results in 
schizophrenia patients, studies using ketamine also reported reduced frontal but not temporal MMN 
amplitudes (Heekeren et al., 2008; Umbricht et al., 2000) (Figure 4). Hence, the MMN is a promising 
paradigm to study PE processing during implicit perceptual learning within a bidirectional connected 
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hierarchical architecture, which coupling may rest on NMDA-dependent synaptic plasticity and its 
regulation by modulatory transmitters like 5-HT(Friston, 2005a). 
 
 
 
Figure 4 Effects of ketamine on the MMN (difference wave: deviant - standard) in the pitch A) and 
duration B) deviance condition. The gray lines represent the MMN wave before ketamine 
administration; the black line, the MMN wave under ketamine; and the dark area, the difference 
between the 2 curves (ie, the reduction of MMN during ketamine administration). Adapted from 
Umbricht et al. (2000). 
 
Given the above, in chapter 2 of this thesis we challenged subjects with a psychological task (MMN), 
which engages a specific cognitive process (implicit perceptual learning). We further indexed this 
cognitive process with a physiological brain marker, and finally relate the individual baseline marker to 
the subjective variability in pathophysiological experiences they had (psychotic symptoms). Such a 
principle is suitable to test hypotheses about the cognitive and neural bases of specific symptoms 
(Brown, 2011; Corlett et al., 2011; Honey et al., 2008). In particular, we investigated (i) whether the 
MMN encoding of PE is affected by the NMDAR antagonist S-ketamine and the preferential 5-HT2AR 
agonist psilocybin using a roving MMN paradigm and (ii) whether the encoding of PE under placebo 
can be used to predict specific drug-induced symptoms. Based on the functional anatomy underlying 
the MMN generation (Garrido et al., 2008), in chapter 3 we provide a model-based approach (DCM) to 
understand the obtained results of chapter 2 by investigating effective connectivity within the network 
underlying the MMN generation. DCM is an established technique to estimate how ERPs (e.g. MMN) 
result as an output of causal dynamics between coupled neural systems (e.g. temporal and frontal 
MMN sources) and how these cortico-cortical connections are modulated by experimental 
manipulations (Friston et al., 2003). This means that opposed to functional connectivity, DCM uses the 
concept of effective connectivity, which describes the influence one neural system exerts over another 
(Friston, 1994). DCM uses a biologically informed causal model to make inferences about the 
underlying neural mechanisms that generates the observed event-related responses. This approach 
provides an important advancement over conventional source reconstruction techniques of ERP data, 
because it places neurobiological constraints on the model inversion, in which the parameters of the 
reconstruction have a specific neuronal interpretation. The parameters thus encode the coupling 
among sources and how coupling depends upon stimulus attributes or experimental manipulations 
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(David et al., 2006; Kiebel et al., 2006). Therefore, DCM is a useful approach to study 
neuromodulation and synaptic plasticity (Stephan et al., 2010). 
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1.2. The Role of Glutamate and Serotonin in Emotional Processing 
 
The crucial role of 5-HT in emotional processing is evidenced by pharmacological and genetic studies 
(Elliott et al., 2011; Sharp and Cowen, 2011). It’s a long-standing theory that a breakdown in 5-HT 
transmission is strongly implicated in the pathophysiology of affective disorders such as depression 
(Sharp and Cowen, 2011). In consequence, compounds that inhibit the 5-HT re-uptake and thereby 
increasing 5-HT brain level have been used to treat depression for more than 40 years such as SSRIs 
(Harmer, 2008). Figure 6 shows the neurobiological and neuropsychological effect of increased 5-HT 
brain levels. SSRIs are certainly safe and relatively easy to use, but do not exhibit rapid effects 
(Skolnick et al., 2001). In more detail, almost one-third of patients with depression achieve remission 
after SSRI treatment using citalopram, and the participants who respond show an antidepressant 
effect not until 8 weeks after the first administration (Trivedi et al., 2006). This delay period of action 
may have devastating effects, because high rates of mortality and morbidity are present during this 
period (Machado-Vieira et al., 2008). 
 
 
 
Figure 6 Illustration of adaptive neurobiological and neuropsychological processes following several 
weeks of SSRI treatment. The induction of a positive emotional bias occurs after acute treatment and 
forms the basis for the gradual relearning of positive emotional associations. As indicated by the 
framed box, the increase in neural plasticity and formation of neural circuits occurs within emotional 
processing networks to allow positive emotional stimuli (e.g. social cues) to act and to be relearned 
and bring about improved mood. Adapted from Sharp and Cowen (2011). 
 
Previous research has also been focused on the application of psychedelics as therapeutic agent to 
treat affective disorders. In this view, recent data showed that psychedelics modulate neural circuits 
that have been implicated in mood and affective disorders, and can reduce the clinical symptoms 
of these disorders (Vollenweider and Kometer, 2010). For example, convincing evidence in the 
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1960s have already suggested a therapeutic benefit of classical hallucinogens such as LSD and 
psilocybin in the treatment of OCD (Brandrup and Vanggaard, 1977; Leonard and Rapoport, 1987; 
Moreno and Delgado, 1997) alcoholism (Kurland et al., 1967) and cluster headache (Sewell et al., 
2006), as well as to treat pain in terminal cancer patients (Pahnke et al., 1969). Motivated by these 
early findings in the sixties, previous works confirmed that psilocybin acutely reduced OCD symptoms 
in treatment-resistant patients (Moreno et al., 2006) and produced a gradual reduction of anxiety in 
advanced-stage cancer patients within a month (Grob et al., 2011). Furthermore and crucial for 
therapeutic agents, there were no clinically significant adverse events following psilocybin 
administration in patients. In healthy subjects, the effect of psilocybin at low to medium doses is 
characterized by distinct altered states of consciousness including changes in mood states (Geyer and 
Vollenweider, 2008). In particular, acute psilocybin administration in healthy subjects leads to 
heightened mood, increased emotional excitation and sensitivity (Studerus et al., 2010b). Importantly, 
administration of psilocybin to healthy, well-instructed volunteers in the context of a carefully monitored 
research environment provides acceptable level of risk (Studerus et al., 2010b). The molecular 
mechanism of psilocybin is not fully understood. Findings from animal studies proposed that psilocybin 
might produce his effects primarily through agonistic actions at cortical 5-HT2AR (Aghajanian and 
Marek, 1999; Aghajanian and Marek, 1997; González-Maeso and Sealfon, 2009). Furthermore, 
activation of 5-HT2AR by psilocybin leads to robust glutamate-dependent increase in the activity of 
pyramidal neurons, preferentially those in layer V of the prefrontal cortex (Béïque et al., 2007). It has 
been suggested that the psilocybin-induced glutamate release is triggered by stimulation of 
postsynaptic 5-HT2AR on a subpopulation of pyramidal cells in the deep layers of the PFC (Béïque et 
al., 2007; Puig et al., 2003). Figure 7 shows a rough overview of psilocybin’s mechanism of action. 
 
 
 
Figure 7 Activation of the prefrontal network and glutamate release by classical hallucinogens. The 
figure shows a model in which psilocybin, LSD and dimethyltryptamine (DMT) increase extracellular 
glutamate levels in the prefrontal cortex through stimulation of postsynaptic 5-HT2AR that are located 
on large glutamatergic pyramidal cells in deep cortical layers (v and vi) projecting to layer v pyramidal 
neurons. This glutamate release leads to an activation of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPAR) and NMDAR on cortical pyramidal neurons. In addition, 
hallucinogens directly activate 5-HT2AR located on cortical pyramidal neurons, might be leading to an 
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increased expression of brain-derived neurotrophic factor (BDNF). Adapted from Vollenweider and 
Kometer (2010). 
 
Aside the well established role of the 5-HT system in the pathophysiology of affective disorders (Elliott 
et al., 2011; Sharp and Cowen, 2011), more recent research these days focus on the glutamate 
system (Sanacora et al., 2008; Skolnick et al., 2009). According to animal data from the inescapable 
stress paradigm introduced by Shors and colleagues (1989), exposure to inescapable stress, which 
induces a syndrome of behavioral depression that is antagonized by clinically effective 
antidepressants (Desan et al., 1988; Shanks and Anisman, 1989), impaired the induction of NMDAR-
dependent long-term potentiation in the hippocampus. Based on these findings, it was first 
hypothesized that the NMDAR could be involved in modulating the behavioral deficits induced by 
inescapable stressors (Trullas and Skolnick, 1990). This hypothesis was explored by examining the 
effects of compounds that reduce transmission at NMDAR in different animal models of depression, 
i.e. by NMDAR antagonists (Papp and Moryl, 1993; Papp and Moryl, 1994a; Papp and Moryl, 1994b). 
Translated into human studies, increasing evidence revealed that the NMDAR antagonist ketamine 
has rapid antidepressant effects in depressed patients (Berman et al., 2000; Diazgranados et al., 
2010; Zarate et al., 2006), in contrast to the late occuring effect of SSRIs. Specifically, a single dose of 
ketamine in treatment-resistant patients with depression and bipolar depression resulted in a rapid 
(hours) and significant antidepressant effect, which sustained for about one week (Diazgranados et al., 
2010; Zarate et al., 2006). Importantly, subanesthetic doses of ketamine to humans is not associated 
with physical dependences (Britt and McCance-Katz, 2005), and an increased risk of more protracted 
psychosis in both healthy (Perry et al., 2007) and patients (Carpenter, 1999). The molecular 
mechanism underlying ketamine’s rapid antidepressant effect is focus of current research. It has been 
suggested that acute ketamine exposure blocks NMDAR and facilitates glutamate release by 
decreasing GABAergic inhibitory feedback in pyramidal cells (Homayoun and Moghaddam, 2007), 
what further translate into increased AMPAR throughput, which is probably determining for the 
subjective and rapid antidepressant effect of ketamine (Vollenweider and Kometer, 2010) (Figure 8). 
 
 
 
Figure 8 Activation of the prefrontal network and glutamate release by ketamine. The figure shows a 
model in which ketamine blocks inhibitory GABAergic interneurons in cortical and subcortical brain 
areas, leading to enhanced firing of glutamatergic projection neurons and increased extracellular 
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glutamate levels in the prefrontal cortex. As ketamine also blocks NMDAR on cortical pyramidal 
neurons, the increased glutamate release in the cortex is thought to stimulate cortical AMPA more 
than NMDA receptors. The increased AMPAR-mediated throughput relative to NMDAR-mediated 
throughput is thought ultimately to lead to increased expression of BDNF. Adapted from Vollenweider 
and Kometer (2010). 
 
More recent animal studies have extensively investigated the molecular action of ketamine and 
revealed exciting new findings (Autry et al., 2011; Li et al., 2010). Nevertheless, further studies are 
needed to precisely understand the exact molecular mechanism of ketamine’s rapid antidepressant 
action. Although the molecular mechanisms underlying psilocybin’s and ketamine’s actions are 
currently being investigated in animal studies, however, the acute effects of both drugs on emotional 
processing in humans are less well understood. In the following, I provide a concept how both drugs 
can be used to study acute serotonergic and glutamatergic effects on emotional processing and to 
further investigate the potential of both drugs to treat affective disorders. In particular, we were 
particularly interested in investigating how acute serotonergic and glutamatergic manipulations 
modulated emotional processing biases. Such an approach provides a useful framework to 
disentangle pharmacological mechanisms of emotional processing biases and its dysfunctions in 
affective disorders, as well as to assess the efficacy of novel therapeutic treatments to resist such 
dysfunctional emotional biases. 
 
Facial expressions are critical signals of affective states and tasks referring to the recognition of 
other’s people facial expressions provide a useful framework to study emotional processing biases 
both in healthy subjects and in relation to affective disorders. When we see a face, we confer and infer 
the state of mind of ourselves and of our peers to permit highly adaptive social behavior. The critical 
importance of face recognition in the human social functioning is shown by the fact that emotional 
faces can be processed without conscious awareness (Smith, 2011). Along this line, Ekman and 
Friesen (1971) already proposed that there are six basic emotional face expressions, which could be 
recognized among different cultures, namely happy, sad, fearful, angry, disgusted and surprised faces 
(Figure 6). 
 
 
Figure 6 Six basic facial expressions proposed by Ekman and Friesen (1971), which are constant 
across cultures. From left to right: Anger, fear, disgust, surprise, happiness, sadness. 
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Of clinical relevance, several affective disorders are accompanied by deficits in the recognition of other 
people’s emotion from their facial expression (dysfunctional emotional biases). In particular, facial 
processing biases towards the processing of negative and away from positive facial expressions are 
key impairments in depression (Beck, 2008; Surguladze et al., 2004). Notably, such dysfunctional 
facial processing biases actually occur not only from deficits in conscious recognizing of facial 
expressions (Joormann and Gotlib, 2006) but also from deficits during non-conscious emotion 
processing (Yang et al., 2011) 
 
The neuronal network underlying emotional face processing has been well studied in healthy 
volunteers and involves the same circuitry that has been implicated in fear and anxiety responses in 
humans (Shin and Liberzon, 2010). Generally, emotional faces increase neuronal activity in a 
distributed network including visual cortical, limbic and prefrontal regions, as well as regions of the 
reward circuitry, including the ventral striatum and the prefrontal cortex (Ishai, 2007; Ishai et al., 2005; 
Phan et al., 2002). In particular, increased brain responses to emotional relative to neutral faces have 
been observed within visual face-selective areas of the brain, even when emotional facial expressions 
are masked to prevent conscious awareness (Anderson et al., 2011; Demenescu et al., 2011; 
Kleinhans et al., 2011) (Figure 7). In this view, modulations of face-selective responses in the visual 
cortex by emotional expressions have been interpreted as fundamental regulation of basic emotional 
signals closely associated with social appraisal and cognition (Schultz et al., 2003; Singer et al., 2004). 
Face-selective regions in the visual cortex can thus be viewed as core components of the “social 
brain” (Schultz et al., 2003). However, while numerous studies are currently investigating the neuronal 
pathways of conscious and non-conscious emotional processing (Pessoa and Adolphs, 2010; 
Tamietto and de Gelder, 2010), it is less well understood how visual responses to emotional facial 
expressions are altered under specific pharmacological manipulations during conscious and non-
conscious processing. 
 
 
 
Figure 7 Main eﬀects of viewing photographs of faces (> scrambled faces) within controls and 
depressed patients. Main activations were in the fusiform gyrus and amygdala. Color bar indicates t 
value. Abbrivations: HC, healthy controls; MDD, major depression. Adapted from Demenescu et al. 
(2011). 
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Emotional face processing is modulated both by 5-HT (Elliott et al., 2011), and glutamate (Abel et al., 
2003). The 5-HT system is of considerable relevance because cortical regions affected by 5-HT 
manipulation overlap with those regions associated with emotional processing (Smith et al., 2002). For 
example, administration of the SSRI citalopram increases the recognition of happy and fearful faces in 
healthy volunteers (Browning et al., 2007; Harmer et al., 2003). Interestingly, imaging studies revealed 
that SSRI administration acutely increased fusiform gyrus (FG) activity to aversive stimuli in healthy 
volunteers (Del-Ben et al., 2005; McKie et al., 2005), what might partly mediate the increase in fear 
recognition after a single SSRI dose. Noteworthy, the FG represents an important visual face-selective 
area of the brain. Thus, acute SSRI administration affects the processing of social relevant cues by 
modulating visual responses in face-selective area of the brain. In addition, emotional processing can 
also be modulated by glutamate. Specifically, a previous fMRI study revealed that following ketamine 
administration, fearful faces no longer activate the amygdala and other limbic regions, and that FG 
activity in response to fearful faces is significantly reduced compared to placebo (Abel et al., 2003). All 
together, these data in healthy subjects indicate that acute serotonergic and glutamatergic 
manipulations change emotional processing as indexed by the assessment of visual cortex responses 
to emotional facial expressions. 
 
A suitable method to assess visual activity in response to emotional facial expressions even during 
non-conscious processing provides the recording of visual ERPs (Liddell et al., 2004; Pegna et al., 
2008; Smith, 2011; Williams et al., 2004). Two ERPs with selective responses to emotional relative to 
neutral faces are the P100 and N170 ERP (Fichtenholtz et al., 2009; Pegna et al., 2008; Smith, 2011) 
(Figure 8). 
 
 
 
Figure 8 A) Topography of the N170 ERP signal evoked by the presentation of the faces, averaged 
across all expressions, in each of the selected time windows for the 2 temporal delay conditions [8, 
132 ms]. B) N170 ERP responses to emotional vs. neutral faces over electrodes P8 during non-
conscious (8 ms) and conscious processing (132 ms). Bar charts indicate the averaged ERP for each 
expression. Adapted from Smith (2011). 
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The P100 ERP reflects rapid extraction of information related to emotion or salience that occurs before 
more fine-grained perceptual analyses are completed (Vuilleumier and Pourtois, 2007). Modulation of 
the P100 ERP has been shown with fearful (Fichtenholtz et al., 2009; Pourtois and Vuilleumier, 2006), 
angry (Santesso et al., 2008), and positive expressions (Batty and Taylor, 2003; Brosch et al., 2008). 
The later N170 ERP is associated with structural encoding of facial configurations (Itier and Taylor, 
2004) and is highly correlated with FG activity (Deffke et al., 2007; Sadeh et al., 2010). The N170 ERP 
is also increased for a broad spectrum of emotional facial expressions relative to neutral ones (Blau et 
al., 2007; Leppänen et al., 2007), even during conscious processing (Pegna et al., 2008; Smith, 2011). 
 
Given this background, in chapter 4 of this thesis we used emotional facial expressions to investigate 
further the neuronal underpinnings of the effect of psilocybin and S-ketamine on emotional processing 
using backward masking procedures. Backward masking is a key experimental paradigm for 
investigating sensory unawareness, because this method interferes with the activity in the ventral 
occipito-temporal cortex, an area, which is highly relevant for visual awareness (Macknik and 
Livingstone, 1998; Tamietto and de Gelder, 2010). The concept of backward masking supposes that 
the mask, which is present after the target face, interrupts the processing of the target face (Morris et 
al., 1996; Morris et al., 1998; Whalen et al., 1998). We first examined whether psilocybin and S-
ketamine affect early visual ERP responses to facial expressions in a valence specific manner, and 
second whether these effects vary as a function of visual awareness. Specifically, signal detection 
theory was applied to establish objective threshold for conscious awareness irrespective of subject’s 
response bias. Furthermore, early visually evoked ERP responses to fearful, happy and neutral faces 
were quantified by the P100 and N170 ERP during non-conscious compared to conscious processing. 
Chapter 1  André Schmidt 2012 
22 
References 
 
Abel KM, Allin MP, Kucharska-Pietura K, David A, et al. (2003). Ketamine alters neural processing 
of facial emotion recognition in healthy men: an fMRI study. Neuroreport, 14(3): 387-391. 
Adler C, Malhotra A, Elman I, Goldberg T, et al. (1999). Comparison of ketamine-induced thought 
disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry, 156: 
1646-1649. 
Aghajanian G, Marek G (1999). Serotonin, via 5-HT2A receptors, increases EPSCs in layer V 
pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain 
Res, 825: 161-171. 
Aghajanian GK, Marek GJ (1997). Serotonin induces excitatory postsynaptic potentials in apical 
dendrites of neocortical pyramidal cells. Neuropharmacology, 36(4-5): 589-599. 
Allen P, Stephan KE, Mechelli A, Day F, et al. (2010). Cingulate activity and fronto-temporal 
connectivity in people with prodromal signs of psychosis. Neuroimage, 49(1): 947-955. 
Anderson IM, Juhasz G, Thomas E, Downey D, et al. (2011). The effect of acute citalopram on face 
emotion processing in remitted depression: a pharmacoMRI study. Eur 
Neuropsychopharmacol, 21(1): 140-148. 
Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV, et al. (2003). The epidemiology of major 
depressive episodes: results from the International Consortium of Psychiatric Epidemiology 
(ICPE) Surveys. Int J Methods Psychiatr Res, 12(1): 3-21. 
Atkinson RJ, Michie PT, Schall U (2011). Duration Mismatch Negativity and P3a in First-Episode 
Psychosis and Individuals at Ultra-High Risk of Psychosis. Biol Psychiatry. 
Autry AE, Adachi M, Nosyreva E, Na ES, et al. (2011). NMDA receptor blockade at rest triggers 
rapid behavioural antidepressant responses. Nature, 475(7354): 91-95. 
Baldeweg T (2006). Repetition effects to sounds: evidence for predictive coding in the auditory 
system. Trends Cogn Sci, 10: 93-94. 
Baldeweg T, Klugman A, Gruzelier J, Hirsch S (2002). Impairment in frontal but not temporal 
components of mismatch negativity in schizophrenia. Int J Psychophysiol, 43: 111-122. 
Baldeweg T, Klugman A, Gruzelier J, Hirsch S (2004). Mismatch negativity potentials and cognitive 
impairment in schizophrenia. Schizophr Res, 69: 203-217. 
Batty M, Taylor MJ (2003). Early processing of the six basic facial emotional expressions. Brain Res 
Cogn Brain Res, 17(3): 613-620. 
Beck AT (2008). The evolution of the cognitive model of depression and its neurobiological correlates. 
Am J Psychiatry, 165(8): 969-977. 
Berman RM, Cappiello A, Anand A, Oren DA, et al. (2000). Antidepressant effects of ketamine in 
depressed patients. Biol Psychiatry, 47(4): 351-354. 
Blau VC, Maurer U, Tottenham N, McCandliss BD (2007). The face-specific N170 component is 
modulated by emotional facial expression. Behav Brain Funct, 3: 7. 
Bodatsch M, Ruhrmann S, Wagner M, Müller R, et al. (2010). Prediction of Psychosis by Mismatch 
Negativity. Biol Psychiatry, 69: 959-966. 
Brandrup E, Vanggaard T (1977). LSD treatment in a severe case of compulsive neurosis. Acta 
Psychiatr Scand, 55(2): 127-141. 
Britt GC, McCance-Katz EF (2005). A brief overview of the clinical pharmacology of "club drugs". 
Subst Use Misuse, 40(9-10): 1189-1201. 
Brosch T, Sander D, Pourtois G, Scherer KR (2008). Beyond fear: rapid spatial orienting toward 
positive emotional stimuli. Psychol Sci, 19(4): 362-370. 
Brown AS (2011). The environment and susceptibility to schizophrenia. Prog Neurobiol, 93(1): 23-58. 
Browning M, Reid C, Cowen PJ, Goodwin GM, et al. (2007). A single dose of citalopram increases 
fear recognition in healthy subjects. J Psychopharmacol, 21(7): 684-690. 
Béïque JC, Imad M, Mladenovic L, Gingrich JA, et al. (2007). Mechanism of the 5-
hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. 
Proc Natl Acad Sci U S A, 104(23): 9870-9875. 
Carpenter WT (1999). The schizophrenia ketamine challenge study debate. Biol Psychiatry, 46(8): 
1081-1091. 
Casey DA, Rodriguez M, Northcott C, Vickar G, et al. (2011). Schizophrenia: medical illness, 
mortality, and aging. Int J Psychiatry Med, 41(3): 245-251. 
Colpaert FC (2003). Discovering risperidone: the LSD model of psychopathology. Nat Rev Drug 
Discov, 2(4): 315-320. 
Corlett PR, Frith CD, Fletcher PC (2009). From drugs to deprivation: a Bayesian framework for 
understanding models of psychosis. Psychopharmacology (Berl), 206(4): 515-530. 
Chapter 1  André Schmidt 2012 
23 
Corlett PR, Honey GD, Aitken MR, Dickinson A, et al. (2006). Frontal responses during learning 
predict vulnerability to the psychotogenic effects of ketamine: linking cognition, brain activity, 
and psychosis. Arch Gen Psychiatry, 63: 611-621. 
Corlett PR, Honey GD, Krystal JH, Fletcher PC (2011). Glutamatergic model psychoses: prediction 
error, learning, and inference. Neuropsychopharmacology, 36: 294-315. 
Corlett PR, Murray GK, Honey GD, Aitken MR, et al. (2007). Disrupted prediction-error signal in 
psychosis: evidence for an associative account of delusions. Brain, 130: 2387-2400. 
David O, Kiebel SJ, Harrison LM, Mattout J, et al. (2006). Dynamic causal modeling of evoked 
responses in EEG and MEG. Neuroimage, 30(4): 1255-1272. 
Deffke I, Sander T, Heidenreich J, Sommer W, et al. (2007). MEG/EEG sources of the 170-ms 
response to faces are co-localized in the fusiform gyrus. Neuroimage, 35(4): 1495-1501. 
Del-Ben CM, Deakin JF, McKie S, Delvai NA, et al. (2005). The effect of citalopram pretreatment on 
neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study. 
Neuropsychopharmacology, 30(9): 1724-1734. 
Demenescu LR, Renken R, Kortekaas R, van Tol MJ, et al. (2011). Neural correlates of perception 
of emotional facial expressions in out-patients with mild-to-moderate depression and anxiety. 
A multicenter fMRI study. Psychol Med: 1-12. 
Desan PH, Silbert LH, Maier SF (1988). Long-term effects of inescapable stress on daily running 
activity and antagonism by desipramine. Pharmacol Biochem Behav, 30(1): 21-29. 
Diaconescu AO, Jensen J, Wang H, Willeit M, et al. (2011). Aberrant Effective Connectivity in 
Schizophrenia Patients during Appetitive Conditioning. Front Hum Neurosci, 4: 239. 
Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, et al. (2010). A randomized add-on trial of 
an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen 
Psychiatry, 67(8): 793-802. 
Doeller CF, Opitz B, Mecklinger A, Krick C, et al. (2003). Prefrontal cortex involvement in 
preattentive auditory deviance detection: neuroimaging and electrophysiological evidence. 
Neuroimage, 20: 1270-1282. 
Eimer M, Holmes A (2007). Event-related brain potential correlates of emotional face processing. 
Neuropsychologia, 45(1): 15-31. 
Ekman P, Friesen WV (1971). Constants across cultures in the face and emotion. J Pers Soc 
Psychol, 17(2): 124-129. 
Elliott R, Zahn R, Deakin JF, Anderson IM (2011). Affective cognition and its disruption in mood 
disorders. Neuropsychopharmacology, 36(1): 153-182. 
Fichtenholtz HM, Hopfinger JB, Graham R, Detwiler JM, et al. (2009). Event-related potentials 
reveal temporal staging of dynamic facial expression and gaze shift effects on attentional 
orienting. Soc Neurosci, 4(4): 317-331. 
Fletcher PC, Frith CD (2009). Perceiving is believing: a Bayesian approach to explaining the positive 
symptoms of schizophrenia. Nat Rev Neurosci, 10(1): 48-58. 
Fontenelle LF, Oostermeijer S, Harrison BJ, Pantelis C, et al. (2011). Obsessive-compulsive 
disorder, impulse control disorders and drug addiction: common features and potential 
treatments. Drugs, 71(7): 827-840. 
Friston K (1994). Functional and effective connectivity in neuroimaging: A Synthesis. Human Brain 
Mapping, 2: 56-78. 
Friston K (2005a). A theory of cortical responses. Philos Trans R Soc Lond B Biol Sci, 360: 815-836. 
Friston K (2005b). Disconnection and cognitive dysmetria in schizophrenia. Am J Psychiatry, 162(3): 
429-432. 
Friston KJ (1998). The disconnection hypothesis. Schizophr Res, 30(2): 115-125. 
Friston KJ, Frith CD (1995). Schizophrenia: a disconnection syndrome? Clin Neurosci, 3(2): 89-97. 
Friston KJ, Harrison L, Penny W (2003). Dynamic causal modelling. Neuroimage, 19(4): 1273-1302. 
Funk AJ, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH (2011). Abnormal Activity of 
the MAPK- and cAMP-Associated Signaling Pathways in Frontal Cortical Areas in Postmortem 
Brain in Schizophrenia. Neuropsychopharmacology. 
Garrido M, Friston K, Kiebel S, Stephan K, et al. (2008). The functional anatomy of the MMN: a 
DCM study of the roving paradigm. Neuroimage, 42: 936-944. 
Garrido M, Kilner J, Kiebel S, Friston K (2009a). Dynamic causal modeling of the response to 
frequency deviants. J Neurophysiol, 101: 2620-2631. 
Garrido M, Kilner J, Stephan K, Friston K (2009b). The mismatch negativity: a review of underlying 
mechanisms. Clin Neurophysiol, 120: 453-463. 
Geert-Jörgensen E (1968). Further observations regarding hallucinogenic treatment. Acta Psychiatr 
Scand Suppl, 203: 195-200. 
Chapter 1  André Schmidt 2012 
24 
Geyer MA, Vollenweider FX (2008). Serotonin research: contributions to understanding psychoses. 
Trends Pharmacol Sci, 29: 445-453. 
González-Maeso J, Sealfon S (2009). Psychedelics and schizophrenia. Trends Neurosci, 32: 225-
232. 
Gouzoulis-Mayfrank E, Habermeyer E, Hermle L, Steinmeyer A, et al. (1998). Hallucinogenic drug 
induced states resemble acute endogenous psychoses: results of an empirical study. Eur 
Psychiatry, 13: 399-406. 
Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, et al. (2005). Psychological effects of (S)-
ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy 
volunteers. Pharmacopsychiatry, 38: 301-311. 
Gray JA, Feldon J, Rawlins JNP, Smith AD (1991). The neuropsychology of schizophrenia. 
Behavioral and Brain Sciences, 18: 617-680. 
Grob CS, Danforth AL, Chopra GS, Hagerty M, et al. (2011). Pilot study of psilocybin treatment for 
anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry, 68(1): 71-78. 
Harmer CJ (2008). Serotonin and emotional processing: does it help explain antidepressant drug 
action? Neuropharmacology, 55(6): 1023-1028. 
Harmer CJ, Bhagwagar Z, Perrett DI, Völlm BA, et al. (2003). Acute SSRI administration affects the 
processing of social cues in healthy volunteers. Neuropsychopharmacology, 28(1): 148-152. 
Harrison PJ, Weinberger DR (2005). Schizophrenia genes, gene expression, and neuropathology: 
on the matter of their convergence. Mol Psychiatry, 10(1): 40-68; image 45. 
Heckers S (2011). Bleuler and the neurobiology of schizophrenia. Schizophr Bull, 37(6): 1131-1135. 
Heekeren K, Daumann J, Neukirch A, Stock C, et al. (2008). Mismatch negativity generation in the 
human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology 
(Berl), 199: 77-88. 
Hemsley DR (1993). A simple (or simplistic?) cognitive model for schizophrenia. Behav Res Ther, 
31(7): 633-645. 
Homayoun H, Moghaddam B (2007). NMDA receptor hypofunction produces opposite effects on 
prefrontal cortex interneurons and pyramidal neurons. J Neurosci, 27(43): 11496-11500. 
Honey GD, Corlett PR, Absalom AR, Lee M, et al. (2008). Individual differences in psychotic effects 
of ketamine are predicted by brain function measured under placebo. J Neurosci, 28: 6295-
6303. 
Insel TR (2010). Rethinking schizophrenia. Nature, 468(7321): 187-193. 
Insel TR, Charney DS (2003). Research on major depression: strategies and priorities. JAMA, 
289(23): 3167-3168. 
Ishai A (2007). Sex, beauty and the orbitofrontal cortex. Int J Psychophysiol, 63(2): 181-185. 
Ishai A, Schmidt CF, Boesiger P (2005). Face perception is mediated by a distributed cortical 
network. Brain Res Bull, 67(1-2): 87-93. 
Itier RJ, Taylor MJ (2004). N170 or N1? Spatiotemporal differences between object and face 
processing using ERPs. Cereb Cortex, 14(2): 132-142. 
Javitt DC (2010). Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci, 47(1): 4-16. 
Javitt DC, Spencer KM, Thaker GK, Winterer G, et al. (2008). Neurophysiological biomarkers for 
drug development in schizophrenia. Nat Rev Drug Discov, 7(1): 68-83. 
Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J 
Psychiatry, 148: 1301-1308. 
Joormann J, Gotlib IH (2006). Is this happiness I see? Biases in the identification of emotional facial 
expressions in depression and social phobia. J Abnorm Psychol, 115(4): 705-714. 
Jääskeläinen I, Ahveninen J, Bonmassar G, Dale A, et al. (2004). Human posterior auditory cortex 
gates novel sounds to consciousness. Proc Natl Acad Sci U S A, 101: 6809-6814. 
Kessler RC, Berglund P, Demler O, Jin R, et al. (2003). The epidemiology of major depressive 
disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA, 289(23): 
3095-3105. 
Khorramzadeh E, Lotfy AO (1973). The use of ketamine in psychiatry. Psychosomatics, 14(6): 344-
346. 
Kiebel SJ, David O, Friston KJ (2006). Dynamic causal modelling of evoked responses in EEG/MEG 
with lead field parameterization. NeuroImage, 30(4): 1273-1284. 
Kleinhans NM, Richards T, Johnson LC, Weaver KE, et al. (2011). fMRI evidence of neural 
abnormalities in the subcortical face processing system in ASD. Neuroimage, 54(1): 697-704. 
Kornhuber J (1990). Glutamate and schizophrenia. Trends Pharmacol Sci, 11: 357. 
Krystal J, Karper L, Seibyl J, Freeman G, et al. (1994). Subanesthetic effects of the noncompetitive 
NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and 
neuroendocrine responses. Arch Gen Psychiatry, 51: 199-214. 
Chapter 1  André Schmidt 2012 
25 
Kurland AA, Unger S, Shaffer JW, Savage C (1967). Psychedelic therapy utilizing LSD in the 
treatment of the alcoholic patient: a preliminary report. Am J Psychiatry, 123(10): 1202-1209. 
Lawrie SM, Buechel C, Whalley HC, Frith CD, et al. (2002). Reduced frontotemporal functional 
connectivity in schizophrenia associated with auditory hallucinations. Biol Psychiatry, 51(12): 
1008-1011. 
Leonard HL, Rapoport JL (1987). Relief of obsessive-compulsive symptoms by LSD and psilocin. 
Am J Psychiatry, 144(9): 1239-1240. 
Leppänen JM, Moulson MC, Vogel-Farley VK, Nelson CA (2007). An ERP study of emotional face 
processing in the adult and infant brain. Child Dev, 78(1): 232-245. 
Li N, Lee B, Liu RJ, Banasr M, et al. (2010). mTOR-dependent synapse formation underlies the rapid 
antidepressant effects of NMDA antagonists. Science, 329(5994): 959-964. 
Liddell BJ, Williams LM, Rathjen J, Shevrin H, et al. (2004). A temporal dissociation of subliminal 
versus supraliminal fear perception: an event-related potential study. J Cogn Neurosci, 16(3): 
479-486. 
Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, et al. (2008). Rapid onset of 
antidepressant action: a new paradigm in the research and treatment of major depressive 
disorder. J Clin Psychiatry, 69(6): 946-958. 
Macknik SL, Livingstone MS (1998). Neuronal correlates of visibility and invisibility in the primate 
visual system. Nat Neurosci, 1(2): 144-149. 
Malhotra AK, Pinals DA, Weingartner H, Sirocco K, et al. (1996). NMDA receptor function and 
human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology, 
14: 301-307. 
McDougle CJ, Erickson CA, Stigler KA, Posey DJ (2005). Neurochemistry in the pathophysiology of 
autism. J Clin Psychiatry, 66 Suppl 10: 9-18. 
McKie S, Del-Ben C, Elliott R, Williams S, et al. (2005). Neuronal effects of acute citalopram 
detected by pharmacoMRI. Psychopharmacology (Berl), 180(4): 680-686. 
Moreno FA, Delgado PL (1997). Hallucinogen-induced relief of obsessions and compulsions. Am J 
Psychiatry, 154(7): 1037-1038. 
Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006). Safety, tolerability, and efficacy of 
psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry, 67(11): 1735-
1740. 
Morris JS, Frith CD, Perrett DI, Rowland D, et al. (1996). A differential neural response in the 
human amygdala to fearful and happy facial expressions. Nature, 383(6603): 812-815. 
Morris JS, Ohman A, Dolan RJ (1998). Conscious and unconscious emotional learning in the human 
amygdala. Nature, 393(6684): 467-470. 
Murray SO, Kersten D, Olshausen BA, Schrater P, et al. (2002). Shape perception reduces activity 
in human primary visual cortex. Proc Natl Acad Sci U S A, 99(23): 15164-15169. 
Nagels A, Kirner-Veselinovic A, Krach S, Kircher T (2011a). Neural correlates of S-ketamine 
induced psychosis during overt continuous verbal fluency. Neuroimage, 54: 1307-1314. 
Nagels A, Kirner-Veselinovic A, Wiese R, Paulus FM, et al. (2011b). Effects of ketamine-induced 
psychopathological symptoms on continuous overt rhyme fluency. Eur Arch Psychiatry Clin 
Neurosci. 
Näätänen R (1992). Attention and Brain Function.: Erlbaum: Hillsdale. 
Näätänen R, Gaillard AW, Mäntysalo S (1978). Early selective-attention effect on evoked potential 
reinterpreted. Acta Psychol (Amst), 42: 313-329. 
Ohman A, Carlsson K, Lundqvist D, Ingvar M (2007). On the unconscious subcortical origin of 
human fear. Physiol Behav, 92(1-2): 180-185. 
Opitz B, Rinne T, Mecklinger A, von Cramon DY, et al. (2002). Differential contribution of frontal 
and temporal cortices to auditory change detection: fMRI and ERP results. Neuroimage, 15: 
167-174. 
Orosz AT, Feldon J, Simon AE, Hilti LM, et al. (2011). Learned irrelevance and associative learning 
is attenuated in individuals at risk for psychosis but not in asymptomatic first-degree relatives 
of schizophrenia patients: translational state markers of psychosis? Schizophr Bull, 37(5): 
973-981. 
Pahnke WN, Kurland AA, Goodman LE, Richards WA (1969). LSD-assisted psychotherapy with 
terminal cancer patients. Curr Psychiatr Ther, 9: 144-152. 
Papp M, Moryl E (1993). New evidence for the antidepressant activity of MK-801, a non-competitive 
antagonist of NMDA receptors. Pol J Pharmacol, 45(5-6): 549-553. 
Papp M, Moryl E (1994a). Antidepressant activity of non-competitive and competitive NMDA receptor 
antagonists in a chronic mild stress model of depression. Eur J Pharmacol, 263(1-2): 1-7. 
Chapter 1  André Schmidt 2012 
26 
Papp M, Moryl E (1994b). Rewarding properties of non-competitive and competitive NMDA 
antagonists as measured by place preference conditioning in rats. Pol J Pharmacol, 46(1-2): 
79-81. 
Pegna AJ, Landis T, Khateb A (2008). Electrophysiological evidence for early non-conscious 
processing of fearful facial expressions. Int J Psychophysiol, 70(2): 127-136. 
Perry EB, Cramer JA, Cho HS, Petrakis IL, et al. (2007). Psychiatric safety of ketamine in 
psychopharmacology research. Psychopharmacology (Berl), 192(2): 253-260. 
Pessoa L, Adolphs R (2010). Emotion processing and the amygdala: from a 'low road' to 'many 
roads' of evaluating biological significance. Nat Rev Neurosci, 11(11): 773-783. 
Phan KL, Wager T, Taylor SF, Liberzon I (2002). Functional neuroanatomy of emotion: a meta-
analysis of emotion activation studies in PET and fMRI. Neuroimage, 16(2): 331-348. 
Pourtois G, Vuilleumier P (2006). Dynamics of emotional effects on spatial attention in the human 
visual cortex. Prog Brain Res, 156: 67-91. 
Puig MV, Celada P, Díaz-Mataix L, Artigas F (2003). In vivo modulation of the activity of pyramidal 
neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to 
thalamocortical afferents. Cereb Cortex, 13(8): 870-882. 
Rao RP, Ballard DH (1999). Predictive coding in the visual cortex: a functional interpretation of some 
extra-classical receptive-field effects. Nat Neurosci, 2: 79-87. 
Rinne T, Alho K, Ilmoniemi R, Virtanen J, et al. (2000). Separate time behaviors of the temporal and 
frontal mismatch negativity sources. Neuroimage, 12: 14-19. 
Ross S, Peselow E (2009). The neurobiology of addictive disorders. Clin Neuropharmacol, 32(5): 
269-276. 
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, et al. (2006). Acute and longer-term 
outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D 
report. Am J Psychiatry, 163(11): 1905-1917. 
Sadeh B, Podlipsky I, Zhdanov A, Yovel G (2010). Event-related potential and functional MRI 
measures of face-selectivity are highly correlated: a simultaneous ERP-fMRI investigation. 
Hum Brain Mapp, 31(10): 1490-1501. 
Saha S, Chant D, McGrath J (2007). A systematic review of mortality in schizophrenia: is the 
differential mortality gap worsening over time? Arch Gen Psychiatry, 64(10): 1123-1131. 
Sanacora G, Zarate CA, Krystal JH, Manji HK (2008). Targeting the glutamatergic system to 
develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov, 7(5): 426-
437. 
Santesso DL, Meuret AE, Hofmann SG, Mueller EM, et al. (2008). Electrophysiological correlates of 
spatial orienting towards angry faces: a source localization study. Neuropsychologia, 46(5): 
1338-1348. 
Sato Y, Yabe H, Todd J, Michie P, et al. (2003). Impairment in activation of a frontal attention-switch 
mechanism in schizophrenic patients. Biol Psychol, 62: 49-63. 
Schultz RT, Grelotti DJ, Klin A, Kleinman J, et al. (2003). The role of the fusiform face area in social 
cognition: implications for the pathobiology of autism. Philos Trans R Soc Lond B Biol Sci, 
358(1430): 415-427. 
Schultz W, Dayan P, Montague PR (1997). A neural substrate of prediction and reward. Science, 
275(5306): 1593-1599. 
Sewell RA, Halpern JH, Pope HG (2006). Response of cluster headache to psilocybin and LSD. 
Neurology, 66(12): 1920-1922. 
Shanks N, Anisman H (1989). Strain-specific effects of antidepressants on escape deficits induced 
by inescapable shock. Psychopharmacology (Berl), 99(1): 122-128. 
Sharp T, Cowen PJ (2011). 5-HT and depression: is the glass half-full? Curr Opin Pharmacol. 
Shin KS, Kim JS, Kang DH, Koh Y, et al. (2009). Pre-attentive auditory processing in ultra-high-risk 
for schizophrenia with magnetoencephalography. Biol Psychiatry, 65: 1071-1078. 
Shin LM, Liberzon I (2010). The neurocircuitry of fear, stress, and anxiety disorders. 
Neuropsychopharmacology, 35(1): 169-191. 
Shors TJ, Seib TB, Levine S, Thompson RF (1989). Inescapable versus escapable shock 
modulates long-term potentiation in the rat hippocampus. Science, 244(4901): 224-226. 
Singer T, Kiebel SJ, Winston JS, Dolan RJ, et al. (2004). Brain responses to the acquired moral 
status of faces. Neuron, 41(4): 653-662. 
Skolnick P, Legutko B, Li X, Bymaster FP (2001). Current perspectives on the development of non-
biogenic amine-based antidepressants. Pharmacol Res, 43(5): 411-423. 
Skolnick P, Popik P, Trullas R (2009). Glutamate-based antidepressants: 20 years on. Trends 
Pharmacol Sci, 30(11): 563-569. 
Chapter 1  André Schmidt 2012 
27 
Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K, et al. (2010). Neuroimaging predictors of 
transition to psychosis--a systematic review and meta-analysis. Neurosci Biobehav Rev, 
34(8): 1207-1222. 
Smith GS, Ma Y, Dhawan V, Gunduz H, et al. (2002). Serotonin modulation of cerebral glucose 
metabolism measured with positron emission tomography (PET) in human subjects. Synapse, 
45(2): 105-112. 
Smith ML (2011). Rapid Processing of Emotional Expressions without Conscious Awareness. Cereb 
Cortex. 
Stephan K, Baldeweg T, Friston K (2006). Synaptic plasticity and dysconnection in schizophrenia. 
Biol Psychiatry, 59: 929-939. 
Stephan KE, Friston KJ, Frith CD (2009). Dysconnection in schizophrenia: from abnormal synaptic 
plasticity to failures of self-monitoring. Schizophr Bull, 35: 509-527. 
Stephan KE, Penny WD, Moran RJ, den Ouden HE, et al. (2010). Ten simple rules for dynamic 
causal modeling. Neuroimage, 49(4): 3099-3109. 
Studerus E, Kometer M, Hasler F, Vollenweider F (2010). Acute, subacute and long-term subjective 
effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J 
Psychopharmacol. 
Surguladze SA, Young AW, Senior C, Brébion G, et al. (2004). Recognition accuracy and response 
bias to happy and sad facial expressions in patients with major depression. Neuropsychology, 
18(2): 212-218. 
Tamietto M, de Gelder B (2010). Neural bases of the non-conscious perception of emotional signals. 
Nat Rev Neurosci, 11(10): 697-709. 
Todd J, Robinson J (2010). The use of conditional inference to reduce prediction error--a mismatch 
negativity (MMN) study. Neuropsychologia, 48: 3009-3018. 
Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, et al. (2006). Evaluation of outcomes with 
citalopram for depression using measurement-based care in STAR*D: implications for clinical 
practice. Am J Psychiatry, 163(1): 28-40. 
Trullas R, Skolnick P (1990). Functional antagonists at the NMDA receptor complex exhibit 
antidepressant actions. Eur J Pharmacol, 185(1): 1-10. 
Umbricht D, Krljes S (2005). Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res, 
76: 1-23. 
Umbricht D, Schmid L, Koller R, Vollenweider F, et al. (2000). Ketamine-induced deficits in auditory 
and visual context-dependent processing in healthy volunteers: implications for models of 
cognitive deficits in schizophrenia. Arch Gen Psychiatry, 57: 1139-1147. 
Vollenweider F, Kometer M (2010). The neurobiology of psychedelic drugs: implications for the 
treatment of mood disorders. Nat Rev Neurosci, 11: 642-651. 
Vollenweider FX, Leenders KL, Oye I, Hell D, et al. (1997a). Differential psychopathology and 
patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy 
volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol, 7: 25-38. 
Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, et al. (1997b). Positron emission 
tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology 
in the psilocybin model of psychosis. Neuropsychopharmacology, 16: 357-372. 
Vollenweider FX, Geyer MA (2001). A systems model of altered consciousness: integrating natural 
and drug-induced psychoses. Brain Res Bull, 56: 495-507. 
Vuilleumier P, Pourtois G (2007). Distributed and interactive brain mechanisms during emotion face 
perception: evidence from functional neuroimaging. Neuropsychologia, 45(1): 174-194. 
Whalen PJ, Rauch SL, Etcoff NL, McInerney SC, et al. (1998). Masked presentations of emotional 
facial expressions modulate amygdala activity without explicit knowledge. J Neurosci, 18(1): 
411-418. 
Williams LM, Liddell BJ, Rathjen J, Brown KJ, et al. (2004). Mapping the time course of 
nonconscious and conscious perception of fear: an integration of central and peripheral 
measures. Hum Brain Mapp, 21(2): 64-74. 
Winder R, Cortes CR, Reggia JA, Tagamets MA (2007). Functional connectivity in fMRI: A modeling 
approach for estimation and for relating to local circuits. Neuroimage, 34(3): 1093-1107. 
Winkler I, Karmos G, Näätänen R (1996). Adaptive modeling of the unattended acoustic environment 
reflected in the mismatch negativity event-related potential. Brain Res, 742: 239-252. 
Yang Z, Zhao J, Jiang Y, Li C, et al. (2011). Altered negative unconscious processing in major 
depressive disorder: an exploratory neuropsychological study. PLoS One, 6(7): e21881. 
Zarate CA, Singh JB, Carlson PJ, Brutsche NE, et al. (2006). A randomized trial of an N-methyl-D-
aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry, 63(8): 
856-864.. 
Chapter 2  André Schmidt 2012 
28 
2. Mismatch Negativity Encoding of Prediction Errors 
Predicts S-ketamine-induced Cognitive Impairments 
 
André Schmidt1,*, Rosilla Bachmann1, Michael Kometer1, Philipp A Csomor1, Klaas E 
Stephan2,3, Erich Seifritz4 and Franz X Vollenweider1 
 
1Neuropsychopharmacology and Brain Imaging, University Hospital of Psychiatry, University of Zurich, 
Zurich, Switzerland; 
2Laboratory for Social and Neural Systems Research, Department of Economics, University of Zurich, 
Zurich, Switzerland; 
3Wellcome Department of Neuroimaging, University College London, London, UK; 
4Clinic of Affective Disorders and General Psychiatry, University Hospital of Psychiatry, Zurich, 
Switzerland; 
 
 
*Corresponding author 
Article published in Neuropsychopharmacology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Personal contribution: 
AS, MK, KES, and FXV contributed to the study design of this paper. PAC and AS developed the 
MMN roving paradigm. AS and RB contributed to the conduction of the experiments and AS analyzed 
the data. AS contributed to the writing of the manuscript, with additional contributions by RB, MK, 
PAC, KES, ES, and FXV, who appears as co-authors in the published paper. 
Chapter 2  André Schmidt 2012 
29 
Abstract 
 
Psychotomimetics like the N-methyl- D -aspartate receptor (NMDAR) antagonist ketamine and the 5-
hydroxytryptamine2A receptor (5-HT 2A R) agonist psilocybin induce psychotic symptoms in healthy 
volunteers that resemble those of schizophrenia. Recent theories of psychosis posit that aberrant 
encoding of prediction errors (PE) may underlie the expression of psychotic symptoms. This study 
used a roving mismatch negativity (MMN) paradigm to investigate whether the encoding of PE is 
affected by pharmacological manipulation of NMDAR or 5-HT 2A R, and whether the encoding of PE 
under placebo can be used to predict drug-induced symptoms. Using a double-blind within-subject 
placebo-controlled design, S-ketamine and psilocybin, respectively, were administrated to two groups 
of healthy subjects. Psychological alterations were assessed using a revised version of the Altered 
States of Consciousness (ASC-R) questionnaire. As an index of PE, we computed changes in MMN 
amplitudes as a function of the number of preceding standards (MMN memory trace effect) during a 
roving paradigm. S-ketamine, but not psilocybin, disrupted PE processing as expressed by a frontally 
disrupted MMN memory trace effect. Although both drugs produced positive-like symptoms, the extent 
of PE processing under placebo only correlated significantly with the severity of cognitive impairments 
induced by S-ketamine. Our results suggest that the NMDAR, but not the 5-HT 2A R system, is 
implicated in PE processing during the MMN paradigm, and that aberrant PE signaling may contribute 
to the formation of cognitive impairments. The assessment of the MMN memory trace in schizophrenia 
may allow detecting early phases of the illness and might also serve to assess the efficacy of novel 
pharmacological treatments, in particular of cognitive impairments. 
 
Keywords: model psychosis; NMDAR; 5-HT; predictive coding; MMN memory trace effect; cognitive 
impairment 
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Introduction 
 
Dissociative N-methyl-D-aspartate receptor (NMDAR) antagonists such as ketamine and classic 
hallucinogens like psilocybin, which activate 5-hydroxytryptamine2A receptors (5-HT2AR) constitute 
two models of psychosis that are used to study the neurobiology of psychotic symptom formation in 
schizophrenia (González-Maeso and Sealfon, 2009; Javitt and Zukin, 1991; Vollenweider and Geyer, 
2001). While administration of ketamine to healthy volunteers reproduces both positive and negative 
symptoms of schizophrenia (Adler et al., 1999; Malhotra et al., 1996; Vollenweider et al., 1997a), 
psilocybin engenders positive symptoms that are highly reminiscent of those observed in 
schizophrenia (Geyer and Vollenweider, 2008; Gouzoulis-Mayfrank et al., 1998). In neuroimaging 
studies, both ketamine and psilocybin altered the activity in frontotemporal regions associated with 
depersonalization and thought disorder (Vollenweider et al., 1997a; Vollenweider et al., 1997c). 
Furthermore, ketamine infusion in schizophrenia patients transiently exacerbated positive symptoms 
(Lahti et al., 1995b) associated with an activation of PFC and thalamic structures (Lahti et al., 1995a). 
Although ketamine- and psilocybin-like drugs differ in their primary mechanism of action, both classes 
of drugs increase extracellular glutamate in PFC (Moghaddam et al., 1997; Muschamp et al., 2004), 
which may explain some of the common psychotic symptoms. However, while the pharmacological 
properties of these psychotomimetics are well documented (Fantegrossi et al., 2008; Nichols, 2004a), 
the neuronal and cognitive mechanisms underlying ketamine- and psilocybin-induced symptoms are 
less well understood. 
 
Recent works suggest that the formation of symptoms induced by psychomimetics could be 
understood within the framework of predictive coding models (Corlett et al., 2009; Corlett et al., 2011). 
These suggestions followed from predictive coding models of learning and inference (Friston, 2005b; 
Rao and Ballard, 1999) and their specific application to schizophrenia (Stephan et al. 2006). Predictive 
coding assumes a hierarchical neural architecture where each level provides predictions about the 
state of the level below and evaluates the discrepancy with the actual inputs from the lower level, i.e. 
prediction error (PE) (Friston, 2005b; Rao and Ballard, 1999). Predictions and PE are conveyed via 
synaptic connections instantiating a Bayesian message passing scheme. Simply speaking, both 
perceptual inference and learning rely on minimization of PE throughout the hierarchy. Neuronal states 
and connection strengths are adjusted during inference and learning, respectively, in order to minimize 
PE at all levels of the hierarchy. 
It has repeatedly been proposed that aberrant PE processing might be involved in the formation of 
psychosis, originally in the context of associative learning theory (Gray et al., 1991; Hemsley, 1993) 
and more recently in terms of Bayesian concepts (Fletcher and Frith, 2009; Murray et al., 2008; 
Stephan et al., 2006). Broadly speaking, these theories constitute two non-exclusive classes which 
stress either (i) inappropriate timing of PE signals (King et al., 1984; Shaner, 1999); or (ii) inadequate 
magnitude or precision (inverse variance) of PE estimates during hierarchical Bayesian inference 
(Corlett et al, 2009; Friston, 2005; Stephan et al, 2006). These general concepts have been used to 
explain a range of empirical findings about schizophrenia, such as interpreting fMRI data in terms of a 
disruption of PE processing in the PFC of schizophrenia patients with delusions (Corlett et al., 2007b) 
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Critically, the extent of this PE disruption was related to an individual's propensity to delusion 
formation. Another example is that in the early stage of psychosis, schizophrenia patients often 
describe how irrelevant stimuli capture their attention (Chapman, 1966). This has been framed in 
terms of “aberrant salience”, a phenomenological concept originally developed without explicit 
reference to PEs (Kapur, 2003). More recent proposals (Roiser et al., 2009) have speculated about a 
link of aberrant salience to contextually irrelevant or “chaotic” PEs (King et al., 1984) which may 
underlie formation of inappropriate statistical associations, leading to maladaptive inference about the 
causes of sensory inputs. In summary, abnormal PEs may represent a general mechanism for the 
emergence of psychotic symptoms in schizophrenia and understanding these symptoms requires 
formal models that link cognitive impairments to psychopathology. 
 
A commonly used physiological paradigm to estimate PE signaling is the mismatch negativity (MMN) 
event-related potential (ERP) (Garrido et al., 2009b; Todd and Robinson, 2010), which is most 
relevant to psychotic symptoms in naturally occurring and drug-induced psychosis (Corlett et al., 2011; 
Kantrowitz and Javitt, 2010). MMN is an electrophysiological event-related response to unexpected 
sensory (typically auditory) stimuli, so-called “deviants”, that differ in one physical stimulus dimension 
from a sequence of preceding identical “standards” (Näätänen et al., 1978). Indeed, deficits in MMN 
amplitude have been repeatedly reported in schizophrenic patients (Umbricht and Krljes, 2005), and a 
comparable deficit was found in healthy volunteers after exposure to ketamine (Heekeren et al., 2008; 
Umbricht et al., 2000). Furthermore, the MMN amplitude assessed under placebo correlated positively 
with the ketamine-induced positive-like symptoms as indexed by the global score of the Altered State 
of Consciousness rating scale (5D-ASC) and the BPRS psychosis score in healthy subjects (Umbricht 
et al., 2002). This correlation was significant over frontal electrodes suggesting that the integrity of 
PFC is crucial for PE processing in MMN. Another study using a different modality (fMRI) and different 
paradigm (an associative learning task) suggested that this role of the PFC for PE processing may 
generalize, reporting that ketamine disrupted PE dependent activity in the right PFC of healthy 
volunteers (Corlett et al., 2006). 
 
In the current study, we investigated how PE processing is altered under NMDAR antagonist and/or 5-
HT2AR agonist manipulation, and whether ketamine- and psilocybin-induced symptoms can be 
predicted by the MMN. Instead of a classical oddball paradigm, we use a “roving” MMN paradigm and 
examine the formation and strengthening of memory traces (by quantifying the amplitude of the MMN 
as a function of the number of preceding standards) (Haenschel et al., 2005; Imada et al., 1993). A 
notable advantage of the roving paradigm is that physical stimulus differences between standards and 
deviants are varied independently from the number of standard repetitions in the roving paradigm. This 
ensures that the ensuing MMN memory trace effect is entirely due to learning and cannot result from 
differential states of frequency-specific auditory neurons in the temporal cortex. 
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Materials and Methods 
 
This study was approved by the Ethics Committee of the University Hospital of Psychiatry, Zurich. 
After receiving a written and oral description of the aim of this study, all participants gave written 
informed consent statements before inclusion. The use of psychoactive drugs was approved by the 
Swiss Federal Health Office (BAG), Department of Pharmacology and Narcotics (DPN), Bern, 
Switzerland. 
 
Subjects 
 
Healthy subjects were recruited at the local university and technical college through advertisement and 
were then divided into two groups, either receiving (S)-ketamine or psilocybin (ketamine group: N = 19 
[male: 12], mean age = 26 ± 5.09 y; psilocybin group: N = 20 [male: 12], mean age = 23 ± 2.27 y). 
Prior to the inclusion, subjects’ physical health was confirmed by medical history, clinical examination, 
electrocardiography, and blood analysis. To ascertain the subjects’ mental status, all subjects were 
screened by the DIA-X diagnostic expert system (Wittchen and Pfister, 1997b), a semi-structured 
psychiatric interview, and the Hopkins Symptom Checklist (SCL-90–R) (Derogatis, 1994b). 
Furthermore, subjects replied to the Mini-International Neuropsychiatric Interview (M.I.N.I.), a short 
structured psychiatric interview (Sheehan et al., 1998). We verified the absence of a history of drug 
dependence or present drug abuse by urine drug-screening and a questionnaire of drug consumption. 
 
Drug administration 
 
In both groups, subjects underwent two sessions (placebo/active drug) in a counterbalanced order. 
Both subjects and principal investigator were blind to drug order. Subjects stayed monitored and under 
constant supervision until all drug effects had worn off, and were then released into the custody of a 
partner or immediate relative. 
For the S-ketamine/placebo infusion, an in-dwelling catheter was placed in the antecubital vein of the 
non-dominant arm. The infusion scheme can be summarized as BET (Krüger-Thiemer, 1968). Once 
the subject was ready, a bolus injection over 5 min with 10 mg of S-ketamine was given (B). Following 
one minute break, a continuous infusion with 0.006mg/kg per minute was started (E). To keep S-
ketamine levels fairly constant and prevent accumulation in the brain, the dose was reduced by 
titrating (T). In the placebo session, the same procedure was followed. Instead of S-ketamine, an 
infusion of physiological sodium chloride solution and 5% glucose was given. Psilocybin was given 
p.o. at a dose of 115 μg/kg. The specific doses were chosen based on previous studies (Kometer et 
al., 2011; Vollenweider and Kometer, 2010). 
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Psychometric assessment of S-ketamine- and psilocybin-induced states (ASC-R) 
 
A revised form of the Altered State of Consciousness (ASC) questionnaire, a visual analogue and self-
rating scale, was used to assess the subjective effects of ketamine and psilocybin (Dittrich, 1975; 
Dittrich, 1998). This revised scale (ASC-R) (Studerus et al., 2010a) comprises three primary 
dimensions and their respective subscales: (i) “oceanic boundlessness” (OB), referring to positively 
experienced ego-dissolution associated with changes in the sense of time and emotions, ranging from 
heightened mood to sublime happiness and feelings of unity with the environment, subsuming the 
subscales disembodiment, blissful state, spiritual experience, and experience of unity and 
insightfulness; (ii) “anxious ego-disintegration” (AED), comprising the subscales anxiety and impaired 
control and cognition including items for disordered thought and loss of control over body and thought; 
and (iii) visionary restructuralization (VR), including the subscales elementary and complex imagery, 
audio-visual synesthesias, changed meaning of percepts and auditory alterations. 
 
Auditory test paradigm (mismatch negativity) 
 
Electroencephalograhic (EEG) activity was measured during an auditory “roving” oddball paradigm 
(Baldeweg et al., 2004; Boly et al., 2011; Garrido et al., 2008a; Haenschel et al., 2005), originally 
developed by Cowan and colleagues (Cowan et al., 1993b). Acoustic stimuli were generated by E-
prime software (Schneider et al., 2002), and applied binaurally through headphones (TDH-39-P, 
Maico, Minneapolis, MN, USA). 
Stimuli comprised a structured train of pure sinusoidal tones, with a roving changing tone (Figure 1). 
Within each stimulus train, all tones were of one frequency and were followed by a train of a different 
frequency. The first tone of a train represents the deviant (red), which becomes the standard tone after 
a few repetitions (blue). Hence, the deviants and standards tones have exactly the same physical 
properties within one stimulus train, differing only in the number of times they have been presented in 
the recent past (in a prior stimulus train). The number of times the same tone was presented within 
one stimulus train varied pseudo-randomly between one and eleven (t = 1-11). The probability that the 
same tone was presented in one stimulus train (i) was 2.5% for trains with 1 or 2 identical tones, (ii) 
3.75% for trains with 3 or 4 identical tones, and (iii) 12.5% for trains with 5-11 identical tones.  In other 
words, 5% of all stimulus trains consisted of 1-2 identical tones, 7.5% of all stimulus trains consisted of 
3-4 identical stimuli, and 87.5% of all stimulus trains consisted of 5-11 identical stimuli. The frequency 
of the tones varied from 500 to 800 Hz in random steps with integer multiples of 50 Hz, tone duration 
was set at 70 ms, and the inter-stimulus interval was 500 ms. 
In parallel, subjects performed a distracting visual task and were instructed to ignore the sounds. It has 
been argued that the best condition to observe an MMN is when the subject’s attention is directed 
away from the stimulus (Näätänen, 2000). The task consisted of button-pressing whenever a fixation 
cross changed its luminance, which occurred pseudo-randomly every 2 to 5 s (not coinciding with 
auditory changes). The testing session lasted approximately 15 minutes. The purpose of the additional 
distracting task was to ensure that the participant´s attention was not focused on the tones. 
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Figure 1 Stimulus design is characterized by a sporadically changing standard stimulus. The first 
presentation of a novel tone is a deviant (D/t(1); circle) that becomes a standard (triangle), through 
repetition (t(6)). Standard repetition varied between 1 and 11 (i = 1-11). 
 
EEG/ERP recording 
 
EEG recordings were made from 64 scalp electrodes using the ActiveTwo system (Biosemi, The 
Netherlands). The horizontal electroocculogram (EOG) was recorded from electrodes attached on the 
outer canthus of each eye. Similarly, vertical EOG was recorded from electrodes attached infraorbitally 
and supraorbitally to the left eye. Data were recorded at a sampling rate of 512 Hz. All electrodes were 
active silver/silver chloride electrodes and were referenced during recording to a common-mode signal 
(CMS) electrode between POz and PO3 (see http://www.biosemi.com/faq/cms&drl.htm for more 
details on this setup); the offset of all electrodes was below 25mV, indicating good recording quality. 
For ERP analysis, independent component analysis (ICA) was used to remove artifacts due to eye 
movements and blinks. Following ICA, epochs with a 200-ms prestimulus baseline and a 500-ms 
poststimulus interval were constructed. Epochs with amplitudes that exceeded ± 100 µV at any 
electrode were excluded from further averaging. Following artifact rejection, epochs were averaged 
offline for each subject and were digitally filtered with a band-pass filter (1-30 Hz). MMN was 
measured as the peak negativity within the 100 to 200 ms window latency of difference waveform 
(deviant minus standard waveforms). Here, we followed previous studies of the roving paradigm (e.g., 
(Garrido et al., 2008a) in focusing only on deviants preceded by at least 6 standards. Waveforms were 
mathematically referenced to an average-mastoid reference prior to peak detection, analogously 
analyzed as previous studies (Umbricht et al., 2002; Umbricht et al., 2000; Umbricht et al., 2003). 
Based on previous studies, a set of fronto-central (Fz, F3 and F4) and temporal electrodes (TP7 and 
TP8) were preselected (Alho et al., 1996; Sato et al., 2000; Tiitinen et al., 1993; Waberski et al., 2001). 
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Statistical analysis 
 
All statistical analysis was conducted using Statistica 7.1 for Windows (Statsoft Inc., OK, USA). 
Results of the distracting visual task were evaluated according to signal detection theory (Macmillan, 
1991) to determine sensitivity indexes (d’) under placebo and following drug administration, which 
were entered into a repeated-measures analysis of variance (repeated-measures ANOVA) with 
between-subjects factor group (ketamine group vs psilocybin group). Furthermore, averaged means of 
MMN difference wave amplitude and latency were subjected to a repeated-measures ANOVA using 
the within-subjects factors electrode (frontal vs temporal), treatment (placebo vs drug) and standard 
repetition (t = 6, 8, 10) and the between-subjects factor group (ketamine group vs psilocybin group). 
Where the ANOVA null hypothesis of equal means was rejected, we used post-hoc tests (Fisher’s 
least significant difference test, LSD). Additionally, correlations were conducted to examine the effect 
of the distracting visual task (d’ values) on the MMN difference wave amplitudes. Another repeated-
measures ANOVA was done to study ketamine- and psilocybin-induced symptoms. 
For further analysis, the relative increase of the MMN difference waveform from t(6) to t(8) and further 
from t(8) to t(10) was computed and the average of these values expressed as “MMN slope”. To 
assess the relationship between MMN slope under “baseline” (drug-free) conditions and drug-induced 
psychopathology, we correlated (over subjects) the MMN slope under placebo with each symptom 
rating in the ASC-R questionnaire and Bonferroni-corrected the significance level for multiple testing. 
 
Results 
 
Distracting visual vigilance test 
 
Repeated-measures ANOVA revealed that both drugs produced significantly prolonged reaction times 
[F(1,37) = 31.4, p < .0000, η2 = .46], as well as reduced sensitivity indices (d’) [F(1,37) = 20.8, p < 
.00001, η2 = .36] (Table 1). Drug effects did not differ from each other, as indicated by the lack of 
interaction with the between-subjects factor group. 
 
Table 1 Behavioral Results of the Distracting Visual Vigilance Task 
 
 
 
Mean reaction times (RT) and sensitivity indices (d’) ±SE. Both measures were significantly worsened 
by both drugs, but did not differ significantly between drugs. 
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MMN memory trace effect (prediction error processing) 
 
A significant main effect for standard repetition revealed the systematic increase in MMN amplitude 
with increasing number of standard tones (memory trace effect) [F(2,74) = 3.58, p < .05, η2 = .1]. In 
general, both overall MMN amplitude and MMN trace effect were more pronounced over frontal than 
temporal electrodes (p < .000001), as indicated by a significant main effect for electrode [F(1,37) = 
145, p < .000001, η2 = .8] and a significant electrode × standard repetition interaction [F(2,74) = 5.1, p 
< .01, η2 = .12]. Furthermore, a main effect of treatment was found [F(1,37) = 8.35, p < .01, η2 = .18] 
reflecting an overall attenuation of the MMN amplitude, irrespective of standard repetition, following 
drug administration. Furthermore, a treatment × electrode interaction [F(1,37) = 5, p < .05, η2 = .12] 
revealed that this treatment effect occurred only over frontal electrodes (p < .00000). However, the 
electrode × treatment × group interaction revealed that this treatment effect depended on the location 
of the electrodes and on the specific drug used [F(1,37) = 10.5, p < .01, η2 = .22]. While psilocybin did 
not affect the MMN over frontal or temporal electrodes, ketamine did disrupt the MMN but only at 
frontal electrodes (p < .00001) (Figure 2). 
 
 
Figure 2 Mean amplitudes ± SE of mismatch negativity (MMN) difference waveforms across standard 
repetitions (t = 6–10) at frontal electrodes (Fz, F3, and F4) following placebo (green) or drug 
administration (red: ketamine; blue: psilocybin), respectively. Note: Significant differences between 
treatment conditions at (*) p at 0.0001 and at (**) p < 0.000001. 
 
A subsequent ANOVA of the ketamine group revealed that ketamine disrupted the MMN memory trace 
effect over frontal electrodes, indicated by a triple electrode × treatment × standard repetition 
interaction [F(2,36) = 4.7, p < .05, η2 = .21]. Post-hoc analysis showed that for the frontal electrodes 
Fz, F3 and F4 shown in Figure 2 the treatment × standard repetition interaction was also significant (p 
at t(6) < .0001; p at t(8) < .0001; p at t(10) < .000001), indicating that the difference in the effect of 
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ketamine vs. placebo on the MMN trace effect became more pronounced with longer trace length. The 
corresponding MMN difference waves for the ketamine group were plotted in Figure 3. Finally, as 
shown by a significant treatment × group interaction (Figure 3), ketamine but not psilocybin caused a 
latency shift of the MMN, irrespective of standard repetition [F(1,37) = 5.29, p < .05, η2 = .13]. 
 
 
Figure 3 Corresponding mismatch negativity (MMN) difference waveforms following placebo (black 
line) and ketamine administration (red line) at frontal electrodes (Fz, F3, and F4) for t(6) (above), t(8) 
(middle), and t(10) (below). 
 
Notably, no significant correlations between the behavioral results of the distracting visual vigilance 
task (d’ values) and the MMN slope in either group were found, suggesting a functional dissociation. 
 
S-ketamine- and psilocybin-induced symptoms (ASC-R questionnaire) 
 
At the dose tested, both ketamine and psilocybin produced similar alterations on the global ASC score 
that were characterized by derealization and depersonalization phenomena, affective changes, 
cognitive impairments, and perceptual alterations, reflected by a main effect for treatment [F(1,37) = 
69.5, p < .000001, η2 = .65]. Subsequent ANOVA with treatment and subscale as repeated measures 
and group as between-subject factor revealed that both drugs significantly increased all subscale 
scores (all p’s < .01), with the exception of the anxiety score ([F(11,407) = 4.6, p < .00001, η2 = .11]. 
Additionally, psilocybin-induced auditory alterations were not significantly higher than under placebo. 
Moreover, post-hoc analysis showed that ketamine produced significantly higher scores than 
psilocybin for auditory alterations (p < .05), for depersonalization as indexed by disembodiment 
(p < .000001) and for cognitive impairments as indexed by impaired control and cognition (p < .05) 
(Figure 4). Otherwise, psilocybin produced more severe elementary imagery (p < .01) including visual 
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illusions and (pseudo-) hallucinations than ketamine. Notably, no correlation was found between drug-
induced cognitive impairments (impaired control and cognition) and drug-induced perceptual 
alterations (auditory and visual). This speaks against the possibility that drug-induced perceptual 
aberrations induced cognitive impairments. 
 
 
 
Figure 4 Means ± SE of ketamine- (solid line) and psilocybin-induced (dashed line) symptoms relative 
to placebo (dotted line) measured with the revised form of the Altered State of Consciousness (ASC-
R). Note: Significant differences (least significant difference (LSD) test) between drugs at *p < 0.05 
and at **p < 0.01. Symptoms scores were expressed as the percent of scale maximum. The 
abbreviation VR comprised ‘visionary restructuralization’, OB means ‘oceanic boundlessness’, and 
AED stands for ‘anxious ego-disintegration’. Both ketamine and psilocybin increased the global ASC 
score relative to placebo, but did not differ from each other. Ketamine produced higher score than 
psilocybin for auditory alterations, disembodiment, and impaired control and cognition. Otherwise, 
psilocybin produced higher score for elementary imagery than ketamine. No correlation between drug-
induced cognitive impairments (impaired control and cognition) and drug-induced perceptual 
alterations (auditory and visual) was found. 
 
Linking MMN slope and drug-induced symptoms 
 
We assessed the relation between MMN slope under “baseline” (drug-free) conditions at frontal 
electrodes and drug-induced psychopathology by correlating the MMN slope under placebo with each 
Chapter 2  André Schmidt 2012 
39 
symptom rating from the ASC-R questionnaire (under Bonferroni-correction for multiple testing). We 
found a significant correlation between the MMN slope under placebo and ratings pertaining to 
impaired control and cognition (which includes items for disordered thought and loss of control over 
body and thought). Critically, this correlation was significant under ketamine (r = -.67; p < 0.05 
Bonferroni-corrected), but not under psilocybin (r = -.11; p =ns) (Figure 5). Those subjects who 
showed the greatest MMN slope under placebo experienced the lowest ketamine-induced cognitive 
impairments. No other correlations between the MMN slope under placebo and any other drug-
induced symptom was found. 
 
 
 
Figure 5 Relationship between the mismatch negativity (MMN) slope under placebo over frontal 
electrodes and the subscale impaired control and cognition, which includes disordered thought and 
loss of control over body and thought, induced by ketamine (solid line) and psilocybin (dotted line). 
Impaired control and cognition scores are expressed as the percentage of the maximum points 
possible. Notably, the MMN slope under placebo was predictive of ketamine-induced cognitive 
impairments (r = - 0.67; p < 0.05), but not of psilocybin-induced cognitive impairments (r = - 0.11; p = 
NS). 
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Discussion 
 
Our study provides two major results: Firstly, prefrontal PE processing during the roving MMN 
paradigm is disrupted by the NMDAR antagonist S-ketamine, but not by the 5-HT2AR agonist 
psilocybin. Secondly, the processing of PE under placebo predicts the severity of ketamine-induced 
cognitive impairments. In the following, we discuss these findings within a predictive coding framework 
of MMN (Baldeweg, 2006b; Friston, 2005b; Garrido et al., 2009a; Garrido et al., 2009b), relating them 
to putative neurobiological mechanisms for the emergence of cognitive impairments. 
 
According to classical theories (Näätänen, 1992), the MMN potential originates from a network 
comprising the superior temporal gyrus (STG) and the inferior frontal gyrus (IFG) (Garrido et al., 
2008a; Opitz et al., 2002b; Rinne et al., 2000c) which detects a disruption within a regularity of 
preceding standards based on a comparison of the actual sensory input with the already established 
memory trace (Doeller et al., 2003b; Giard et al., 1990). In this study, we have performed an analysis 
in sensor space; since EEG sensor signals result from a mixture of neuronal sources, one should be 
cautious about relating our findings to neural sources in specific locations. In other words, an MMN 
effect observed at frontal electrodes must not necessarily correspond to a frontal source, and the 
following discussion should be read with this caveat in mind. 
Consistent with other reports using a “roving” oddball design (Baldeweg et al., 2004; Haenschel et al., 
2005), a MMN memory trace effect was found in the present study over the frontal cortex; however, no 
comparable effect was detected over temporal cortical regions. The absence of a temporal MMN 
memory trace effect suggests that the adaptation hypothesis (Jääskeläinen et al., 2004b), which posits 
that the MMN results from local neuronal adaptation in the auditory cortex, cannot easily explain the 
MMN memory trace effect found in the present study. Instead, the frontal MMN memory trace effect 
may be more plausible understood as a marker of PE caused by the deviation from a learned 
regularity. This interpretation would be in line with the model adjustment hypothesis (Näätänen and 
Winkler, 1999; Winkler et al., 1996). However, another roving MMN study in healthy volunteers (which 
focused on MMN amplitudes in reference to the 6th standard and did not quantify memory trace 
effects) used dynamic causal modeling and Bayesian model selection to suggest that the model 
explaining MMN amplitude best was a combination of the adaptation and model adjustment 
hypotheses. This model accommodates intra-areal adaptation within the STG combined with plasticity 
of inter-areal connections between temporal and frontal regions (Garrido et al., 2008a). The authors 
explicitly interpreted their findings within the predictive coding framework, emphasizing that this theory 
includes both adaptation and model adjustment in the sense that “model adjustment” corresponds to 
the adjustment of a generative model of future stimuli and “adaptation” corresponds to local changes 
in post-synaptic gain (Garrido et al., 2008a). Thus, from this perspective, the MMN would arise from a 
failure to predict bottom-up input and suppress the resulting PE (Garrido et al., 2008a; Garrido et al., 
2009b). 
 
As previously reported (Heekeren et al., 2008; Umbricht et al., 2000), the temporal MMN (TP7/TP8) 
was not significantly altered by S-ketamine in this study, although this lack of effect may have resulted 
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from the chosen nearby mastoid (TP9/10) reference, which might mask a drug effect on this 
component. However, similar to the present study, no disruption of the temporal MMN was observed in 
schizophrenic patients versus healthy controls in two recent studies using the nose as reference and 
applying a similar “roving” paradigm as used in the present study (Baldeweg et al., 2004; Sato et al., 
2003). In contrast to S-ketamine’s lack of effect on temporal MMN, our study found that S-ketamine 
did disrupt the frontal MMN, which is consistent with previous human studies using different MMN 
paradigms (Heekeren et al., 2008; Umbricht et al., 2000). Here we extend these previous findings by 
showing that S-ketamine not only reduced the MMN amplitude, but also disrupted the frontally 
generated MMN memory trace effect compared to placebo. A similar reduction of the frontal memory 
trace effect was observed in schizophrenic patients (Baldeweg et al., 2004). This finding, together with 
the established importance of the NMDAR for synaptic plasticity during perceptual learning (Kandel, 
2001b; Morris et al., 1986), fits nicely to the role which neurobiologically specific predictive coding 
theories of MMN have assigned to NMDAR-dependent plasticity. In these theories (Friston, 2005b; 
Stephan et al., 2006), NMDAR-dependent short-term plasticity is critical for adjusting the strength of 
glutamatergic synapses connecting hierarchically related cortical areas during perceptual learning. 
Computationally, this synaptic adjustment is driven by the magnitude of trial-wise PEs in lower-level 
structures, leading to adjustment of predictions generated by higher-level structures. From this 
perspective, our finding of a reduced frontal MMN memory trace may reflect the drug-induced 
perturbation of NMDAR-dependent plasticity of temporo-frontal (forward) connections that serves to 
adjust PE message passing between the superior temporal gyrus (STG) and the inferior frontal gyrus 
(IFG) during MMN generation (Garrido et al., 2008a; Opitz et al., 2002b). In other words, the disruption 
of frontal MMN by S-ketamine may result from a deficient adjustment of prefrontally generated 
predictions about temporal inputs due to insufficient PE-dependent plasticity of forward connections. 
We will examine the plausibility of this potential mechanism in future modeling studies. However, the 
present data cannot fully exclude that increased AMPA receptor conductance following NMDAR 
blockade (Shi and Zhang, 2003) or downstream effects on the dopaminergic system (Kapur and 
Seeman, 2001; Vollenweider et al., 2000) may also have contributed to the present findings. Indeed, 
in the context of predictive coding accounts of psychosis, it was suggested recently that both NMDAR 
(for backward connections) and AMPAR (for forward connections) contribute to conveying prediction 
error information (Corlett et al., 2009). In contrast, the empirical data from studies examining the MMN 
under dopaminergic manipulations indicate that dopamine does not modulate the MMN 
(Korostenskaja et al., 2008; Leung et al., 2007; Leung et al., 2010). 
 
Some symptoms frequently observed in schizophrenia are not typically interpreted within a Bayesian 
framework and are usually examined from different perspectives. For example, this include deficits in 
early information processing as indexed by measures as prepulse inhibition of startle reflex or the P50 
auditory evoked potential suppression (Braff et al., 2001; Turetsky et al., 2007). In this context, it has 
been recently suggested that in schizophrenic patients deficits in early sensory processing may 
explain the observed reduction in MMN (Leitman et al., 2010). If one accepts S-ketamine as a valid 
model of schizophrenic symptoms, then this may be seen as a challenge for to our findings. However, 
given that physical differences between deviant and standard tones were independent of the number 
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of standard tones in the roving paradigm and that the difference in the effect of ketamine vs. placebo 
on the MMN trace effect became more pronounced with longer trace length, it seems unlikely that a 
pure deficit in early sensory processing could account for the ketamine-induced disruption of the MMN 
memory trace effect. This interpretation is further supported by a lack of correlation between ketamine-
induced auditory alterations and the generation of the MMN memory trace effect. 
 
Contrary to S-ketamine, the 5-HT2AR agonist psilocybin neither reduced the MMN amplitude- nor the 
MMN memory trace effect, which is consistent with a previously reported lack of psilocybin on MMN 
measured by a classical paradigm (Umbricht et al., 2003). Similarly, a recent MMN study with S-
ketamine and the 5-HT2AR agonist DMT showed that the frontal MMN was only affected by S-
ketamine and not by DMT (Heekeren et al., 2008). Although 5-HT2AR seems to be involved in different 
forms of working memory (Williams et al., 2002) and 5-HT2AR agonists such as LSD or DOM 
enhanced associative learning as measured by eyeblink conditioning in rabbits (Harvey, 2003), the 
implicit perceptual learning as indexed by the frontal memory trace effect appeared not to be sensitive 
to manipulations of the 5-HT2AR system (or to the dose of psilocybin used in this study). While, it has 
been proposed that neuromodulators like serotonin may influence the processing of PE (Corlett et al., 
2009) and may be one of the key modulators interacting with NMDARs to produce aberrant synaptic 
plasticity in schizophrenia (Stephan et al., 2009a), this does not necessarily contradict our findings 
since such a putative role of serotonin could be expressed in a regionally specific fashion (i.e., in other 
circuits than the auditory system) and may thus not be a critical factor in PE processing during the 
MMN paradigm (cf. Garrido et al, 2009). 
 
Furthermore, we also explored whether ketamine- or psilocybin-induced symptoms could be predicted 
by the MMN slope (in the absence of any drug) (i.e., under placebo); in other words, we used two 
pharmacological models of psychosis to relate individual “baseline” physiology to his/her 
predisposition to develop psychotic symptoms under pharmacological challenge. This approach is 
inspired by the general notion that the development of psychiatric disease may result from the 
interplay between the (genetically determined) susceptibility of an individual and the expose to 
environmental stressors (Brown, 2011) and follows previous studies which examined whether 
physiological markers can predict the individual degree of psychotic symptoms in drug-induced 
psychosis and schizophrenia (Corlett et al., 2006; Honey et al., 2008; Krystal et al., 2003; Umbricht et 
al., 2002). Here, we found that the MMN slope under placebo showed a negative correlation with the 
subsequent ketamine-induced extent of cognitive impairments across subjects; in contrast, no 
comparable relationship was found for psilocybin. While this result is in accordance with Umbricht’s 
MMN study (Umbricht et al., 2002), it may not appear to be fully consistent with the results by Corlett 
et al (2006) who found that frontal PE signals under placebo, measured during an associative learning 
task with fMRI, exhibited a positive correlation with the severity of positive symptoms (delusions, 
perceptual aberrations) under ketamine. However, the results from the two studies are not directly 
comparable due to a number of major methodological differences, including different symptom rating 
scales, different ketamine dosage and application regimes, different measurement techniques (fMRI 
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vs. EEG) and, perhaps most importantly, fundamentally different cognitive paradigms. Still, one may 
wonder why individual MMN slope under placebo should predict ketamine-induced cognitive 
impairments (rather than other symptoms). This can be understood by considering that ketamine 
disrupts (short- and long-term) NMDAR mediated synaptic plasticity which is a crucial mechanism for 
PE dependent learning (for review, see Stephan et al. 2006). This is relevant for understanding 
cognitive impairments or “negative symptoms”, such as thought disorder, in schizophrenia because 
“many, if not all, of them can also be understood as a consequence of aberrant modulation of synaptic 
plasticity” (Stephan et al., 2009a). In brief, if one is endowed with inadequate PE dependent learning 
(due to NMDAR related deficiencies) one may be impaired in learning about the statistical structure of 
the (social and physical) environment and adapting one’s beliefs and behavior accordingly. This could 
explain a wide range of symptoms, from social withdrawal and apathy to thought disorders and 
aberrant perceptual inference (see Stephan et al, 2009 for details). On the other hand, the magnitude 
of the MMN slope can be seen as expressing the individual capacity for PE dependent learning, i.e., 
how trial-wise “surprise” about a deviant induces NMDAR dependent short-term plasticity to update 
predictions about the next trial. In other words, MMN slope may serve as an index of individual 
capacity of utilizing PEs for adaptive cognition through NMDAR dependent plasticity. From this 
perspective, one would predict that the higher this individual capacity in the drug-free state (i.e., the 
higher the MMN slope under placebo), the less pronounced the effects of ketamine on PE dependent 
learning and subsequent aberrations in adaptive cognition. This is what we found.  
 
To conclude, the present results suggest that the frontal MMN memory trace effect may provide a 
useful approach to study NMDAR- dependent PE processing during the MMN as a form of implicit 
perceptual learning. Unraveling the role of NMDAR function in predictive coding may provide valuable 
insights into pathophysiological mechanisms of schizophrenia in general and the emergence of 
cognitive impairments in psychosis in particular. This may particularly benefit from a computational 
modeling approach which uses physiologically interpretable model parameters for clinical predictions 
(Stephan et al., 2006). In relation to this, recent studies demonstrated that a reduction of MMN can 
predict the transition of “ultra-high risk” to first-episode psychosis (Bodatsch et al., 2010; Shin et al., 
2009). Finally, the assessment of the MMN memory trace effect may also provide a promising tool to 
assess the efficacy of novel pharmacological treatment, in particular for treatment of cognitive 
impairments. 
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Abstract 
 
This paper presents a model-based investigation of the mechanisms that underlie the well-established 
reduction of mismatch negativity (MMN) amplitudes under NMDA receptor (NMDAR) antagonists, 
such as ketamine. We used dynamic causal modeling (DCM) and Bayesian model selection (BMS) to 
analyze data from a recent study by Schmidt et al. (2011) of event-related responses (ERPs) in 
healthy volunteers during a roving MMN paradigm, with ketamine applied in a cross-over double-blind 
placebo-controlled fashion. Our modeling was guided by a predictive coding framework that unifies 
contemporary “adaptation” and “model adjustment” explanations for the MMN. To this end, we 
compared a series of alternative dynamic causal models that allowed for different expressions of 
neuronal adaptation and synaptic plasticity, respectively. Under these models, we obtained three 
major results. (i) We replicate previous DCM results from non-pharmacological MMN studies that both 
adaptation and short term plasticity are necessary to explain MMN generation per se. (ii) We find 
significant ketamine effects on synaptic plasticity, but not adaptation, and observe a selective 
ketamine effect on the forward connection from left primary auditory cortex to left superior temporal 
gyrus. (iii) This model-based estimate of ketamine effects on synaptic plasticity correlates significantly 
with ratings of ketamine-induced impairments in cognition and control over subjects. Altogether, 
although the model employed here represents a simple neural mass formulation and leaves 
opportunities for future refinement, it suggests a concrete mechanism for ketamine effects on MMN 
expression that correlates with drug-induced psychopathology. More generally, the present study 
demonstrates the potential of model-based approaches for inferring on synaptic mechanisms of brain 
responses, and their pharmacological modulation, from non-invasive EEG data. 
 
Key words: MMN, NMDA receptor, effective connectivity, dynamic causal modeling, DCM, Bayesian 
model selection, BMS 
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Introduction 
 
The mismatch negativity (MMN) is an event-related response (ERP) component, measured with 
electrophysiological techniques such as electroencephalography (EEG) or magnetoencephalography 
(MEG), observed in response to the violation of a statistical regularity. Operationally, it is defined as 
the difference waveform obtained by subtracting the ERP to predicted (“standard”) stimuli from 
unpredicted (“deviant”) stimuli. While it has been studied most intensively in the auditory domain, it has 
also been elicited using visual and somatosensory stimuli (Astikainen et al., 2004; Czigler et al., 2004). 
Ever since its initial description in 1978 (Naatanen et al., 1978), the MMN has played an increasingly 
important role in cognitive neuroscience. Traditionally, it was seen to reflect a basic process of 
memory trace formation (Naatanen et al., 2001), which enables automatic, pre-attentive novelty or 
change detection (Tiitinen et al., 1994; Naatanen, 2000). More recently, the MMN has been interpreted 
as a electrophysiological index of surprise or prediction error (PE) and treated as a paradigmatic 
example of perceptual inference and learning within a general hierarchical Bayesian framework of 
brain function, namely, predictive coding (Rao and Ballard, 1999; Friston, 2005) that can be regarded 
as an instance of the free energy principle (Friston, 2009). 
Beyond cognitive neuroscience and theories of brain function, the MMN has attracted a lot of attention 
because it is altered in several brain disorders (Naatanen, 2003) with, in particular, significant 
reductions in schizophrenia patients (Javitt et al., 1998; Baldeweg et al., 2002; Baldeweg et al., 2004; 
Umbricht and Krljes, 2005; Stephan et al., 2006). The MMN is well-suited as a potential index of 
pathophysiology because it can be obtained with relatively little effort, and is robust against a number 
of factors that can confound the interpretation of diagnostically relevant measures from cognitive 
paradigms, such as attentional state or vigilance (Naatanen et al., 2001). Moreover, the MMN appears 
to detect the transition of ‘ultra-high risk’ to first-episode psychosis (Shin et al., 2009; Bodatsch et al., 
2010; Atkinson et al., 2011; Orosz et al., 2011), suggesting the potential of the MMN for predicting 
psychosis risk and progress stages. The clinical utility of the MMN is further established by remarkably 
consistent findings from neuropharmacological studies, rendering it potentially informative with regard 
to pathophysiology and treatment: Over the past two decades, numerous pharmacological 
experiments in animals and humans have indicated that MMN expression can be strongly reduced by 
antagonizing NMDA receptors (NMDAR) (Javitt et al., 1996; Umbricht et al., 2000; Kreitschmann-
Andermahr et al., 2001; Ehrlichman et al., 2008; Heekeren et al., 2008). 
 
Understanding the NDMAR dependence of the MMN is best pursued within a comprehensive theory of 
the physiological and computational mechanisms that generate MMN responses. One such theory is 
the so-called adaptation hypothesis, which postulates that the MMN arises from adaptation 
mechanisms in tonotopically organized parts of the auditory system; i.e., neurons in primary auditory 
cortex that are repeatedly excited by auditory stimuli of the same frequency (May et al., 1999; 
Jaaskelainen et al., 2004; Ulanovsky et al., 2004). Biophysically, this appeals to mechanisms such as 
rapid synaptic depression (Zucker and Regehr, 2002) or spike frequency adaptation (Faber and Sah, 
2003). An alternative perspective on MMN mechanisms is the model adjustment hypothesis which 
views the MMN as a response reflecting the update of an environmental model that is represented by 
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a network of temporo-frontal areas and reconfigures in the light of unexpected sensory events (Winkler 
et al., 1996; Winkler, 2007). Neurophysiologically, this theory speaks to the importance of short-term 
plasticity of glutamatergic long-range connections between temporal and frontal areas. More recently, 
a free-energy theory of the MMN was formulated that unifies both the adaptation and model 
adaptation hypothesis and suggests an overarching physiological and computational process that 
requires both adaptation that is intrinsic to cortical sources and short-term plasticity in extrinsic 
connections between sources (Garrido et al., 2008; Garrido et al., 2009b; Garrido et al., 2009a). This 
theory interprets the MMN as a prediction error signal (generated by pyramidal neurons in 
supragranular layers) during predictive coding in the auditory processing hierarchy, where each level 
attempts to minimize the discrepancy between bottom-up inputs from the level below and top-down 
predictions from the level above. By recurrent message passing across levels and prediction error-
dependent synaptic plasticity, this circuit achieves minimizes free-energy (an approximation to the 
information theoretic measure of surprise) across the entire hierarchy, enabling inference about the 
causes of sensory input and optimal learning about statistical regularities (Friston, 2009). Importantly, 
the free-energy theory of the MMN incorporates the two key physiological mechanisms implied by the 
two previous theories: local adaptation and short-term plasticity of inter-regional glutamatergic synaptic 
connections. The former controls the post-synaptic gain of neurons encoding prediction error (such 
that inputs with low precision or high uncertainty have less impact on predictions), while the latter 
optimizes inter-regional synaptic weights during learning and thus regulates the transmission of 
predictions and their errors across the hierarchy.  
While the free energy principle is a very generic theory of brain function (Friston, 2010), it has been 
particularly useful for framing studies of MMN mechanisms. Of particular relevance for the present 
study is that both of the key processes described above – adaptation and short-term plasticity of 
glutamatergic connections – are regulated by NMDARs. The free energy formulation thus offers an 
opportunity to address the question, from a model-based perspective, which synaptic mechanism may 
underlie the empirically well-established NMDAR-mediated reduction of the MMN. It is conceivable 
that this effect could be expressed entirely at the level of neuronal adaptation because spike 
frequency adaptation results from potassium channel dependent hyperpolarization which, in turn, 
relies on intracellular calcium influx that is modulated by NMDAR status (Faber and Sah, 2003). On 
the other hand, it is equally conceivable that the NMDAR-mediated MMN reduction results from 
aberrant short-term plasticity of inter-regional glutamatergic connections. This is because activation of 
NMDARs can lead to rapid changes in the strength of glutamatergic synapses, e.g. via 
phosphorylation of AMPA receptors (AMPARs) (Wang et al., 2005). A third option is that both 
mechanisms contribute to empirically observed NMDAR effects on MMN expression.  
 
Clearly, these competing accounts cannot be disentangled by traditional ERP analyses that rely on 
simple subtraction of evoked responses. Instead, we need to evaluate the relative plausibility of 
different physiologically interpretable models that can be fitted to empirically measured MMN 
responses. This allows us to assess the relative contributions from adaptation and short-term plasticity 
of glutamatergic connections, and how they change under NMDAR antagonists. A general framework 
for model-based assessment of competing theories about neuronal circuits is dynamic causal 
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modelling (DCM; (Friston et al., 2003; Stephan et al., 2010)). DCM is a generic Bayesian system 
identification technique that has gained popularity in neuroimaging and electrophysiology over the past 
few years and allows for inference on “hidden” neurophysiological mechanisms that generated 
observed measures, such as blood oxygen level dependent (BOLD) signal in fMRI or evoked 
responses measured with EEG. The key idea here is to formulate a simplified model of neuronal 
population responses and combine this with a modality-specific forward model such that one can 
predict the measurement that would arise from any particular neuronal circuit. Given such a generative 
model and known experimental perturbations (stimuli), one can invert the model and thereby compute 
the posterior probability of the model parameters, given the data. Furthermore, alternative models 
embodying competing hypotheses about the mechanisms generating the data can be evaluated using 
their model evidence, a principled measure of the balance between model fit and model complexity 
(Penny et al., 2004). While DCM has been formulated for different modalities (cf. (Kiebel et al., 2009; 
Stephan et al., 2007)), its current implementation for ERPs represents a neural mass formulation of 
interacting cortical sources (David et al., 2006), with distinct representations of adaptation and 
synaptic plasticity that have proven very useful in previous MMN studies (Kiebel et al., 2007a; Garrido 
et al., 2008; Garrido et al., 2009b). In this paper, we use this implementation of DCM for inferring on 
the physiological mechanisms that underlie empirically measured reductions of MMN amplitude under 
the influence of the NMDAR antagonist ketamine. The data analyzed here were from a recent study by 
Schmidt et al. (2011) who examined 19 healthy volunteers with a roving MMN paradigm (Haenschel et 
al., 2005; Garrido et al., 2008) on two sessions, using a cross-over double-blind placebo-controlled 
design. As previously reported, the ERP analyses of these data indicated a significant reduction of the 
MMN at fronto-central electrodes following ketamine administration (Schmidt et al., 2011), which is 
consistent with a number of previously published reports in humans and animals, using conventional 
(non-roving) MMN paradigms (Javitt et al., 1996; Umbricht et al., 2000; Umbricht et al., 2002; 
Heekeren et al., 2008). 
 
In this paper, we apply DCM and BMS to the data from Schmidt et al. (2011) to address the following 
three questions. First, can we replicate the results of previous (non-pharmacological) DCM studies of 
the MMN that evaluated a set of competing models inspired by the free energy formulation (Garrido et 
al., 2008; Garrido et al., 2009b)? Secondly, which of the two mechanisms of interest - intrinsic 
adaptation or extrinsic short-term glutamatergic plasticity - contributes most to explaining ketamine 
effects on MMN expression, and are these mechanisms regionally specific? Finally, can we validate 
our model-based approach by finding a correlation between model parameter estimates and cognitive 
measures altered by ketamine?  
In brief, (i) we replicate previous DCM results from non-pharmacological MMN studies that both 
adaptation and short term plasticity are necessary to explain MMN expression per se, (ii) we find 
significant ketamine effects on synaptic plasticity, but not adaptation, and observe a selective 
ketamine effect on forward connections from left primary auditory cortex, and finally, (iii) we observe a 
significant correlation between ketamine-induced changes in plasticity of auditory forward connections 
and introspective measures of cognition. 
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Methods 
 
The participants, drug administration and data acquisition have previously been described in Schmidt 
et al. (2011) and the interested reader is referred to this paper for details. Here, we summarize the 
most important aspects and provide details of data analysis with DCM and BMS. 
 
Subjects 
 
This study was approved by the Ethics Committee of the University Hospital of Psychiatry, Zurich. 
After receiving written and oral descriptions of the aim of the study, all participants gave written 
informed consent statements before inclusion in the study. The use of psychoactive drugs was 
approved by the Swiss Federal Health Office (BAG), Department of Pharmacology and Narcotics 
(DPN), Bern, Switzerland.  
Healthy subjects were recruited at the local university and technical college through advertisement (N 
= 19; male: 12, mean age = 26 ± 5.09 years). The study of Schmidt et al. (2011) also included a group 
of subjects receiving psilocybin vs. placebo. As no effect of psilocybin on the MMN was found, this 
group was not included in the present study. 
Prior to inclusion, the subjects’ physical health was confirmed by medical history, clinical examination, 
electrocardiography, and blood analysis. To ascertain the subjects’ mental status, all subjects were 
screened by the diagnostic expert system (Wittchen and Pfister, 1997), a semi-structured psychiatric 
interview, and the Hopkins Symptom Checklist (SCL-90–R) (Derogatis, 1994). Furthermore, subjects 
also underwent the Mini-International Neuropsychiatric Interview (M.I.N.I.), a short structured 
psychiatric interview (Sheehan et al., 1998). We verified the absence of a history of drug dependence 
or present drug abuse by urine drug-screening and a questionnaire that assessed previous drug 
consumption. 
 
Drug Administration and Psychometric Assessment of S-ketamine State 
 
Subjects underwent two sessions (placebo and S-ketamine) in a counterbalanced fashion at an 
interval of at least 2 weeks. Both subjects and the principal investigator were blind to drug order. 
Subjects were monitored and under constant supervision until all drug effects had worn off, and were 
then released into the custody of a partner or immediate relative. For the S-ketamine/placebo infusion, 
an in-dwelling catheter was placed in the antecubital vein of the non-dominant arm. Once the subject 
was ready, a bolus injection of 10 mg over 5 min was delivered. Following 1 min break, a continuous 
infusion with 0.006mg/kg per min was administered over 80 minutes. To keep S-ketamine’s plasma 
level fairly constant, the dose was reduced every ten minutes by 10% (Feng et al., 1995; Vollenweider 
et al., 1997). In the placebo session, the same procedure was followed and an infusion of 
physiological sodium chloride solution and 5% glucose was administered. 
The Altered State of Consciousness (ASC) questionnaire, a visual analogue and self-rating scale, was 
used to assess the subjective effects of S-ketamine (Dittrich, 1975; Dittrich, 1998). A recent evaluation 
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study of the ASC questionnaires has constructed eleven new lower order scales (Studerus et al., 
2010), which were analyzed in this study. 
 
Experimental Design 
 
Electroencephalographic (EEG) activity was recorded during an auditory “roving” oddball paradigm, 
originally developed by Cowan and colleagues (Cowan et al., 1993) and subsequently modified by 
Baldeweg et al. (2004), to assess the mismatch negativity (MMN) response. Acoustic stimuli were 
generated using the E-prime software (Schneider et al., 2002), and were presented binaurally through 
headphones (TDH-39-P, Maico, Minneapolis, MN, USA). 
The stimuli consisted of seamlessly connected trains of pure sinusoidal tones with a roving frequency 
structure. Within each stimulus train, all tones were of one frequency and were followed by a train of 
tones of a different frequency. The first tone of a train represented the deviant, which became a 
standard tone after a few repetitions. Therefore, the deviant and standard tones had exactly the same 
physical properties within one stimulus train, differing only in the number of times they had been 
presented in the recent past. The number of times the same tone was presented within one stimulus 
train varied pseudo-randomly between one and eleven (t = 1-11). The probability that the same tone 
was presented in one stimulus train was (i) 2.5% for trains with 1 or 2 identical tones, (ii) 3.75% for 
trains with 3 or 4 identical tones, and (iii) 12.5% for trains with 5-11 identical tones. In other words, 5% 
of all stimulus trains consisted of 1-2 identical tones, 7.5% of all stimulus trains consisted of 3-4 
identical stimuli, and 87.5% of all stimulus trains consisted of 5-11 identical stimuli. The frequency of 
the tones varied from 500 to 800 Hz in random steps with integer multiples of 50 Hz, tone duration was 
set at 70 ms, and the inter-stimulus interval was 500 ms. 
In parallel, subjects performed a distracting visual task and were instructed to ignore the sounds. This 
follows the suggestion that MMN assessment is optimal when the subject’s attention is directed away 
from the auditory domain (Naatanen, 2000). The task consisted of button-press responses whenever a 
fixation cross changed its luminance, which occurred pseudo-randomly every 2 to 5 s (not coinciding 
with auditory changes). The experimental session lasted approximately 15 minutes. 
 
Data Acquisition and Preprocessing 
 
The EEG was recorded at a sampling rate of 512 Hz using a Biosemi system with 64 scalp electrodes.  
The horizontal electro-occulogram (EOG) was recorded from electrodes attached on the outer canthus 
of each eye. Similarly, the vertical EOG was recorded from electrodes attached infraorbitally and 
supraorbitally to the left eye. 
Pre-processing and data analysis was performed using SPM8 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm8/). Continuous EEG recordings were referenced to the 
average, down-sampled to 300Hz, and bandpass filtered between 0.5 and 30Hz. The data were then 
epoched into 500ms segments using a peri-stimulus window of 100ms. For each subject and in each 
condition, two trial types were defined, the deviant trial (first tone within a new train) and a standard 
trial (operationally defined as the sixth tone, as in Garrido et al. 2008). The artefact rejection procedure 
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used a thresholding approach to detect problematic trials or channels. Trials in which the signal 
recorded at any of the channels exceeded 80 microvolts relative to the pre-stimulus baseline were 
removed from subsequent analysis. Most of the artefacts that were detected reflected vertical and 
horizontal eye-movements, which were monitored using ocular electrodes. The average number of 
artefact-free trials was 124 and 172 for standard and deviant trials in the placebo condition, and 153 
and 207 for standard and deviant trials in the ketamine condition. Grand averages were computed 
using robust averaging, a weighted least squares procedure which incorporates a weighting matrix into 
the estimation so that outlier values exhibit less influence on the overall mean (Wager et al., 2005).  
The data were subject to standard analyses using statistical parametric mapping (SPM) – over 
channels and peristimulus time – to establish condition (standard versus oddball) effects and any 
interaction with ketamine at the between subject level. The same data were then subject to dynamical 
causal modelling in an attempt to explain the differences observed in terms of adaptation and changes 
in extrinsic connectivity. For the SPM analyses, the averaged data from each trial type and each 
condition were converted to scalp images for all 64 channels and 151 time points using a voxel size of 
4.25mm x 5.38mm x 3.33mm. The images were constructed using linear interpolation for (removed) 
bad channels and smoothing to accommodate for between-subject spatial and temporal variability in 
channel space. Dynamic causal modelling was applied to the preprocessed channel data to explain 
observed responses in source states. For computational expediency, all dynamic causal models (see 
below) were computed on a reduced channel space that corresponded to eight channel mixtures or 
spatial modes.  The eight spatial modes were calculated using singular value decomposition (SVD) of 
the channel data over a temporal window of interest.  Following Garrido et al. (2008), the temporal 
window of interest was confined to 0-250ms post-stimulus to ensure selective modelling of the MMN 
response (as opposed to later components). 
 
Dynamic Causal Modelling 
 
Neurophysiologically plausible forward models are essential for understanding how event-related 
potentials (ERPs) are generated. One such approach is dynamic causal modelling (DCM) which was 
originally developed for connectivity analysis of fMRI data (Kiebel et al., 2007b) and was subsequently 
implemented for a range of other data modalities and features, such as ERPs measured by EEG 
(David et al., 2006). DCM uses a biologically informed causal model to make inferences about the 
underlying neural mechanisms that generate observed event-related responses. This approach 
provides an important advance over conventional source reconstruction techniques for ERP data 
because it places neurobiological constraints on the model inversion, in which the parameters of the 
reconstruction have a specific neuronal interpretation. These parameters describe, for example, the 
synaptic coupling strength among sources and post-synaptic gain, and how these properties depend 
upon stimulus attributes or experimental manipulations (David et al., 2006; Kiebel et al., 2006).  
The implementation of DCM for ERPs in SPM8 uses a neural mass model of cortical source (Jansen 
and Rit, 1995) that contains interacting inhibitory and excitatory subpopulations of neurons. 
Specifically, each source is described in terms of the average post-membrane potentials and firing 
rates of three neuronal subpopulations of pyramidal cells, spiny-stellate cells and inhibitory 
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interneurons. The cortical sources are linked by forward, lateral and backward connections (Linn et al., 
1999) and conform to a hierarchical model of intrinsic and extrinsic connections within and between 
multiple sources as described in previous studies (David et al., 2005; Nee et al., 2007).  
In order to estimate the model parameters that best explain how the observed data were generated, 
DCM inverts a spatio-temporal model covering all sensors or spatial modes and the temporal window 
of interest. The neural parameters describe synaptic connectivity strengths, post-synaptic gain, 
propagation delays among sources and various synaptic rate constants. The spatial parameters, on 
the other hand, specify the location and orientation of equivalent current dipoles. We used a four 
concentric sphere head model with homogenous and isotropic conductivity as an approximation to the 
brain, the cerebrospinal fluid (CSF), skull and scalp surfaces. We specified an equivalent current 
dipole (ECD) model with uninformed priors about the dipole orientations and informed priors about the 
source locations (Penny, 2011), using the same coordinates as Garrido et al. (2008) for defining prior 
surface location means with a prior variance of 16 mm2. The moment (orientation) parameters had 
prior means of zero and a variance of 256 mm2 in each direction, which is equivalent to assuming 
uninformed priors on the orientations of the dipoles. 
Bayesian inversion of the combined neuronal and spatial model provides a posterior distribution for 
each parameter whose variance represents the uncertainty about the parameter after observing the 
data. Furthermore, the uncertainty about the model itself is addressed using Bayesian model 
comparison based on an approximation to the model evidence. These procedures are explained in 
detail elsewhere (Penny et al. 2004; Stephan et al. 2009) and are briefly summarized below. 
 
Model specification 
 
DCM is a hypothesis driven method that does not explore all possible models, but tests a specified 
model space based on prior knowledge about the system of interest. The network architectures that 
we tested in the present study were motivated by the results of previous MMN examinations (Doeller 
et al., 2003; Garrido et al., 2008; Grau et al., 2007; Opitz et al., 2002; Rinne et al., 2000). These 
studies suggest that the main cortical generators of the MMN include bilateral primary auditory cortex 
(A1), bilateral superior temporal gyrus (STG) and the right inferior frontal gyrus (IFG). The coordinates 
used for specification of our ECD model were informed by the above studies and identical to the ones 
previously used by Garrido et al. (2008) in the original DCM examination of the roving MMN. 
In this study, we compared 8 distinct models that might underlie the generation of MMN in response to 
a deviant tone. These models were created by systematic combinations of the two key mechanisms 
proposed by predictive coding schemes under the free-energy principle. The first mechanism was 
short-term plasticity of glutamatergic long-range connections. In DCMs of the MMN, this is typically 
modeled by allowing for a modulation of the synaptic coupling strength of inter-regional forward and 
backward connections when the deviant tone is presented (cf. (Garrido et al., 2008; Garrido et al., 
2007). The corresponding DCM parameters express (as a multiplicative factor or scaling coefficient) 
the coupling change relative to the standard tone. We allowed for different expression of this type of 
plasticity, creating four models: no modulation of connections by the deviant tone (model 1), 
modulation of either forward or backward connections among A1, STG, and IFG (models 2 and 3), and 
Chapter 3  André Schmidt 2012 
58 
modulation of both forward and backward connections among the three brain regions (model 4). With 
these four models, we hypothesized that the differences between the deviant and the standard are 
caused by short-term plasticity of connections within the temporofrontal network, representing the 
reconfiguration of this network in response to prediction error or surprise (cf. model adjustment). 
The second mechanism represented by our models concerned neuronal adaptation. That is, in models 
5 through 8 we repeated the same variations in synaptic plasticity as for the first 4 models, but 
additionally we allowed for variations in adaptation, expressed in terms of deviant-induced modulation 
of the post-synaptic gain (responsiveness or excitability) in left and right A1 (see Figure 7a). This 
addressed the adaptation hypothesis, which postulates that the MMN arises predominantly from post-
synaptic mechanisms such as spike-frequency adaptation as result of an increase in calcium-
dependent potassium conductance (May et al., 1999; Ulanovsky et al., 2004). In DCMs of the MMN, a 
lumped representation of adaptation mechanisms can be achieved by allowing for a modulation of 
post-synaptic gain parameters (this has previously also been referred to as modulation of “intrinsic 
connections”; (Kiebel et al., 2007a). Thus, models 5 through 8 examine the hypothesis of both fronto-
temporal interactions and local adaptation within A1 as the neural mechanisms underlying the 
generation of the MMN response. 
Overall, the 8 models tested here are similar, but not identical, to the 6 models considered by Garrido 
et al. (2008). We used the same type of DCM, time window (0-250ms), number of spatial modes and 
dimensions of model space (i.e., adaptation and synaptic plasticity). In addition to Garrido et al. 
(2008), however, we also tested models without synaptic plasticity anywhere in the network (models 1 
and 5; Figure 7a) and introduced additional inter-hemispheric connections between A1 and STG, 
respectively, in both hemispheres (Figure 7a). 
 
Statistical analysis 
 
The statistical analyses employed in this paper were based on the standard two-stage (summary 
statistics) approach in DCM, i.e., model selection followed by interrogation of posterior estimates 
(Stephan et al., 2010).  In the first stage, Bayesian model selection (BMS) was used to determine the 
optimal network architecture underlying electrophysiological responses to auditory stimulation. In a 
second stage, posterior parameter estimates were examined to detect differences between placebo 
and ketamine conditions. This second stage used the posterior means averaged over the DCMs of 
each subject (Bayesian model averaging, BMA) as the dependent variables for a multivariate 
Hotelling’s T2 test and subsequent univariate t-tests (see below for details). 
 
Bayesian Model Selection and Bayesian Model Averaging 
 
From a Bayesian perspective, alternative models that represent competing hypotheses about the 
mechanisms generating observed data are evaluated by comparing their (log) evidence. The log-
evidence corresponds to negative surprise about the data or the (log) probability of the data given a 
model. It represents a principled measure, derived from probability theory, of the balance between 
model fit and model complexity. Since it cannot be computed analytically except for linear Gaussian 
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models, approximations to the log-evidence are usually required. The approximation used here is the 
(negative) free energy that provides a bound-approximation on the log evidence and can be obtained 
using Variational Bayes (VB) (Friston et al., 2007).  
The evidence can be decomposed into two components: the accuracy term, which quantifies the data 
fit, and a complexity term which penalizes models with many degrees of freedom (e.g., many and/or 
uninformed parameters). The best model given the data is the one with the largest log model 
evidence, ln p(y|m) (assuming a uniform prior over all models). Models can be compared by 
computing evidence ratios (Bayes factors) or log evidence differences. Following conventional 
classifications (Kass and Raftery, 1995) ), one concludes that there is strong evidence in favour of a 
model if the difference in log evidence is greater than 3 compared to another model (i.e., a Bayes 
factor of 20). 
Furthermore, inference about general characteristics of model architecture can be obtained by using 
family-based inference, which compares sets of models grouped by architectural properties (Heresco-
Levy et al., 2007). In the present study we used family level inference to determine whether 
modulation of post-synaptic gain in bilateral A1 constituted an important addition to the model 
architecture. Thus, we specified two model families, the first without and the second with post-synaptic 
gain modulation present at the level of bilateral A1. We performed family-wise inference, using a 
random effects approach, which is robust to potential outliers in the population (Stephan et al., 2009b). 
Prior to the subsequent analysis of differences in posterior parameter estimates across drug 
conditions, we used Bayesian model averaging (BMA) (Penny et al., 2010) which averages over 
models, weighted by the posterior model probabilities. In this way, BMA provides parameter estimates 
that account for model uncertainty. 
 
Analysis of Model Parameter Estimates 
 
Following BMA, we used the resulting posterior means from the averaged DCMs for examining 
differences in deviant-induced changes in adaptation (post-synaptic gain) and synaptic plasticity 
(parameterized in terms of condition dependent coupling changes) between placebo and ketamine 
conditions. First, we used a multivariate Hotelling’s T2 test, testing whether the two sets of parameter 
estimates encoding neuronal adaptation and short-term synaptic plasticity, respectively, were 
significantly different between ketamine and placebo conditions. This drug-induced difference was 
significant for the parameters representing synaptic plasticity, but not for neuronal adaptation. Based 
on this result we used, in a second step, univariate post-hoc t-tests, asking which of the six forward 
and backward connections in the model contributed individually to explaining the ketamine effects. We 
Bonferroni-corrected the results for the number of parameters tested. Finally, in a third step, we used a 
simple regression analysis to examine the relationship between the model parameters showing 
significant changes under ketamine and the independent ratings on the ASC questionnaire after 
ketamine administration.
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Results 
 
MMN responses due to repetition effects 
 
A conventional analysis of MMN amplitudes and latencies from this group of subjects has been 
presented by Schmidt et al. (2011). Here, we complement these analyses by a spatiotemporal 
characterization of the MMN response using statistical parametric mapping (in sensor space) and 
whole-brain correction for multiple tests (family-wise error correction using Gaussian random field 
theory as implemented in SPM8). The goal of this initial analysis was to verify the presence of a MMN 
response for each subject and each condition, prior to subsequent modeling. Two out of 19 subjects 
failed to show a significant MMN response in both placebo and ketamine conditions, and were 
therefore excluded from subsequent DCM analyses. In the placebo condition, the MMN response was 
observed over frontal and central electrodes between 110 and 220 ms. Figure 1 illustrates the grand 
mean responses averaged across all subjects in the placebo condition, comparing responses to 
“deviant” trials (first tone within stimulus trains, dashed lines) with responses to “standard” trials (sixth 
tone, solid black lines). 
 
 
 
Figure 1 Grand average ERP responses in the placebo condition to the sixth tone of stimulus trains 
(“standard tone”; black line) and the first tone of stimulus trains (“deviant” tone; dashed line) across 
frontal and central electrodes. 
 
The MMN response peaked at 177ms from tone onset, which is consistent with previous studies 
(c.f.,(Cowan et al., 1993; Fletcher and Frith, 2009; Garrido et al., 2008). Figure 2 shows a 3D 
spatiotemporal characterization of the MMN response using statistical parametric mapping to compare 
the deviant to the standard tones in the placebo condition. The analysis was performed across the 
entire epoch [-100 400] and over all 64 channels. As noted above, for these analyses the scalp 
topography at any time-bin was interpolated from 64 channels and smoothed. Figure 2 shows the 
statistical parametric map (SPM) where, over subjects, there is a significant negative amplitude 
deflection as a result of the deviant tone [t (32) = 5.26, p < 0.05, family-wise error corrected]. This 
result suggested a significant MMN response over bilateral frontal channels between 160 and 180ms 
with maximum at 180 ms. 
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Figure 2 Spatiotemporal representation of the MMN response in the placebo condition: comparison 
between the first and the sixth tone presentations, the “deviant” and the “standard”, respectively. SPM 
analysis was performed across all 64 channels and across the entire epoch [-100 400]. The SPM 
results show a significant negative difference over bilateral frontal electrodes in the range of 160 and 
180 ms, peaking at 177 ms. 
 
In the ketamine condition, we also observed a MMN response over frontal and central electrodes 
between 110 and 220 ms. Figure 3 shows the grand mean responses across all subjects in the 
ketamine condition in response to the deviant tone (dashed lines) compared to the standard tone 
(grey). 
 
 
 
Figure 3 Grand average ERP responses in the ketamine condition to the sixth tone of stimulus trains 
(“standard tone”; black line) and the first tone of stimulus trains (“deviant” tone; dashed line) across 
frontal and central electrodes. 
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In the ketamine condition, the MMN response was also seen in right frontal channels between 140 and 
160ms with a maximum at 150ms [t (32) = 5.25, p < 0.05 FWE]. A late response was observed on the 
ketamine as well, peaking at 390ms in central electrodes. 
 
 
Figure 4 Spatiotemporal representation of the MMN response in the ketamine condition: comparison 
between the first and the sixth tone presentations, the “deviant” and the “standard”, respectively.  SPM 
analysis was performed across all 64 channels and across the entire epoch [-100 400].  Similarly to 
the placebo group, the SPM results show a significant negative difference over right frontal electrodes 
in the range of 140 and 160 ms, peaking at 150 ms. 
 
Importantly and in accordance with previous studies, the MMN response was significantly attenuated 
in the ketamine compared to the placebo condition. Figure 5 illustrates the difference waveform, which 
contrasts the deviant tone to the standard tone, in placebo and ketamine conditions. In the placebo 
condition, the MMN response was larger over frontal and central electrodes between 150 and 180ms 
and between 220 and 300ms. 
 
 
 
Figure 5 Grand average difference waveform in placebo (black line) and S-ketamine (grey line) 
conditions across frontal and central electrodes. 
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A paired SPM t-test was performed in order to compare the MMN (differences between standard and 
oddball tones) between placebo and ketamine conditions. Significant differences between the MMN 
under placebo and ketamine conditions were observed [t (16) = 3.68, p < 0.05 corrected for a search 
volume defined by the main effect of MMN] in fronto-central and central electrodes between 220 and 
240ms with a maximum at 230ms. See Figure 6. These results confirm that the MMN response was 
significantly larger in the placebo compared to the ketamine condition. 
 
 
 
Figure 6 Spatiotemporal representation of the effect of S-ketamine administration: comparison 
between placebo and S-ketamine conditions. SPM analysis was performed across all 64 channels and 
across the entire epoch [-100 400]. The SPM results show a significantly larger MMN response in the 
placebo condition compared to the S-ketamine condition over frontal and central electrodes in the 
range of 220 and 240 ms, peaking at 230 ms. 
 
DCMs of the MMN response 
 
As described in the Methods section, we defined a space of 8 models systematically combining 
mechanisms of adaptation in A1 with synaptic plasticity expressed by different extrinsic connections of 
our temporo-frontal network. Random effects BMS indicated that the model with plasticity in forward 
and backward connections as well as adaptation (expressed via post-synaptic gain modulation in A1) 
had the largest model evidence and was clearly superior to all other models at the group level 
(exceedance probabilities >80% for placebo and >70% for ketamine; see Fig. 7a-c).  
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Figure 7: Model specification. (A) The 8 DCMs used for Bayesian model comparison.  Auditory input 
first affects primary auditory cortex, from where activity is propagated to the remaining sources. Dotted 
lines indicate which model allow for adaptation and synaptic plasticity that are expressed as 
modulation in post-synaptic gain and effective connectivity for deviant vs. standard tones, respectively. 
(B and C) Random effects Bayesian model selection showed that the model with synaptic plasticity 
(modulation of connection strength) in both forward and backward connections as well as adaptation 
in A1 (post-synaptic gain modulation) had the greatest evidence for both placebo and ketamine 
conditions. (D and E) Family-wise Bayesian model selection showed that the presence of adaptation 
(post-synaptic gain modulation) improved models considerably, regardless of the presence of synaptic 
plasticity. (F and G) Family-wise Bayesian model selection showed that the presence of synaptic 
plasticity improved models considerably, regardless of the presence of adaptation. 
 
Furthermore, we exploited the factorial nature of our model space to examine the importance of each 
mechanistic factor (adaptation and synaptic plasticity, respectively) on its own. Random effects family-
level BMS showed that “adaptation models” that allowed for post-synaptic gain modulation in A1 
(models 5-8) were generally superior to models without adaptation (models 1-4) in both placebo and 
ketamine conditions (exceedance probabilities >99%), regardless of synaptic plasticity elsewhere in 
the model (Figs. 7d and 7e). Conversely, models which allowed for the expression of synaptic 
plasticity at inter-regional connections (models 2-4, 6-8) were generally superior to models without 
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such plasticity (models 1 and 5) in both placebo and ketamine conditions (exceedance probabilities 
>99%), regardless of whether the model included adaptation or not (Figs. 7f and 7g). 
 
Effects of ketamine 
 
To examine the effects of ketamine on mechanisms underlying the NMDAR-dependence of the MMN 
response, we compared the parameter estimates from subject-specific DCMs that were averaged 
(using BMA) separately for placebo and ketamine conditions. First, we used a multivariate Hotelling’s 
T2 test to examine whether the distinct sets of parameter estimates encoding neuronal adaptation and 
short-term synaptic plasticity, respectively, were significantly different between ketamine and placebo 
conditions. This drug-induced difference was significant for the parameter set representing synaptic 
plasticity (T = 14.771 with p<0.023), but not for the parameter set representing neuronal adaptation (T 
= 0.217 with p = 0.897). In other words, while adaptation was critical for explaining the MMN (see 
above), it did not change under ketamine compared to placebo. Based on this result we used, in a 
second step, univariate post-hoc t-tests, asking where in the network synaptic plasticity was affected 
by ketamine (i.e., at which of the six forward and backward connections in the model). We found a 
significant reduction of synaptic plasticity, following ketamine administration, of the forward connection 
from left A1 to left STG (see Fig. 8 and Table 1). In other words, under placebo, the left A1→STG 
connection almost doubled in strength when a deviant tone was presented; in contrast, under 
ketamine, this increase was almost absent (Figure 8; note that the modulatory parameters in DCM for 
ERPs are scaling coefficients, not additive contributions as in DCM for fMRI). 
 
Table 1 Paired T test results: Reductions in forward and backward modulation in the ketamine 
compared to the placebo condition. 
 
*FWE p < 0.05 
 
Notably, this effect of ketamine on synaptic plasticity remained significant after Bonferroni-correction 
for multiple comparisons (t=4.60, p<0.001). Furthermore, there was a trend towards a significant 
reduction in the forward connection from the right A1 to the right STG (t=1.55, p = 0.14).  
 
 
  Postsynaptic 
Modulation 
Foward Connections Backward Connections  
  left A1 > 
left A1 
right A1 > 
right A1 
left A1 > 
left STG 
right A1 > 
right STG 
right STG 
> right IFG 
left STG > 
left A1 
right STG > 
right A1 
right IFG > 
right STG 
Z 0.672 0.310 3.148 1.728 1.065 0.114 1.136 0.284 
Sig. 
(2-
tailed) 
0.501 0.756 0.001* 0.084 0.287 0.910 0.256 0.776 
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Figure 8 The plasticity of the forward connection from the left A1 to the left STG was significantly 
reduced after ketamine administration (p < 0.001). The y-axis denotes the average value (± SD) of the 
scaling parameter that indicates changes in connection strength for deviant vs. standard tones. 
 
Finally, we related this selective effect of ketamine on plasticity of the left A1→STG connection to the 
impact of ketamine on subjects’ ASC-R questionnaire scores. Specifically, Schmidt et al. (2011) had 
reported an effect of ketamine on the “control and cognition” subscale of the ASC, and we now tested, 
using a simple linear regression analysis, whether this effect of ketamine might be explained through 
its effects on plasticity of the left A1→STG connection. Indeed, there was a significant linear relation 
between drug effects on “control and cognition” ratings (score under ketamine minus score under 
placebo) and drug effects on plasticity (ratios of condition-specific changes in coupling, i.e. Relative 
plasticity under ketamine vs. placebo) of the left A1→STG connection (F= 4.45, p < 0.006). 
 
 
 
Figure 9 Figure 9: Linear regression indicated a significant relation between drug effects on “control 
and cognition” ratings (score under ketamine minus score under placebo) and drug effects on plasticity 
(ratios of modulatory scaling factors, i.e. % plasticity under ketamine vs. placebo) of the left A1→STG 
connection (F= 4.45, p < 0.006). 
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Discussion 
 
In this paper we present a model-based investigation of the physiological mechanisms that underlie 
the well-established reduction of the MMN following administration of the NMDAR antagonist 
ketamine. Specifically, we used DCM and BMS to analyze data from a recent study by Schmidt et al. 
(2011) of healthy volunteers during a roving MMN paradigm with a cross-over double-blind placebo-
controlled design. In the following, we summarize the results of our model-based investigations, 
discuss their implications and consider potential limitations of our study. 
 
In a first step, we verified that we could replicate the results of a previous DCM study of the roving 
MMN paradigm (Garrido et al., 2008). Specifically, we specified a set of 8 models that differed 
systematically in (i) whether or not they allowed for a differential expression of adaptation (post-
synaptic sensitivity) during standard and deviant stimuli and (ii) which connections were allowed to 
change – show short-term plasticity – between deviant and standard stimuli. (These models were very 
similar to those of Garrido et al. (2008) except that we added interhemispheric connections at the level 
of both primary and secondary auditory areas (Figure 7). These connections do not change the 
relative evidence for different models, but increase overall model evidence.) Reassuringly, our model 
selection results replicate those by Garrido et al. (2008): regardless of drug condition, both adaptation 
in primary auditory cortex and short-term plasticity of forward and backward connections across the 
auditory hierarchy markedly improved the model evidence (Figure 7). In other words, as postulated by 
MMN theories resting on the free-energy principle (Garrido et al., 2009b), both adaptation and synaptic 
plasticity are required to explain the MMN generation per se. 
 
While both adaptation and plasticity of forward and backward connections were required to explain 
MMN, which of these mechanisms, if any, would be attenuated by ketamine? Using Bayesian model 
averaging (Penny et al., 2010), we asked whether ketamine effects on the MMN generation were 
reliably models by DCM such that the pharmacological effects were clearly reflected in the models 
parameters (changes in coupling). To this end we used a multivariate Hotelling’s T2 test, testing 
separately whether the parameter estimates encoding neuronal adaptation and short-term synaptic 
plasticity, were significantly different between ketamine and placebo conditions. This drug-induced 
difference was significant for the parameters representing synaptic plasticity, but not adaptation. We 
then proceeded to ask, using univariate t-tests, which of the six forward and backward connections 
were most critical for explaining the ketamine effects. Correcting for multiple comparisons, we found 
that only plasticity in the forward connection from left A1 to left STG showed a significant change 
under ketamine, compared to placebo. A similar trend was observed for the homologous forward 
connection from right A1 to right STG, but this did not quite reach significance.  
Finally, we examined whether our model-based estimates of ketamine-induced attenuation of short-
term plasticity in the left A1→STG connection correlated with a measure of ketamine-induced change 
in cognition. The previous study by Schmidt et al. (2011) had found a correlation between relative 
ketamine-induced impairments of subjective ratings of impaired control and cognition (subsuming 
items for disordered thought and loss of control over body and thought) and the MMN “slope” under 
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placebo, which indexes the systematic increase in MMN amplitude with the number of preceding 
standards (a specific index of prediction error processing). In brief, the previous study showed that 
MMN expression under placebo predicted the effects of ketamine on introspective ratings of symptoms 
that are reminiscent of schizophrenic symptoms (e.g., thought disorder). Our present analyses suggest 
a more fine-grained interpretation of this relationship: our model-based analyses report a significant 
correlation between ketamine effects on short-term plasticity of the left A1→STG connection and 
ketamine-induced changes in “control and cognition” ratings. In other words, we empirically 
demonstrated that blocking NMDARs by ketamine leads to impaired plasticity by reducing changes in 
connection strength from the left A1 to the left STG, the extent of which predicted significant S-
ketamine-induced psychopathology. It is interesting to note that ketamine selectively exerted effects 
on the left, but not right A1→STG connection. This hemispheric asymmetry is reminiscent of the left-
hemispheric dominance of inner speech that has been linked to disordered thought in schizophrenia; 
e.g., (Strik et al., 2008). However, this is clearly a speculative observation at the present time. 
 
Our results are consistent with the free-energy account of the MMN in that they highlight the 
importance of both adaptation (in primary auditory cortex) and short-term plasticity (of inter-regional 
connections) for the generation of the MMN. Put simply, the sensory learning that is assumed to 
underlie the MMN calls on associative plasticity in the extrinsic connections communicating predictions 
and prediction errors between levels of the auditory hierarchy. As the oddball is repeated, sensory 
learning produces more efficient predictions of auditory stimuli and a decrease in effective connectivity 
of extrinsic connections (as the oddball becomes a standard). Our analyses suggest that this decrease 
is eliminated by ketamine – consistent with its antagonism of NMDAR–dependent plasticity. 
Adaptation – or changes in postsynaptic gain – is thought, in the context of predictive coding, to 
encode the precision of bottom-up information. This precision is itself optimized as a function of 
stimulus repetition. The present results suggest that this neuromodulatory optimization may be less 
sensitive to NMDAR blockade. 
One point of contention, however, may be that our present analyses identified a predominant impact of 
NMDAR antagonism on the plasticity of the forward connections of the auditory hierarchy. From the 
perspective of predictive coding, the free energy formulation suggests forward connections convey 
prediction errors, i.e. phasic signals requiring fast synaptic transmission. In contrast, predictive coding 
regards backward connections as conveying predictions, which may be of a more modulatory nature 
and elicit more enduring effects. This view draws on the concept of “driving” forward and “modulatory” 
backward connections in sensory processing streams (Sherman and Guillery, 1998) and led to 
proposals (Friston, 2005; Corlett et al., 2011) that forward connections predominantly employ fast 
AMPARs, whereas the more modulatory backward connections also engage NMDARs, whose time 
constants are an order of magnitude larger than those of AMPARs. From this perspective, one may 
thus have expected our DCMs to identify a predominant effect of ketamine on the plasticity of 
backward, rather than forward, connections. It may be useful to consider, however, that NMDARs, 
despite their slower time constants compared to AMPARs, are nevertheless ionotropic receptors and 
are capable of conveying driving effects in the presence of other excitatory inputs (i.e., once the cell 
membrane is depolarized) (Daw et al., 1993). Indeed, such “driving” effects of NMDARs are 
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established, e.g., in visual cortex (Fox et al., 1990) and auditory cortex (Kelly and Zhang, 2002). In line 
with this, the original notion of “driving” and “modulatory” connections, as proposed by Sherman and 
Guillery (1998), jointly considers AMPARs and NMDARs as ionotropic receptors for driving 
connections and focuses on metabotropic glutamate receptors (mGluRs) for modulatory (backward) 
connections. In other words, while it is perfectly plausible that NMDARs play an important role in 
synaptic transmission along backward connections, “it is unlikely that NMDA receptors only signal 
predictions and AMPA receptors signal prediction errors; rather there may be a division of labour 
where AMPA receptors are relatively more engaged in bottom-up and NMDA receptors are relatively 
more involved in top-down processes” (Corlett et al., 2011). Our present results are in line with this 
view and imply a less strict dichotomy between AMPAR and NMDAR mediated effects at forward and 
backward connections, respectively, as considered in previous MMN models. 
 
Having said this, it is important to keep in mind that we used a fairly simplistic model for inferring the 
physiological mechanisms of the MNN. While the DCM used in this study does distinguish between 
different neuronal populations (pyramidal cells, granular cells and inhibitory interneurons), it does not 
distinguish between pyramidal cells in supra- and infragranular layers, which take on different roles 
within predictive coding schemes (Friston, 2010). Furthermore, while the model does make a 
distinction between glutamatergic and GABAergic synapses, there is no explicit distinction between 
fast (AMPA) and slower (NMDA) ionotropic receptors, not to mention the modulatory contributions 
from mGluRs. The parameter estimates we obtain from our present model are therefore rather coarse, 
lumped summaries of numerous physiological processes, and the estimates obtained for short-term 
synaptic plasticity cannot be split up into distinct contributions from different glutamatergic receptors.  
There is, however, recent progress in developing DCMs that move towards a much more fine grained 
representation of synaptic physiology. These “conductance-based” DCMs use a simplified Morris-
Lecar formulation to infer the relative contributions of separate ion channel types (with different ligand-
/voltage-gated behavior and time constants) to measured potentials (Marreiros et al., 2010). Recently, 
this model was extended to include an explicit NMDAR representation, rendering it potentially capable 
of inferring on differential contributions of NMDAR and non-NMDAR mediated transmission at 
glutamatergic synapses (Moran et al., 2011a). This extended model is currently being validated and 
when these studies are complete we will re-examine our present data using models of this sort.  
Another opportunity to complement the analysis from the present study is to employ recently 
developed computational models which use the same Bayesian inference framework as DCM but are 
agnostic about physiological mechanisms. Instead, they enable the investigation of trial-by-trial 
changes in MMN amplitude from a purely computational (information theoretic) perspective. In other 
words, they help clarifying which computational quantities (e.g., prediction errors or surprise) are 
reflected by the trial-by-trial dynamics of MMN expression (Lieder et al., in preparation). These 
models, once they are fully established, should enable us to examine the effects of ketamine on MMN 
generation from a complementary perspective.  
In summary, the present study has presented a novel model-based characterization of the effects of 
NMDAR antagonism during the MMN roving paradigm. This study is part of ongoing efforts to 
establish model-based assays of brain disease processes; a theme that plays a major role in 
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computational approaches to dissecting the pathophysiology of spectrum diseases, such as 
schizophrenia, into physiologically well-defined subgroups (Stephan et al., 2009a). A recent proof-of-
concept study demonstrated that one can infer, from scalp MEG recordings, dopaminergic effects of 
NMDA and AMPA receptors (Moran et al., 2011b). Furthermore, several validation studies have 
demonstrated that estimates of glutamatergic synaptic physiology – obtained using a DCM that is 
similar to the DCM used in this study – can be obtained from intracerebral and extradural local field 
potential recordings (Moran et al., 2008; Moran et al., 2011c). The present study has extended this 
program towards inference on NMDAR mediated synaptic effects from EEG data. Clearly, the present 
study is only a modest step towards non-invasive, model-based inference on glutamatergic synaptic 
physiology, and more sophisticated models and further validation studies are needed. Eventually, 
however, we hope that carefully validated model-based approaches will enable diagnostically useful 
applications of MMN recordings in the future, e.g., for pathophysiologically grounded diagnostic 
classification of spectrum diseases such as schizophrenia (Stephan et al., 2006). 
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Abstract 
 
Emotional expressions trigger increased visual responses, even in the absence of conscious 
awareness. Although the serotonin and glutamate systems are implicated in emotional processing, 
their differential contribution to visually evoked responses to non-consciously and consciously 
perceived emotional facial expressions is less well understood. Here, we used backward masking and 
event-related potentials (ERPs) recording to investigate the effect of the N-methyl-D-aspartate 
receptor antagonist S-ketamine and the mixed 5-hydroxytryptamine receptor agonist psilocybin on 
early visual ERP responses to emotional faces over parieto-occipital brain regions. In a double-blind 
within-subject placebo-controlled design, S-ketamine and psilocybin, were administrated to two groups 
of healthy subjects, respectively. Objective threshold for conscious awareness following drug 
administration was determined by signal detection theory. Early visual ERP responses to fearful, 
happy and neutral faces were quantified by the valence-specific P100 and N170 either during non-
conscious or during conscious processing. Both psilocybin and S-ketamine reduced early visual N170 
ERP responses to fearful faces, whereas S-ketamine, but not psilocybin, reduced the N170 ERP 
response to happy faces. Moreover, the effect of psilocybin and S-ketamine on the N170 ERP 
response to facial expressions depended on the extent of visual awareness. Our results suggest that 
psilocybin and S-ketamine differentially contribute to the modulation of visual responses to emotional 
facial expressions. The assessment of early visual responses to emotional expressions may provide a 
useful framework to detect pharmacologically induced changes in emotional processing and might 
also lead to a greater understanding of pharmacological mechanisms underlying emotional processing 
and its dysfunction in affective disorders. 
 
Key words: emotional face processing, NMDAR, 5-HT, conscious awareness, mood and anxiety 
disorders. 
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Introduction 
 
Emotional processing including the recognition of other people’s feelings from their facial expression is 
fundamental to social interaction and behavior. The critical importance of face recognition in the 
human social functioning is shown by the fact that emotional faces increase neuronal activity relative 
to neutral faces in specific neural pathways. In particular, increased brain responses to emotional 
faces have been observed within visual face-selective areas of the brain, even when emotional facial 
expressions are masked to prevent conscious awareness (Anderson et al., 2011; Demenescu et al., 
2011; Kleinhans et al., 2011). Thus, modulation of face-selective responses in the visual cortex by 
emotional expression might correspond to a fundamental regulatory role of basic emotional signals 
associated with social appraisal and cognition (Schultz et al., 2003; Singer et al., 2004). 
It has been shown that emotional processing is modulated by serotonin (5-hydroxytryptamine, 5-HT). 
For example, acute selective serotonin reuptake inhibitor (SSRI) administration immediately increases 
the recognition of fearful and happy faces in healthy subjects (Bhagwagar et al., 2004; Browning et al., 
2007; Harmer et al., 2003). The neural mechanisms underlying this effect are not fully understood. An 
imaging study in healthy humans revealed that SSRI acutely increases visual activity in face-selective 
areas in response to aversive stimuli (Del-Ben et al., 2005). Thus, it has been proposed that the 
heightened recognition of fearful faces induced by SSRI (Harmer et al., 2003) may be related to an 
increased processing in visual areas. Furthermore, previous studies found that acute SSRI 
administration inhibits visually evoked electrophysiological responses to unpleasant expressions, but 
enhances the responses to pleasant expressions (i.e. steady-state visual evoked potential latency 
reductions) (Kemp et al., 2003; Kemp et al., 2004; Nathan et al., 2003). Such changes in emotional 
processing - increased positive and decreased negative bias - are highly relevant to the action of SSRI 
treatment in mood and anxiety disorders (Harmer, 2008). Emotional processing is also modulated by 
glutamatergic manipulations. Specifically, a functional imaging study in healthy humans revealed that 
the visual response to fearful faces is abolished after the administration of the N-methyl-D-aspartate 
(NMDA) receptor antagonist ketamine (Abel et al., 2003). Taken together, these findings indicate that 
acute serotonergic and glutamatergic manipulations change emotional processing as indexed by the 
assessment of visual cortex responses to facial expressions. 
 
Recent studies used event-related potential (ERP) recording to study the time course of neural 
responses to non-conscious versus conscious processing of facial expressions within a masking 
paradigm (Liddell et al., 2004; Pegna et al., 2008; Williams et al., 2004). Backward masking is a key 
experimental paradigm to investigate neural responses to below-awareness stimuli (Tamietto and de 
Gelder, 2010). The two ERP components P100 and N170 are related to early visual processing and 
are suitable to distinguish between emotional and neutral faces. The P100 is an early positive occipital 
potential, peaking at around 80-120 ms post-stimulus and reflects rapid extraction of information 
related to emotion or salience that occurs before more fine-grained perceptual analyses are completed 
(Vuilleumier and Pourtois, 2007). Modulation of the P100 has been shown with fearful (Fichtenholtz et 
al., 2009; Pourtois and Vuilleumier, 2006), angry (Santesso et al., 2008), and positive expressions 
(Batty and Taylor, 2003; Brosch et al., 2008). The N170 is a negative occipito-temporal potential at 
Chapter 4   André Schmidt 2012 
79 
approximately 170 ms post-stimulus and is associated with structural encoding of facial configurations 
(Itier and Taylor, 2004; Rossion and Jacques, 2008). The N170 is also increased by emotional relative 
to neutral faces (Blau et al., 2007; Leppänen et al., 2007), even when faces are subliminally presented 
below visual awareness (Pegna et al., 2008; Smith, 2011). In the current study, we use backward 
masking to investigate how early visually evoked ERP responses to emotional facial expressions 
during non-conscious and conscious processing are modulated by the NMDA receptor antagonist S-
ketamine and the mixed 5-HT receptor agonist psilocybin. Both S-ketamine and psilocybin modulate 
neuronal activity in circuits implicated in the regulation of mood and anxiety (Vollenweider and 
Kometer, 2010) and were suggested to have a clinical potential. Acute ketamine administration 
ameliorates depressive symptoms in treatment-resistant depression within a few hours persisting for 
several days (Diazgranados et al., 2010; Zarate et al., 2006), while acute psilocybin administration in 
healthy subjects leads to heightened mood, increased emotional excitation and sensitivity (Studerus et 
al., 2010b) and decreases anxiety in terminal cancer patients within a month (Grob et al., 2011). To 
investigate further the neuronal underpinnings of the effect of psilocybin and S-ketamine on emotional 
processing, first we examined whether psilocybin and S-ketamine affect visually evoked ERP 
responses to facial expressions in a valence specific manner, and second whether these effects vary 
as a function of visual awareness. Specifically, signal detection theory was applied to behaviorally 
establish objective threshold for conscious awareness irrespective of subject’s response bias. 
Furthermore, early visually evoked ERP responses to fearful, happy and neutral faces were quantified 
by the P100 and N170 during non-conscious compared to conscious processing. 
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Method 
 
Participants 
 
Healthy subjects were recruited through advertisement from the local universities and were then 
separated into two groups (S-ketamine group: N = 21, [male: 12], mean age = 26 ± 5.39 y; psilocybin 
group: N = 21, [male: 13], mean age = 23 ± 2.22 y, all were students). Subjects were healthy 
according to medical history, clinical examination, electrocardiography, and blood analysis. Subjects 
were screened by the DIA-X diagnostic expert system (Wittchen and Pfister, 1997a), a semi-structured 
psychiatric interview to exclude those with personal of family (first-degrees relatives) histories of major 
psychiatric disorders, and by standard psychometric instruments including the Symptom Checklist 
(SCL-90–R) (Derogatis, 1994a) and the State Trait Anxiety Inventory STAI (Spielberger et al., 1970). 
Furthermore, subjects replied to the Mini-International Neuropsychiatric Interview (M.I.N.I.), a brief, 
structured psychiatric interview (Sheehan et al., 1998). No subjects had to be excluded using these 
criteria. We verified the absence of a history of drug dependence by urine drug-screening and a self-
made consumption questionnaire. In the S-ketamine group, seven subjects were occasional smokers 
(<10 cigarettes/day), eight subjects reported a sporadic or rare cannabis use in the past (<3 
joints/month), and two subjects reported experiences with MDMA (three pills lifetime). In the psilocybin 
group, eight subjects were occasional smokers (<6 cigarettes/day), eight subjects reported a sporadic 
or rare cannabis use in the past (<2 joints/month), one subject reported experiences with MDMA (two 
pills lifetime), and two reported experiences with psilocybin (two administrations lifetime). All subjects 
were free of any medication for at least 3 weeks before the experiment. This study was approved by 
the Ethics Committee of the University Hospital of Psychiatry, Zurich. After receiving a written and oral 
description of the aim of this study, all participants gave written informed consent statements before 
inclusion. The use of psilocybin was authorized by the Swiss Federal Office for Public Health, 
Department of Pharmacology and Narcotics, Berne, Switzerland. 
 
Drug administration 
 
In both groups, subjects underwent two sessions (placebo/active drug) in a balanced and random 
order at an interval of at least 2 weeks. Both subject and principal investigator were blind to drug 
order. Subjects stayed monitored until all drug effects had worn off, and were then released into the 
custody of a partner. For the S-ketamine/placebo infusion, an in-dwelling catheter was placed in the 
antecubital vein of the nondominant arm. Once the subject was ready, a bolus injection of 10 mg over 
5 min was given. Following 1 min break, a continuous infusion with 0.006mg/kg per min was 
administered over 80 minutes. To keep S-ketamine’s plasma level fairly constant, the dose was 
reduced every ten minutes by 10% (Feng et al., 1995; Vollenweider et al., 1997b). In the placebo 
session, the same procedure was followed and an infusion of physiological sodium chloride solution 
and 5% glucose was given. Psilocybin (115 μg/kg) and lactose placebo were orally administered in 
gelatin capsules of identical number and appearance. The doses of S-ketamine and psilocybin 
selected in this study were previous shown to produce similar overall effects on subjective experiences 
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including robust emotional effects and only moderate visual disturbances (Gouzoulis-Mayfrank et al., 
2005; Hasler et al., 2004; Studerus et al., 2010b; Vollenweider and Kometer, 2010). 
 
Psychological assessment 
 
The Altered State of Consciousness (ASC) questionnaire, a visual analogue and self-rating scale, was 
used to assess the subjective psychological effects induced by S-ketamine and psilocybin (Dittrich, 
1975; Dittrich, 1998). A recent evaluation study of the ASC questionnaires has constructed eleven new 
lower order scales (Studerus et al., 2010a), which were analyzed in this study. The ASC questionnaire 
was given 240 min post-treatment to rate retrospectively their experiences since drug intake. 
 
Stimuli and backward masking procedure 
 
As stimulus material we took black and white photographs taken from the Ekman–Friesen series 
(Ekman and Friesen, 1976). To limit the contribution of low-level effects of the photographs, faces 
were modified using Adobe Photoshop, so that only the eyes, eyebrows, nose and mouth were visible 
features, while other characteristics such as the skin texture, wrinkles, etc. were hidden. This 
modification was intended to prevent subjects from utilizing a strategy to discriminate emotional from 
neutral facial expressions by using such low-level cues. The final facial images subtended a visual 
angle of 3° horizontally and 4.4° vertically and were displayed in the center of a CRT monitor. 
Backward masking procedures were generated by E-prime software (Schneider et al., 2002) (Fig. 1). 
Timing issues were confirmed by using an oscilloscope. Subjects first underwent a mismatch 
negativity event-related paradigm for 15 minutes, which has been published elsewhere (Schmidt et al., 
2011). Emotional measures were started 25 min after S-ketamine infusion and 110 min following 
psilocybin administration during the known plateau (Hasler et al., 2002; Passie et al., 2002). 
Facial affect discrimination: Two discrimination tasks were designed to establish thresholds for 
conscious awareness, i.e. to determine the time point, at which subjects can distinguish emotional 
from neutral expression above chance level. In a first task, subjects had to discriminate fearful from 
neutral faces, while in a second task they had to discriminate happy from neutral faces. For each 
discrimination task, target faces consisted of neutral, fearful and happy faces, respectively, and were 
presented for 20, 30, 50, 90 or 170 ms (Williams et al., 2004). Target faces were immediately followed 
by a neutral mask lasting for 150 ms. Participants performed 5 blocks of 40 trials (target-mask pairs) 
for each of both tasks, in which target faces were randomly presented with equal probability. Before 
each target-mask pair, a fixation cross was presented for 1000 ms. Subjects made an objective 
forced-choice decision about the valence of the target face (fearful/happy vs. neutral) via button-press 
after each target-mask pair. 
 
EEG/ERP recording: During ERP recording, stimuli were identical to those used during facial affect 
discrimination. Target faces including neutral, fearful or happy faces and were immediately followed by 
a neutral mask for 150 ms. Each trial began with a fixation cross that lasted for 2000 ms. The 
presentation time of the target face depended on the condition, 10 ms during non-conscious and 200 
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ms during conscious awareness (Williams et al., 2004). No subject response (botton-press) was 
required. Participants were given instructions that pairs of target-mask faces would be presented and 
that they would be asked questions about the first faces after testing. 
 
Figure 1 Schematic of the backward masking paradigm. During the discrimination threshold tasks, a 
fixation cross was first presented for 1000 ms, followed by the target face, which lasted for 20, 30, 50, 
90 or 170 ms, respectively. Finally, a neutral mask was presented for 150 ms. After each target-mask 
pair subjects were asked to answer via key press. During ERP recording, the fixation cross was 
presented for 2000 ms. The presentation time for the target faces was 10 ms for non-conscious 
processing, and 200 ms for conscious processing. 
 
EEG/ERP recording 
 
EEG recordings were made from 64 scalp electrodes using the ActiveTwo system (Biosemi, The 
Netherlands). The horizontal electroocculogram (EOG) was recorded from electrodes attached on the 
outer canthus of each eye. Similarly, vertical EOG was recorded from electrodes attached infraorbitally 
and supraorbitally to the left eye. All electrodes were active silver/silver chloride electrodes and the 
offset of all electrodes was below 25mV. Data were recorded at a sampling rate of 512 Hz. The 
common mode sense (CMS) active electrode and the driven right leg (DRL) passive electrode were 
used as reference and ground electrodes, respectively (see http://www.biosemi.com/faq/cms&drl.htm 
for more details on this setup). 
For ERP analysis, independent component analysis was used to remove artifacts due to eye 
movements and blinks (Lee et al., 1999). The EEG data were recalculated offline against average 
reference. Then, epochs with a 200-ms prestimulus baseline and a 500-ms post-stimulus interval were 
constructed. Epochs with amplitudes that exceeded ± 100 µV at any electrode were excluded from 
further averaging. After artifact rejection, epochs were averaged for each subject and were digitally 
filtered with a band-pass filter (1-30 Hz). P100 and N170 ERPs were scored at electrodes 
P08/P8/P10/O2 (right hemisphere) and PO7/P7/P9/O1 (left hemisphere) as peak positivity/negativity 
relative to baseline within the 130-200 ms and 150-250 ms window latency, respectively, as previously 
described (Frühholz et al., 2011; Jaworska et al., 2010; Wronka and Walentowska, 2011). 
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Statistical analysis 
 
Discrimination performances were analyzed according to signal detection theory (STD), which 
provides a measure of sensitivity that is independent of subject’s response bias (Macmillan and 
Creelman, 1991). Threshold settings were determined by Students t-tests against chance level (d’ = 
0). Sensitivity indices (d’) were further subjected to a repeated measurement analysis of variance 
(ANOVA) with the within-subject factors target duration (20, 30, 50, 90, 170 ms), valence (fearful, 
happy) and treatment (placebo, drug), as well as with the between-subject factor group (S-ketamine, 
psilocybin). Based on significant main effects or interactions, Fisher’s least significant difference tests 
(LSD) were performed. Repeated measurement ANOVA on the ASC data with treatment and scale as 
within-subject factors and group as between-subject factor was used to examine drug-induced 
psychological effects. P100 and N170 ERP data for each group were subjected to repeated 
measurement ANOVAs with the within-subject factors treatment (placebo, drug), target duration (non-
conscious, conscious), valence (fearful, happy and neutral) and laterality (right, left). To compare both 
drug effects on the specific ERPs, we further computed the relative change scores between placebo 
and drug conditions (placebo/drug). Change scores were subjected to a repeated-measures ANOVA 
with the within-subject factors target duration (non-conscious, conscious), valence (fearful, happy and 
neutral) and laterality (right, left); and with the between-subject factor group. Where the ANOVA null 
hypothesis of equal means was rejected, we used LSD post-hoc tests. 
 
Results 
 
Facial affect discrimination 
 
Students t-tests against d’ = 0 revealed that for the discrimination of fearful relative to neutral faces 
(Fig. 2), d’ values at 20 ms for both groups under placebo did not differ significantly from chance level 
(mean d’ = 0.07, SD = 0.32) (p’s = 0.15), while d’ values at 30 ms were clearly above chance level 
(mean d’ = 0.33, SD = 0.48) (p’s < 0.00001). Following drug administration, d’ values at 30 ms were 
still not above chance level (mean d’ = 0.08, SD = 0.68, p’s = 0.46), whereas performances at 50 ms 
reached significance (mean d’ = 0.28, SD = 0.36, p’s < 0.0001). Thus, the point at which subjects can 
discriminate fearful from neutral facial expressions with above-chance accuracy was shifted relative to 
placebo after both S-ketamine and psilocybin administration. During happiness discrimination (Fig. 3), 
all d’ values significantly varied from chance level, irrespective of treatment. 
Repeated-measures ANOVA revealed that d’ values significantly increased across target duration 
[F(4,160) = 195.19; p < 0.00001; η2 = 0.83]. In general, d’ values for happy faces were more 
pronounced than for fearful faces (p < 0.05), as indicated by a significant main effect for valence 
[F(1,40) = 4.15; p < 0.05; η2 = 0.09]. Furthermore, a significant main effect for treatment was found 
[F(1,40) = 36.04; p < 0.00001; η2 = 0.47]. Particularly, a treatment × valence × group interaction 
[F(1,40) = 4.11; p < 0.05; η2 = 0.09] revealed that this treatment effect depended on the valence and 
on the specific drug used. Although S-ketamine significantly reduced d’ values for both fearful (p < 
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0.001) and happy faces (p < 0.001) relative to placebo, psilocybin did not affect d’ values for happy 
faces (p = 0.87). 
A 
 
B 
 
Figure 2 Sensitivity indices (d’) ± SE represented as a function of target duration during A) fear 
discrimination and B) happiness discrimination. Notably, S-ketamine significantly reduced d’ values for 
fearful and happy faces, while psilocybin only reduced d’ values for fearful but not for happy faces. 
 
ERP results 
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Mean of grand averages over both hemisphere of the P100 and N170 ERP during non-conscious and 
conscious processing are shown in Figure 3. 
 
 
Figure 3 Mean of grand averages over both hemispheres of the P100 and N170 ERP for fearful (A), 
neutral (B) and happy faces (C) during non-conscious (left) and conscious awareness (right) following 
placebo (solid line), S-ketamine (Ket: dashed line) and psilocybin (psi: dotted line) administration, 
respectively. 
 
P100 ERP 
 
Repeated-measures ANOVA revealed that P100 amplitudes were generally more pronounced over 
right compared to left electrodes both in the S-ketamine [F(1,20) = 18.23; p < 0.001; η2 = 0.48] and in 
the psilocybin group [F(1,20) = 22.22; p < 0.001; η2 = 0.53]. No other main effects or interactions were 
observed for P100 amplitudes in both groups. Comparing the effect of S-ketamine and psilocybin, 
repeated-measures ANOVA on the change scores for the P100 ERP showed no main effects and 
interactions, reflecting that the effect of S-ketamine and psilocybin on the P100 ERP were broadly 
similar. 
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N170 ERP 
 
Repeated-measures ANOVA on the S-ketamine data revealed that N170 amplitudes were generally 
more pronounced over right compared to left electrodes, indicated by significant main effects for 
laterality (F(1,20) = 25.97; p < 0.0001; η2 = 0.56). Furthermore, a main effect of treatment was found 
(F(1,20) = 8.73; p < 0.01; η2 = 0.30), reflecting an overall attenuation of the N170 amplitude following 
S-ketamine administration (Fig. 4 left). The treatment × laterality interaction (F(1,20) = 46.70; p < 
0.00001; η2 = 0.7) showed that this treatment effect occurred only over right electrodes (p < .000001) 
but not over left electrodes (p = .14). Furthermore, the treatment effect also depended on the target 
duration, revealed by the treatment × target duration interaction (F(1,20) = 4.75; p < 0.05; η2 = 0.19). 
LSD post-hoc testing showed that S-ketamine’s effect on the N170 amplitude was more pronounced 
during conscious (p < 0.00001) than non-conscious awareness (p < 0.001). 
Repeated-measures ANOVA on the psilocybin data revealed significant main effects for laterality 
(F(1,20) = 39.43; p < 0.00001; η2 = 0.66) and treatment (F(1,20) = 14.21; p < 0.01; η2 = 0.42), 
reflecting the more pronounced response over right relative to left electrodes (p < 0.00001) and the 
general reduction by psilocybin relative to placebo (p < 0.01). This treatment effect was found only 
over right electrodes (F(1,20) = 6.61; p < 0.05; η2 = 0.25). Furthermore, the laterality × treatment × 
target duration interaction (F(1,20) = 4.52; p < 0.05; η2 = 0.18) revealed that the N170 reduction over 
right electrodes was more pronounced during conscious (p < 0.000001) compared to non-conscious 
awareness (p < 0.01). However, a treatment × valence interaction was found (F(2,40) = 5.92; p < 0.01; 
η2 = 0.23). Post-hoc testing revealed that psilocybin significantly reduced the N170 amplitudes in 
response to fearful (p < 0.000001) and neutral faces (p < 0.01), but not to happy faces (p = 0.1) (Fig. 4 
right). 
 
Figure 4 Mean N170 amplitudes ± SE over right electrodes for fearful, neutral and happy faces under 
S-ketamine (red line), psilocybin (blue) and placebo (green). Note: Significant differences between 
treatment conditions at (*) p < 0.01 and at (**) p < 0.00001. 
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Comparing the effects of psilocybin and S-ketamine on the N170, repeated-measures ANOVA on the 
change scores revealed a significant valence × group interaction (F(2,80) = 5.19; p < 0.01; η2 = 0.11). 
Post-hoc testing showed that S-ketamine and psilocybin reduced the N170 amplitudes in response to 
fearful (p = 0.20) and neutral faces (p = 0.66) similarly, whereas happy faces were reduced only by S-
ketamine, but not by psilocybin (p < 0.05) (Fig. 5). 
 
 
Figure 5 Mean change scores of N170 ERP ± SE depending on the face valence. Notably, the N170 
ERP reduction for fearful and neutral faces was comparable among both drugs, but the N170 ERP for 
happy faces was significantly more reduced after S-ketamine (dotted line) than psilocybin exposure 
(solid line). (*) indicates a significant difference (LSD) at p < 0.05 between the effect of S-ketamine and 
psilocybin on happy faces and (**) indicates the significant difference at p < 0.001 between psilocybin’s 
effect on fearful and happy faces. 
 
Psychological assessment 
 
Both S-ketamine and psilocybin produced similar alterations on the global ASC scores (Fig. 6). 
ANOVA on the ASC data revealed significant main effects for treatment (F(1,40) = 80.99; p < 0.00001; 
η2 = 0.67) and scale (F(11,440) = 9.73; p < 0.000001; η2 = 0.20). A triple treatment × scale × group 
interaction indicated significant differences between both drug effects on specific scales [F(11,440) = 
5.35; p < 0.00001; η2 = 0.12]. Post-hoc testing showed that S-ketamine increased all scales relative to 
placebo (p’s < 0.01), expect for anxiety (p = 0.09), while psilocybin increased all scales (p’s < 0.01), 
expect for auditory alterations (p = 0.42) and anxiety (p = 0.36). Moreover, post-hoc analysis showed 
that S-ketamine produced significantly higher scores than psilocybin for disembodiment (p < 
0.000001), auditory alterations (p < 0.05) and for impaired control and cognition (p < 0.05). Otherwise, 
psilocybin produced more severe elementary imagery than S-ketamine (p < 0.01). 
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Figure 6. Effects of S-ketamine (dashed line) and psilocybin (dotted line) on the ASC scales.  Mean 
scores and ± SE (both n= 21). Note: (*) indicates significant differences (LSD) between drugs at (*) p < 
0.05, at (**) p < 0.01 and (***) at p < 0.000001. Symptoms scores were expressed as percent of scale 
maximum. 
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Discussion 
 
We investigated how early visually evoked ERP responses over parieto-occipital brain regions during 
conscious compared to non-conscious emotional face processing are altered under the NMDAR 
antagonist S-ketamine and the mixed 5-HT receptor agonist psilocybin. First, both psilocybin and S-
ketamine reduced early visual responses to fearful faces as expressed by a reduced N170 response, 
whereas N170 responses to happy faces were reduced only by S-ketamine. Second, the S-ketamine- 
and psilocybin-induced reduction of the N170 response depended on the extent of visual awareness. 
 
According to several source modeling and functional magnetic resonance imaging (fMRI) studies 
(Deffke et al., 2007; Rossion et al., 2003b; Sadeh et al., 2010), the generators of the N170 ERP have 
been localized to the fusiform gyrus (FG), which encodes the structural configuration of facial features. 
Because we have performed an analysis in sensor space and because EEG sensor signals result from 
a mixture of neuronal sources, one should be cautious to relate the present findings to neural sources 
in specific locations. In other words, the N170 does not necessarily correspond to the FG, and the 
following discussion should be read with this caveat in mind. Nevertheless, consistent with other 
reports investigating the acute effect of SSRI on visual responses to emotional expressions (Kemp et 
al., 2003; Kemp et al., 2004; Nathan et al., 2003), reduced visual responses to fearful faces were 
found in this study after acute administration of the mixed 5-HT receptor agonist psilocybin. However, 
contrary to the finding that citalopram enhances visual responses to pleasant expressions (Kemp et 
al., 2004), we found no alteration of N170 responses to happy faces under psilocybin. This differential 
effect of psilocybin and citalopram on happy face processing may be due to different 
electrophysiological measures used in these studies or to the different pharmacological effects of 
psilocybin and citalopram on the 5-HT system. While SSRI’s increase 5-HT brain levels (Elliott et al., 
2011; Nutt et al., 1999) psilocybin and its active metabolite psilocin are direct agonists at specific 5-HT 
receptors (Blair et al., 2000; Nichols, 2004b). That the different pharmacological mechanism of action 
of psilocybin and SSRI’s may be critical is further supported by previous studies using the same ERP 
marker as used in our study. These studies reported that acute citalopram had no modulatory effects 
on the N170 in healthy subjects (Kerestes et al., 2009; Labuschagne et al., 2010). 
Discussing the effect of S-ketamine’s on visually evoked ERP responses to emotional faces, the only 
work with reference to our result is a previous fMRI study, which explored the neural correlates 
following ketamine administration during emotional face processing (Abel et al., 2003). The key finding 
of this study was that the neuronal response in limbic and visual structures during placebo was 
ameliorated in the amygdala and significantly reduced in the FG following ketamine administration. 
The authors suggested that this ketamine-induced reduction in neuronal responses to emotional 
stimuli in limbic and visual regions is associated with the emotional blunting and depersonalization 
phenomena that are evident in ketamine states (Krystal et al., 1994; Malhotra et al., 1996; 
Vollenweider et al., 1997b). This interpretation is consistent with the present finding that S-ketamine 
reduced the N170 not only in response to fearful but also to neutral and happy faces, reflecting an 
overall emotional blunting of visually induced neural responses. 
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The importance of the FG in emotional processing is further evidenced by the finding of a functional 
relationship between object discrimination performance and FG activity. Particularly, FG activity was 
shown to increase gradually with subjective rating of recognition success (Bar et al., 2001). An 
identical relationship was also suggested following citalopram administration in healthy subjects 
(Harmer et al., 2003). Particularly, it has been proposed that the enhanced fear detection in healthy 
subjects treated with citalopram (Harmer et al., 2003) may be due to the enhancement of visual 
processing in the FG (Del-Ben et al., 2005). Assuming that the EEG source of the N170 ERP 
response to facial expressions is localized in the FG (Deffke et al., 2007; Rossion et al., 2003a; Sadeh 
et al., 2010), our results support and extend such an relationship by showing that the valence-specific 
modulations during facial affect discrimination by psilocybin and S-ketamine is associated with the 
drug-induced N170 modulation. Therefore, it is conceivable that the effects on the N170 might reflect 
drug-specific modulation of FG activity. 
 
In the following section we suggest potential neurobiological mechanisms underlying our key findings. 
The increased visual response to relevant emotional expressions is likely mediated via rich 
interconnections between the FG and the amydgala (Amaral et al., 2003; Freese and Amaral, 2005), 
the coupling of which is additionally strengthened during attentive viewing of affective faces (Fairhall 
and Ishai, 2007; Herrington et al., 2011). This facilitation may relate to a heightened sensitivity to 
visual stimuli with emotional relevance (Lane et al., 1999; Lang et al., 1998). Furthermore, emotional 
face processing also involves prefrontal areas, which are anatomically connected with the FG and the 
amygdala (Dima et al., 2011). Interestingly, both S-ketamine and psilocybin were found to deactivate 
the amygdala and to increase prefrontal neural activity (Vollenweider and Kometer, 2010). Thus, it is 
arguable that the psilocybin- and S-ketamine-induced reduction of the N170 response to fearful faces 
may be due to a functional alteration in this amygdala-prefrontal network. However, why psilocybin 
and S-ketamine had dissociable effects on happy face processing is difficult to derive from the present 
data. A possible explanation could be that S-ketamine and psilocybin differentially modulate circuitries 
responsible for the processing of positive expressions, because the processing of positive information 
such as happy faces also involves reward-related areas (Adolphs, 2003; Ishai, 2007; Singer et al., 
2004) and further because the N170 showed priming effects as a function of reward (Marini et al., 
2011). However, this is highly speculative, and there are a number of other structures involved in face 
processing and social cognition, which could be differentially modulated after psilocybin and S-
ketamine administration. Thus, an important future direction will be to elucidate these valence-specific 
effects of psilocybin and S-ketamine on the functional integration within the face processing network 
using imaging techniques and effective connectivity analysis as used in previous studies (David et al., 
2006b; Dima et al., 2011; Fairhall and Ishai, 2007; Herrington et al., 2011). 
Another key finding of this study was further that the psilocybin- and S-ketamine-induced reduction of 
the N170 was more pronounced during conscious compared to non-conscious awareness. Numerous 
studies have described an increase of the N170 with selective attention (Gazzaley et al., 2005; 
Wronka and Walentowska, 2011), suggesting top-down attentional control. In particular, the visual 
cortex receives top-down modulation from frontal and parietal areas in relation to visual attention 
(Bressler et al., 2008) in the time range of the N170 (Rose et al., 2005). In this view, several studies 
Chapter 4   André Schmidt 2012 
91 
reported that psilocybin attenuates attentional performances (Carter et al., 2005; Gouzoulis-Mayfrank 
et al., 2002; Quednow et al., 2011). A recent study examined the influence of psilocybin on the 
spatiotemporal dynamics of object completion and found a dose-dependent reduction of the N170 
response (Kometer et al., 2011). They suggested that this reduction might reflect a psilocybin-induced 
failure to allocate attention. Similarly, previous evidence revealed that ketamine produce cognitive 
deficits including impairments of attention (Krystal et al., 1994; Morgan et al., 2004; Newcomer et al., 
1999). Therefore, we suggest that the more pronounced reduction of psilocybin and S-ketamine on the 
N170 during conscious relative to non-conscious processing indicates a drug-induced reduction of 
attentional resources. 
 
To conclude, our results suggest that the glutamate and serotonin system differentially contribute to 
the modulation of visual responses to emotional facial expressions in healthy human subjects. 
Unraveling the role of early visual responses to emotional facial expressions might allow detecting 
pharmacologically induced changes in emotional processing and might also help to better understand 
the pharmacological mechanisms underlying the pathophysiology of facial processing biases, which 
are key impairments in several mood and anxiety disorders. In relation to this, previous studies have 
shown that a single dose of ketamine in treatment-resistant depression can produce significant 
antidepressant effects within a few hours persisting for several days (Diazgranados et al., 2010; 
Zarate et al., 2006). Given that psilocybin selectively reduced negative but not positive emotional 
processing, it might provide another promising agent to adjust dysfunctional emotional processing 
biases in mood and anxiety disorders. 
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5. General Discussion 
 
The studies presented in this thesis outline two distinct perspectives for the experimental use of 
glutamatergic and serotonergic psychedelics in psychiatric research. On the one hand, we 
demonstrated how the dissociative NMDAR antagonist S-ketamine and the classical hallucinogen 
psilocybin, which preferentially activate 5-HT2AR, can be used to investigate the formation of psychotic 
symptoms. On the other hand, we provided an approach how S-ketamine and psilocybin can serve as 
research agents to physiologically investigate the role of serotonin and glutamate in emotional 
processing. In the following, I discuss the present findings chapter-by-chapter by expanding the paper 
discussion sections. Discussing model psychoses, I relate the results of chapter 2 to a hypothetical 
framework centered upon learning and inference, namely to predictive coding models. This theoretical 
framework assumes that every neural system forms expectations about their sensory input based on 
previous experiences, and if those expectations do not precisely match with the actual input, the 
neural system adjusts its expectations by learning and inference to render future inputs more 
predictable. In chapter 3, we provide a computational model-based approach, which is guided by a 
free-energy perspective on MMN to explain the known NMDAR-mediated disruption of the MMN 
expression. This means that we provide a possible explanation by using computational modeling how 
and where in the hierarchical network underlying the MMN generation the NMDAR blockade did 
disrupt the processing of PEs. In chapter 4, we used emotional facial expressions to investigate further 
the neuronal underpinnings of serotonergic (via psilocybin) and glutamatergic (via S-ketamine) 
manipulations on emotional processing. Specifically, we assessed how psilocybin and S-ketamine 
affect visually evoked responses to facial expressions in a valence specific manner, and second 
whether these effects vary as a function of visual awareness. I discuss these findings by providing 
possible neurobiological mechanisms. As a last point, I show that the visual responses (N170 ERP) 
obtained in chapter 4 speak to the same underlying idea as the auditory responses (MMN ERP) 
assessed in the model psychosis section (chapter 2 and 3), in particular to predictive coding models or 
more generally to hierarchical inference in the brain. 
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5.1. The Role of Glutamate and Serotonin in Models of Psychosis and 
Schizophrenia 
 
Discussion of Chapter 2 
 
In this study, we used a roving MMN paradigm to compute PEs in healthy humans receiving either the 
NMDAR antagonist S-ketamine or the preferential 5-HT2AR agonist psilocybin. We physiologically 
explored the modulation of the MMN amplitude to an oddball tone by the preceding number of 
standard tones, showing the expected effect under placebo of an enhanced MMN amplitude when a 
large number of preceding standards tones had be presented, an effect called MMN memory trace 
effect (MMN slope). This effect was lost under S-ketamine, but retained under psilocybin. In other 
words, NMDAR blockade but not the 5-HT2AR system is implicated in PE processing as indexed by the 
MMN as a form of implicit perceptual learning. Moreover, the processing of PE at baseline, i.e. without 
any drug intake relates to the extent of S-ketamine-induced cognitive impairments. 
 
A PE reflects the surprise of an unexpected event (Egner et al., 2010). Thus, the frontally generated 
MMN slope under placebo could also be interpreted in such a way that the occurrence of the deviating 
tone becomes continuously more surprising with increasing number of preceding standard tones. This 
increased surprise to the deviant tone is based on suppressed responses to repeated standard tones, 
i.e. to repetition suppression (RP). The “surprise reduction” to repeated standard tones seen under 
placebo is lost under S-ketamine. This means that individuals under S-ketamine were not sensitive to 
contextual factors beyond the physical properties of the stimulus, such as the probability that a 
repetition will occur, or the relevance of the repeated stimulus to the task at hand. Notably, S-ketamine 
disrupted only the frontally generated MMN slope but not the temporal one. A similar reduction of the 
frontal MMN slope was observed in schizophrenic patients (Baldeweg et al., 2004). Our result and the 
established importance of NMDARs for synaptic plasticity during perceptual learning (Kandel, 2001; 
Morris et al., 1986) fits well with predictive coding models of the MMN, which suppose a NMDAR-
dependent plasticity mechanism. In these theories (Friston, 2005; Stephan et al., 2006), the MMN 
generates by information passing across different hierarchically organized neuronal ensembles. Within 
this hierarchy, each level strives to attain a compromise between information about sensory inputs 
provided by the level below and predictions provided by the level above (Friston, 2005; Rao and 
Ballard, 1999). A PE emerges when the higher-level predictions (top-down) do not match with the 
actual sensory input (bottom-up). The general principle of learning is to build flexible models of the 
environment, which is achieved by minimizing PEs at all levels of the hierarchy. Critically, such a 
Bayesian passing scheme depends on NMDAR-dependent short-term plasticity, which is critical for 
adjusting the connection strength of glutamatergic synapses within the hierarchical architecture. 
Motivated by this theoretical concept, a recent MMN study applied DCM to examine effective 
connectivity among different brain regions involved in the MMN generation (Garrido et al., 2008). 
Based on fMRI studies revealing that the MMN propagation involves generators in bilateral A1 and 
STG, and right IFG (Doeller et al., 2003; Opitz et al., 2002) (Figure 1), the DCM work revealed that the 
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most plausible mechanism underlying the MMN generation contains changes in coupling within 
bilateral A1 (post-synaptic modulation), combined with plasticity of inter-areal connections between 
temporal and frontal regions. Thus, in terms of predictive coding models, the MMN would arise from a 
failure to predict bottom-up input and suppress the resulting PE (Garrido et al., 2008; Garrido et al., 
2009). 
 
 
 
Figure 1 MMN underlying sources revealed by EEG and conjoint EEG and fMRI measures. A) Dipoles 
indicated by red arrows at bilateral STG. B) Dipole locations at bilateral STG and right IFG and C) 
significant fMRI activation for deviants. Adapted from Garrido et al. (2009). 
 
According to this, our finding of a reduced frontal MMN memory trace induced by S-ketamine may 
reflect a drug-induced perturbation of NMDAR-dependent plasticity of temporo-frontal connections 
(forward) that serves to adjust PE message passing between the STG and the IFG during MMN 
generation. In other words, the disruption of the frontal MMN by S-ketamine may result from a deficient 
adjustment of frontally generated predictions about temporal inputs due to insufficient PE-dependent 
plasticity of forward connections. The plausibility of this potential mechanism was computationally 
examined in chapter 3, which is discussed below. 
 
It remains the question why manipulation of the 5-HT system via psilocybin did not disrupt PE 
processing in this study, given that modulatory neurotransmitters such as 5-HT are proposed to 
influence PE processing as well (Corlett et al., 2009) and may be one of the key modulators interacting 
with NMDARs to produce aberrant synaptic plasticity in schizophrenia (Stephan et al, 2009). The lack 
of MMN effect following 5-HT manipulation is consistent with previous results (Heekeren et al., 2008; 
Umbricht et al., 2003). However, these findings do not necessarily contradict with that idea that 5-HT 
has an effect on PE processing and synaptic plasticity, but rather implies that the role of 5-HT could be 
expressed in a regionally specific manner, and may thus not be a critical factor in PE processing 
during the MMN paradigm (cf. Garrido et al, 2009). In this view, it is conceivable that psilocybin will 
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modulate for example the processing of visual PEs. Alternatively, recent theoretical works suggested 
crucial differences between PE per se and the precision or uncertainty about those errors (Corlett et 
al., 2009; Corlett et al., 2011). They propose that fast glutamatergic neurotransmission represents PE 
and slower neuromodulators encode the precision of PEs. In accordance, optimal inference relies on 
both the magnitude of PEs and its precision. Consequently, aberrant PE processing did not exclusively 
mean a fault in the PE magnitude as indexed by the MMN amplitude, but also an estimate of its 
precision – its uncertainty (Corlett et al., 2009). The size of the PE is meaningless without an estimate 
of its precision (Fletcher and Frith, 2009). This is different to the effect of S-ketamine here, which 
records only the magnitude of PEs (MMN amplitude). Although psilocybin did not disrupt the 
magnitude of PEs with the MMN generation, its influence on the precision of PEs is still unknown. 
Therefore, implicit perceptual learning as indexed by the MMN amplitude of PEs appeared not to be 
sensitive to 5-HT2AR manipulations (or to the dose of psilocybin used in this study), but may be alter 
the precision of PEs (i.e. MMN latency). 
 
Furthermore, we also explored whether S-ketamine- or psilocybin-induced symptoms could be 
predicted by the MMN slope under placebo. Such an approach based on the assumption that the 
formation of psychiatric disorders is the result of a genetic predisposition and the exposure to different 
kind of external stressors (Brown, 2011), and could be useful to test hypotheses about the cognitive 
and neural bases of specific symptoms (Corlett et al., 2006; Honey et al., 2008; Krystal et al., 2003; 
Umbricht et al., 2002). In this study, the MMN slope in the absence of any drug predicted NMDAR-
mediated cognitive impairments in healthy volunteers. In other words, a poorer learning performance 
or a disruption of PE processing, expressed as a reduced MMN slope, characterized a constitution 
that is more sensitive to disruption of the NMDAR system, which in turns might promote the formation 
of cognitive impairments. But why should the individual MMN slope under placebo predict S-ketamine-
induced cognitive impairments rather than other symptoms? This can be explained by the role of 
NMDARs in synaptic plasticity, which is a crucial mechanism for PE-dependent learning (Stephan et 
al., 2006; Stephan et al., 2009). A lot of symptoms in schizophrenia including cognitive impairments 
can result from aberrant synaptic plasticity during perceptual learning. In this view, aberrant synaptic 
plasticity leads to insufficient PE processing and to inadequate learning, which again results in 
impairments to adapt one’s beliefs and behavior accordingly. Furthermore, the roving MMN paradigm 
requires the encoding of de novo information of echoic memory traces on a trial-by-trial basis 
(Baldeweg et al., 2004; Cowan et al., 1993). Therefore, considering the MMN slope as an index of 
individual capacity of utilizing PEs for adaptive cognition through NMDAR-dependent plasticity, one 
would predict that the higher this individual capacity in the drug-free state (i.e. the higher the MMN 
slope under placebo), the less pronounced the effects of S-ketamine on PE-dependent learning and 
subsequent aberrations in adaptive cognition. This is what we found. However, although in the current 
study the aberrant PE signal is statistically related to cognitive impairments subsuming items for 
disordered thought and loss of control over body and thought, we do not preclude associations with 
others symptoms of psychosis, notably hallucinations, thought disorders or delusions. In this context, 
closer inspection of the impaired control and cognition subscale provides certain inference relative to 
abnormal belief formation, because it comprises items like “I felt like a marionette”, “I had difficulties in 
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distinguishing important from unimportant things”, “I was not able to complete a thought, my thought 
repeatedly became disconnected” or “I had the feeling that I no longer had a will of my own.” Along 
this line, abnormal belief formation emerges when predictions are not updated appropriately on the 
basis of new evidence (Hemsley and Garety, 1986), which nicely corresponds with the disruptions of 
the MMN slope. 
 
Summarized, our results suggest that the frontal MMN memory trace effect may provide a useful 
approach to study NMDAR-dependent PE processing during the MMN as a form of implicit perceptual 
learning, and further provide important insights into the formation of psychosis in general and the 
emergence of cognitive impairments in particular. Such investigations are of considerable interest, 
given the potential of the MMN to predict the risk of psychosis (Bodatsch et al., 2010; Orosz et al., 
2011; Shaikh et al., 2011) and to distinguish further between first-episode psychosis and individuals at 
ultra-high risk of psychosis (Atkinson et al., 2011). Furthermore, many atypical antipsychotics were 
developed on their potential to block the LSD activity at 5-HT2ARs (Colpaert, 2003), or their 
development are inspired by NMDAR antagonist models of psychosis (Anand et al., 2000; Deakin et 
al., 2008; Malhotra et al., 1997; Patil et al., 2007). Under this perspective, we suggest that the 
assessment of the MMN memory trace effect may also provide a promising tool to evaluate the 
efficacy of novel glutamatergic-based treatments, which particularly treat cognitive impairments. To 
conclude, understanding the mechanism of psychedelics provide important insights into the 
pathophysiology of psychosis, what in turn facilitates the development of better pharmacological 
therapies for schizophrenia (González-Maeso and Sealfon, 2009). 
 
In my future research, I aim to investigate the role of different pharmacological manipulations on 
paradigms requiring the processing of PEs using EEG and fMRI analysis in healthy volunteers. The 
purpose is to understand the role of different neurotransmitters on PE processing (notably magnitude 
and precision) and its relation to the formation of specific symptoms. The paradigms I will use contain 
different forms of learning; stimulus-stimulus and stimulus-response associations. The question is 
whether predictive physiological markers for specific symptom expressions can be identified. For that, 
different drug model of psychosis are needed, i.e. serotonin, glutamate, dopamine models of 
psychosis, and tasks requiring specific cognitive challenges, which confer a vulnerability to associated 
symptoms. Briefly, we search robust paradigms to challenge defined cognitive processes linked to 
specific symptoms for different drug-induced psychosis. For example, a failure of self-monitoring may 
lead to the emergence of auditory hallucinations linked to an increased activity in the frontal and 
temporal cortex (McGuire et al., 1995). Thus, we need self-monitoring task to examine whether the 
evoked signal in frontal and temporal brain regions is associated with auditory alterations induced by a 
specific pharmacological agent. Notably, to ensure compelling consistency between task, region-
specific signal and symptom, dose-dependent drug-models are requested. A further step will be to 
translate these models into patient studies. Keeping in mind that the MMN appears to distinguish 
between individual at ultra-high risk of developing schizophrenia and individuals in the first episode of 
a psychosis (Atkinson et al., 2011), a task-specific physiological signal may not only offer the 
possibility to predict specific symptoms, which are robustly associated with a certain pharmacology, 
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but might also lead to some inference about the disease progress. At best, we have brain marker of 
the prodrome. Finally, such kind of works may provide useful evidence to develop early intervention 
strategies to treat an individual pattern of symptoms. In consideration of predictive coding models, we 
may have a concept to examine psychosis translational. Indeed, both the susceptibility to psychosis 
and the responses to drugs are influenced by individual’s genetic variability. In addition, environmental 
factors, such as prenatal exposure to infection (Brown, 2006) and social disadvantage (van Os et al., 
2005) do also contribute to psychosis. Furthermore, psychological factors like suggestibility or 
absorption should be considered as well, because these factors interact on the one hand with drug-
induced symptoms, and on the other hand with the susceptibility to hypnosis (Braffman and Kirsch, 
1999), which recently served as model of psychosis (Barnier et al., 2008; Corlett et al., 2011). Thus, 
the Bayesian model of psychosis allows us to consider the interaction between biological and 
environmental factors, which are relevant to schizophrenia. 
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Discussion of Chapter 3 
 
In chapter 2, we have interpreted the MMN and the effect of the NMDAR antagonist S-ketamine on it 
under the perspective of predictive coding models. Figure 2 depicted a simplified schema of the MMN 
generation within the framework of predictive coding. Although the Bayesian way of thinking provides 
us some possible explanations about the NMDAR-mediated disruption of the MMN, however, it has 
not yet been revealed whether a failure in bottom-up error propagation upwards the neural hierarchy 
or a defect in the top-down inference mechanism downwards the hierarchy reflects the core of the 
problem. What we need to disentangle this question is to compute the effect of S-ketamine on 
effective connectivity within the network underlying the MMN generation. This was exactly the purpose 
of the study outlined in chapter 3. 
 
 
 
Figure 2 The MMN interpreted in terms of predictive coding. Illustrative scheme of the general 
framework of hierarchical Bayes and predictive coding as an explanation for ERP emerge. Adapted 
from Garrido et al. (2009). 
 
The hierarchical neuronal architecture underlying the generation of the MMN was established using 
DCM (Garrido et al., 2008). DCM revealed that the MMN is generated by self-organized interactions 
within a hierarchy of cortical sources comprising bilateral A1 and STG and right IFG. This model 
involves local post-synaptic adaptation within the A1 and temporo-frontal interaction between different 
auditory systems (Figure 3). Computationally, this synaptic adjustment is driven by the magnitude of 
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trial-wise PEs in lower-level structures, leading to adjustment of predictions generated by higher-level 
structures. 
 
 
 
Figure 3 Hierarchical network underlying the MMN generation, comprising five interconnected cortical 
areas; allowing for local adaptation within primary auditory cortices and plastic changes in extrinsic 
connections. Adapted from Garrido et al. (2008). 
 
In keeping with that, we have already hypothesized in chapter 2 that our finding of a reduced MMN 
following S-ketamine administration may reflect a drug-induced perturbation of NMDAR-dependent 
plasticity of temporo-frontal connections (forward) that serves to adjust PE message passing between 
the STG and the IFG during the MMN generation. Here, we have computationally examined this 
hypothesis by combining statistical parametric mapping (SPM) with DCM modeling of ERP data (David 
et al., 2006; Friston et al., 2003). Specifically, using SPM and DCM had three parts: (i) confirmation 
that there is a significant mismatch response (i.e. MMN) between the first and the sixth tone in the 
placebo and drug conditions, i.e. to replicate our previous ERP analysis (Schmidt et al., 2011), (ii) 
hypothesis or model testing to examine whether the MMN response is mediated by changes in 
intrinsic and extrinsic connectivity, i.e. to replicate the initial DCM analysis on MMN data (Garrido et 
al., 2008), and most important (iii) quantitative connectivity analysis to determine the coupling 
parameters, which significantly distinguished between the placebo and S-ketamine condition and also 
predicted psychotic symptom formation following S-ketamine administration. 
 
Briefly summarized, our results revealed a significant MMN response over frontal electrodes in both 
the placebo and S-ketamine condition, consistent with our previous results (Schmidt et al., 2011). It is 
important to note that the MMN response was significantly attenuated in the S-ketamine compared to 
the placebo condition, which also corresponds with our previous finding. Furthermore, DCM 
connectivity analysis of the MMN response revealed that the model with modulation of forward and 
backward connections, as well as post-synaptic modulation had the largest model evidence. This 
suggested that the model that fit the data best also represented specific mechanistic hypotheses 
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about the MMN generation, including predictive coding and adaptation, which is in accordance with 
previous DCM results (Garrido et al., 2008). In addition, random effects family-level analysis showed 
that adaptation models, which assessed whether the amplitude differences between the standard and 
deviant tones were driven by post-synaptic modulations, best explained the MMN responses in both 
placebo and S-ketamine conditions. Most intriguingly, by examining the neuromodulatory effect of S-
ketamine on effective connectivity, a significant reduction in effective connectivity following S-ketamine 
administration was observed in the forward connection from the left A1 to the left STG. Moreover, we 
found that this reduction in bottom-up effective connectivity predicted significant S-ketamine-induced 
cognitive impairments. In what follows, I extend the discussion of chapter 3 by embedding and 
comparing our findings also in the context of an alternative concept instead of Bayesian concepts and 
by providing possible future direction for this field. 
 
According to the disconnection hypothesis of schizophrenia (Friston, 1998; Stephan et al., 2006; 
Stephan et al., 2009), disordered brain connectivity is thought to be a central pathophysiological 
feature of schizophrenia. This hypothesis was motivated by initial positron emission tomography (PET) 
studies revealing abnormal connectivity between frontal and temporal lobe regions in schizophrenia 
(Friston, 1998; Friston and Frith, 1995; Frith et al., 1995), which was recently supported by fMRI works 
in schizophrenia patients (Calhoun et al., 2009; Pettersson-Yeo et al., 2011). However, the 
pharmacological mechanism underlying this failure of integration and its significance for illness 
symptoms has not yet been experimentally investigated. We provide empirical evidence that the 
blockade of the NMDAR system leads to dysfunctional fronto-temporal integration within the 
hierarchical network underlying the MMN generation due to deficient bottom-up effective connectivity, 
which extent was further correlated with S-ketamine-induced cognitive impairments. The relation 
between aberrant functional integration and the emergence of cognitive impairments can be 
understood by considering cognitive symptoms in schizophrenia such as thought disorders as 
instances of NMDAR-mediated disruption of synaptic plasticity, which leads to dysfunctional 
perceptual learning and inferences (Friston, 2005; Friston, 1998). In other words, cognitive 
impairments result from impaired perceptual learning and inferences. Thus, various cognitive or 
negative symptoms frequently seen in schizophrenia, if not all of them, can be understood as deficits 
in different forms of learning and memory (Stephan et al., 2009). For example, one of the cardinal 
cognitive dysfunction associated with schizophrenia is a working memory deficit (Goldman-Rakic, 
1994), which describes a deficit in the short-term storage of salient information in a limited capacity 
storage system in service of behavior (Baddeley, 1981). In this view, working memory processes 
account that behavior, thought and percepts are constrained to what is appropriate to the current 
situation (Barch et al., 2001; Braver et al., 1999). As a consequence, working memory deficits disturb 
contextual appropriateness (Barch et al., 2003) and the ability to logically order thought and produce 
coherent and communicative speech. In accordance, it has frequently been reported that abnormal 
fronto-temporal connectivity in schizophrenia is associated with cognitive impairments as expressed 
by working memory deficits (Allen et al., 2008b; Allen et al., 2010; Crossley et al., 2009; Fusar-Poli et 
al., 2010; Meyer-Lindenberg et al., 2001; Wolf et al., 2007; Wolf et al., 2009), which can manifest 
clinically as thought disorders (Kircher et al., 2001; Leube et al., 2008). Similar to these aberrant 
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pattern activations in schizophrenia patients, ketamine also altered the activity in fronto-temporal 
regions associated with thought disorders (Nagels et al., 2011a; Nagels et al., 2011b). Moreover, the 
level of frontal and temporal activation during task performance was predictive of thought disorder 
experienced under ketamine (Honey et al., 2008). Most important in the context of this work, 
schizophrenia patients do also show aberrant fronto-temporal coupling during the MMN generation as 
evidenced by impaired frontal but not temporal MMN components (Baldeweg et al., 2002; Baldeweg et 
al., 2004; Sato et al., 2003). Moreover, the extent of the frontal MMN deficit was related to the severity 
of cognitive impairments (Baldeweg et al., 2004). The relation between the MMN deficit and cognitive 
impairments in schizophrenia patients correspond precisely with our S-ketamine results. Moreover, by 
using computational modeling we further showed that the relation between cognition and MMN is 
based on NMDAR-mediated dysfunctional integration between temporal and frontal brain regions. 
Given that abnormal fronto-temporal connectivity is associated with working memory deficits (i.e. 
cognitive impairments) in schizophrenia (Crossley et al., 2009; Fusar-Poli et al., 2010) and in S-
ketamine treated individuals (Nagels et al., 2011a; Nagels et al., 2011b) and that the generation of the 
MMN requires echoic memory capacity, one would predict that the extent of fronto-temporal 
dysconnectivity within the MMN network correlate with cognitive impairments in schizophrenia and 
ketamine-induced cognitive impairments. That is precisely what previous studies and we found. We 
suggest that schizophrenic patients and individuals under S-ketamine are not sensitive to contextual 
factors beyond the physical properties of the stimulus, thereby loosing the ability to predict forthcoming 
events and in consequence exhibit aberrant sensitivity to surprising and salient events. In this way, the 
world of schizophrenic patients and individuals administrated with NMDAR antagonists becomes 
highly unpredictable, different things seem important, and important things seem different (Corlett et 
al., 2007), i.e. they build false models of the world. If one assumes that S-ketamine-induced cognitive 
impairments resemble those of schizophrenia, we suggest that the impaired frontal MMN component 
in schizophrenia is based on deficient top-down prediction about the temporal input as a result of a 
reduced NMDAR-mediated bottom-up input from the temporal auditory brain system. However, to fully 
confirm the disconnection hypothesis, patient studies using MMN paradigms in combination with DCM 
are needed. 
 
Previous hypothetical reflections proposed that in general higher levels of the neuronal hierarchy 
specify top-down predictions via NMDAR signaling, while any mismatches between expectancy and 
experience (i.e. PE) are conveyed upwards through the hierarchy via rapid AMPA and GABA receptor 
signalling (Corlett et al., 2009; Corlett et al., 2011; Friston, 2005). Specifically, it has been postulated 
that S-ketamine attains its effect on the one hand over increased random spiking mediated by AMPAR 
up-regulation and GABA receptor signalling, which leads to perturbation of feed-forward processing 
and further over a NMDAR-mediated decrease in burst firing, which should affect specification of prior 
expectation (top-down prediction) (Corlett et al., 2009). To put this more simply, they proposed that 
ketamine disturbs fast feed-forward mechanism (PE signal) through AMPA up-regulation and GABA 
receptor signalling and slow feedback constraint (priors) through NMDA blockade. In this study, we 
experimentally revealed that S-ketamine did not perturb top-down action within the network underlying 
the MMN, in contrast to the proposed model. Furthermore, although S-ketamine indeed disturbed 
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feed-forward connections in this study consistent with the theoretical model, whether our finding of a 
NMDAR-mediated perturbation of bottom-up processing is due to AMPA up-regulation, GABA receptor 
signaling or NMDAR blockade per se is hard to derive from our data. However, previous evidence in 
fact revealed that abnormalities of GABAergic function in schizophrenia may result from NMDAR 
dysfunction (Laruelle et al., 2005) and that the interaction between both neurotransmitter systems 
critically contributes to cortical plasticity (Kubota and Kitajima, 2010) with highly relevance for 
schizophrenia (Frankle et al., 2003), which is in line with the proposed model. In this view, a very 
recent study demonstrated that baclofen, which targets GABAergic neurons, facilitates reinforcement 
learning via increased stimulus-response associations (Terrier et al., 2011), suggesting that GABA 
receptor signaling alters the connection strengths within the hierarchical network underlying 
reinforcement learning. Thus, in a future study, we intend to partly disentangle this open question by 
investigating the role of different doses of baclofen on effective connectivity during stimulus-stimulus 
learning (MMN generation). In regard to the proposed model, we are particularly interested in how 
baclofen affects bottom-up effective connectivity. Based on the fact that baclofen primarily acts as 
GABAB-receptor agonist, one could hypothesize a net GABAergic inhibition with a concomitant 
increase in the MMN amplitude via less restrained NMDA-receptor plasticity. On the other hand, high 
doses (e.g. 100 mg of baclofen) would exert the opposite effect, given that high-dose baclofen not only 
targets GABAergic interneuron’s but also other transmitter systems. 
 
It has been suggested that deficits in early sensory processing may explain the observed MMN 
reduction in schizophrenia patients (Javitt, 2009; Leitman et al., 2010). These bottom-up models 
suggest that NMDAR-mediated deficits in early sensory processing contribute to cognitive impairments 
in schizophrenia (Javitt, 2009). This concept is supported by patient studies in which the latencies of 
the MMN amplitude and the later P300 increases in parallel, suggesting significant contributions of 
early sensory processing dysfunction to higher-order cognitive impairments (Leitman et al., 2010), 
given that they assume that the MMN exclusively represents feed-forward low-level processing and 
that the P300 appears to represent activation of higher-level circuits with the goal of determining the 
higher-level significance of the fact that an unexpected event has just occurred. We partly agree with 
these inferences, but allude that the MMN generation in fact involves both temporal and frontal 
generators (Doeller et al., 2003; Grau et al., 2007; Opitz et al., 2002; Rinne et al., 2000), which reveal 
intra- and inter-areal interactions (Garrido et al., 2008). Regarding the MMN under the framework of 
predictive coding models (Garrido et al., 2009), the frontal MMN component represents the high-order 
neuronal system, while the temporal MMN component is at the bottom of the hierarchy. In this view, 
our finding that NMDAR-mediated perturbation of bottom-up effective connectivity leads to cognitive 
impairments corresponds with these bottom-up models insofar that indeed cognitive impairments are 
might triggered by NMDAR-mediated deficits in bottom-up processing, but importantly, that must not 
necessary imply preserved top-down processes. Notably, in this study we computed effective 
connectivity underlying the generation of single MMN amplitudes independent of the previous context, 
i.e. without parametric modulation of the number of preceding standard tones (no memory trace). 
Given that the MMN memory trace effect is entirely due to learning and cannot result from differential 
states of frequency-specific auditory neurons in the temporal cortex, it seems unlikely that a pure 
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deficit in early sensory processing could account for the reported S-ketamine-induced disruption of the 
MMN memory trace effect, i.e. for the S-ketamine-induced cognitive impairments (Schmidt et al., 
2011). We will examine the neuromodulatory effect of S-ketamine on effective connectivity during the 
generation of the MMN memory trace effect, i.e. parametric modulation of the number of preceding 
standard tones in future modeling studies. Along this line, previous evidence revealed that early ERPs 
have been associated with bottom-up effects, while later components have been ascribed to 
endogenous dynamic involving top-down influences (Schiff et al., 2006). Although, at least in my 
opinion, bottom-up and top-down processing always reflect parallel processes, it has been 
demonstrated by using DCM that top-down prediction are specifically necessary to explain later ERPs 
(Garrido et al., 2007a). Along this line, the generation of the MMN involves both bottom-up and top-
down processing and we showed that S-ketamine disrupted bottom-up processing of PEs, while top-
down processing remained unaffected. Theoretically, these PEs require higher levels of the hierarchy 
to minimize them. However, as the errors are false as in the S-ketamine case here, these adjustments 
can never fully resolve the problem. As a result, PEs will be propagated even further up the system to 
ever-higher levels of abstraction. The severity of the insult to the Bayesian system may account for 
how far up in the hierarchy a false PE will go (Fletcher and Frith, 2009). This means that false upwards 
propagated PEs will consequently lead to false predictions about the incoming input as well in 
dependence of how high in the hierarchical level we are. Under this perspective, although we found no 
aberrant top-down prediction following S-ketamine within the MMN network, however, we suggest that 
in later ERPs involving more top-down control than the MMN, the S-ketamine-induced reduction of 
bottom-up processing would in consequence also affect top-down predictions, what would speak 
against bottom-up models of cognitive impairments in schizophrenia. Thus, actually I’m computing 
DCMs with time ranges from 0-400 ms post-stimulus instead of 0-250 ms to account also for the later 
P300 ERP. We propose that the S-ketamine-induced deficit in bottom-up processing of PEs might lead 
as a consequence to aberrant top-down predictions from the time frame of the P300 ERP. 
 
However, many questions about the role of synaptic plasticity in the pathophysiology of schizophrenia 
remain. As Harrison and Weinberger already proposed (2005), “ ... it will not be synapses per se but 
the neural circuits in which they participate which will prove to be the appropriate explanatory level to 
understand how the genetic influences operate ... various combinations of susceptibility genes can 
converge on synaptic processing in these microcircuits to effect a common pattern of dysfunction and 
emergent symptoms, though the specific combination of genes and possibly alleles can vary across ill 
individuals.” Along this line, susceptibility genes in the case of schizophrenia have been well 
characterized and significant convergence on glutamatergic pathways is observed (Allen et al., 2008a; 
Walsh et al., 2008) (Table 1). For example, the glutamate-related genes NRG1 and DTNBP1 are 
involved in both building of long-range connections during development and in regulating synaptic 
plasticity (Harrison and Weinberger, 2005). This is important, because any impairment in synaptic 
plasticity would affect the way long-range connections are established in the developing brain, given 
that the strength of functional coupling between two neurons determines whether their connection 
survives developmental pruning (Hua and Smith, 2004). Therefore, we have to identify glutamatergic 
susceptibility genes, which alter synaptic plasticity responsible for the connectivity of specific brain 
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systems underlying the formation of psychotic symptoms. This knowledge should be considered in 
computational models of learning (DCMs) to understand the consequence and loci of abnormal 
plasticity processes. 
 
Table 1 Glutamate- and non-glutamate-related genes implicated in schizophrenia. Adapted from Javitt 
(2011). 
 
 
 
Another opportunity to complement the analysis from the present study is to employ recently 
developed computational models, which use the same Bayesian inference framework as DCM but are 
agnostic about physiological mechanisms. Instead, they enable the investigation of trial-by-trial 
changes in MMN amplitude from a purely computational (information theoretic) perspective.  In other 
words, they help clarifying which computational quantities (e.g., prediction errors or surprise) are 
reflected by the trial-by-trial dynamics of MMN expression (Lieder et al., in preparation). These 
models, once they are fully established, should enable us to examine the effects of ketamine on MMN 
generation from a complementary perspective.  
Finally, there is evidence to suggest that illness onset is associated with exacerbation of less severe 
fronto-temporal dysfunctional connectivity seen in those vulnerable to those with psychosis. Crossley 
and colleagues (2009) demonstrated a progressive increase in dysfunctional fronto-temporal 
connectivity during a working memory task from healthy controls to subjects with an at risk mental 
state (UHR) and further to individuals with first psychotic episode (FEP). Supportive for that, the at-risk 
mental state is associated with abnormalities of regional brain function that are qualitatively similar to, 
but less severe than, those in patients who have recently presented with psychosis (Broome et al., 
2009). This is in line with recent studies revealing that the assessment of the MMN may allow 
distinguishing between UHR and FEP (Atkinson et al., 2011; Bodatsch et al., 2010; Orosz et al., 2011; 
Shaikh et al., 2011; Shin et al., 2009). Regarding the MMN as echoic working memory, it is 
conceivable that this differentiation between UHR and FED by means of the extent of MMN reduction 
is due to the extent of fronto-temporal dysconnectivity. Therefore, the assessment of the MMN in 
combination with DCM might allow distinguishing between “ultra-high risk” and first-episode psychosis 
on the basis of dysfunctional fronto-temporal connections. Hence, our findings not only demonstrate 
that DCM in combination with neurophysiological measures and pharmacological manipulations 
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provides a promising framework to identify and understand further the role of different 
neurotransmitters in neuronal plasticity and but also that the combination of MMN and DCM may help 
us to develop diagnostic markers (biomarkers) to subdivide schizophrenic patients into physiologically 
defined groups on the basis of their NMDAR-mediated fronto-temporal dysconnectivity. In 
consequence, such an approach may promote the detection of early cognitive impairments, which in 
turns leads to valuable predictions either about the illness progress or about reasonable 
pharmacological treatments. 
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5.2. The Role of Glutamate and Serotonin in Emotional Processing 
 
Discussion of Chapter 4 
 
Recent evidence show that psychedelics modulate neural circuits that have been implicated in 
affective disorders, and can ameliorate clinical symptoms of such disorders (Vollenweider and 
Kometer, 2010). Indeed, it has been shown that acute administration of the NMDAR antagonist 
ketamine ameliorates depressive symptoms in treatment-resistant depression within a few hours 
persisting for several days (Diazgranados et al., 2010; Zarate et al., 2006), while acute administration 
of the mixed 5-HT receptor agonist psilocybin in healthy subjects leads to heightened mood, increased 
emotional excitation and sensitivity (Studerus et al., 2010) and decreases anxiety in terminal cancer 
patients within a month (Grob et al., 2011). However, although recent studies revealed exciting new 
insights about the underlying molecular mechanism of ketamine’s rapid antidepressant effect (Autry et 
al., 2011; Duman et al., 2012; Li et al., 2010) (Figure 2) and of psilocybin’s mood enhancing effect 
(Vollenweider and Kometer, 2010), the understanding how ketamine and psilocybin acutely modulate 
the processing of emotional stimuli, which requires functional integration within a specific network, is 
far from complete. 
 
 
Figure 2 Translational overview of ketamine’s rapid antidepressant effect and the potential role of 
synaptogenic and neurotrophic mechanisms in depression. Adapted from Murrough & Charney (2010). 
 
To investigate further the neuronal underpinnings of the effect of psilocybin and S-ketamine on 
emotional processing, in this study here, we elucidated first whether psilocybin and S-ketamine affect 
emotional face processing in a valence specific manner. We selected faces due to the fact that the 
recognition of other people’s emotion from their facial expressions is fundamental to social interaction 
and behavior of human beings. Furthermore, because negative processing biases in depression may 
result not only from biased cognitive appraisal, but also from automatic processing biases that 
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influence the access of sensory information to awareness (Suslow et al. 2010, Victor et al. 2010), we 
second investigated whether both drug effects on emotional face processing vary as a function of 
visual awareness. Given that accumulating evidence recommended the use of ketamine to treat 
depression, we took ketamine as proof-of-concept agent to physiologically assess the plausibility of an 
alternative medical agent to treat affective disorders, namely the mixed 5-HT receptor agonist 
psilocybin. The following discussion should be read with this background in mind. Specifically, we 
have investigated how early visually evoked responses to emotional facial expressions during non-
conscious compared to conscious processing are modulated by S-ketamine or psilocybin. Notably, 
visual responses to emotional stimuli are believed to reflect regulation of basic emotional signals 
associated with social cognition (Schultz et al., 2003; Singer et al., 2004). Our data revealed that both 
psilocybin and S-ketamine reduced early visual responses to fearful faces as expressed by a reduced 
N170 ERP response, whereas N170 ERP responses to happy faces were reduced exclusively by S-
ketamine. Furthermore, the S-ketamine- and psilocybin-induced reduction of the N170 ERP response 
to facial expressions was more pronounced during conscious compared to non-conscious processing, 
irrespective of facial valence. In the following, I extend the discussion section of chapter 4 by adding 
some new points concerning the neurobiological mechanism underlying on the one hand the N170 
ERP reduction in response to fearful faces induced by both drugs and on the other hand the 
dissociable effects of psilocybin and S-ketamine on the N170 ERP in response to happy faces. Finally 
and based on these points I provide possible research strategies for this field. 
 
According to several source modeling studies (Deffke et al., 2007; Rossion et al., 2003; Sadeh et al., 
2010), the generators of the N170 ERP have been localized to the FG, which encodes the structural 
configuration of facial features. Since EEG sensor signals result from a mixture of neuronal sources, 
one should be cautious about relating our findings to neural sources in specific locations. In other 
words, the N170 ERP must not necessarily correspond to the FG. Nevertheless, the increased visual 
response to relevant emotional expressions is likely mediated via rich interconnections between the 
FG and the amydgala (Amaral et al., 2003; Freese and Amaral, 2005), the coupling of which is 
additionally strengthened during attentive viewing of emotional faces (Fairhall and Ishai, 2007; 
Herrington et al., 2011) (Figure 3). 
 
 
 
Figure 3 A) Per-voxel tests of faces greater than houses. Circles highlight regions from which ROIs 
were extracted for connectivity analyses (FG = green; amygdala = red). B) Increased effective 
connectivity between FG and amygdala during face processing. Adapted from Herrington et al. (2011). 
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Furthermore, emotional face processing does also involve the PFC, which is effectively connected with 
the amygdala and the FG (Dima et al., 2011). This means that not only the FG and the amygdala are 
bi-directionally connected during emotional face processing, but also the amydgala and the PFC, as 
well as the FG and the PFC. Along this line, both S-ketamine and psilocybin were found to deactivate 
the amygdala and to increase prefrontal neural activity (Vollenweider and Kometer, 2010). Therefore, 
we suggest that the N170 ERP reduction by both drugs in response to fearful faces is due to altered 
PFC-limbic coupling induced by both psilocybin and S-ketamine. Moreover, both drugs also enhance 
extracellular glutamate release into the PFC (Kargieman et al., 2007), which might be responsible for 
this altered PFC-limbic interplay. This fits well with the finding that abnormal glutamate levels have 
been identified in various brain regions of depressed subjects (Sanacora et al., 2008) and also with 
the finding that depressed patients show reduced PFC-limbic connectivity (Dannlowski et al., 2009). 
Glutamate as the driving force for modulating PFC-limbic circuits is supported by the evidence that 
various antidepressant drugs with different primary mechanisms (fluoxetine, reboxetine, desipramine) 
target the glutamatergic system, raising the possibility that glutamate blockade could be a shared 
mechanism of antidepressant action, along with serotonin reuptake inhibitors (Bonanno et al., 2005). 
 
However, it remains unclear why S-ketamine but not psilocybin reduced the N170 ERP in response to 
happy faces. In contrast to the processing of negative material, the processing of positive information 
involves structures, which are associated with reward and motivation including the ventral striatum and 
the orbitofrontal cortex (OFC) (Ishai, 2007). Imaging studies have demonstrated that the ventral 
striatum is recruited by the rewarding properties of happy faces (Monk et al., 2008; Phan et al., 2002), 
and show increased connectivity with the hippocampus during the processing of happy faces 
(Satterthwaite et al., 2011). Furthermore, the hippocampus and the OFC are also significant correlated 
for positive faces (Tsukiura and Cabeza, 2011). Keeping this network in mind, the processing of happy 
faces could be related to the encoding of value-prediction codes that are relevant for the subsequent 
recognition in memory. The expectations about potential reward likely promote motivation to learn and 
encode reward-associated faces (Berridge and Robinson, 2003). Such reward-related processes 
interact with structural encoding processes as indexed by the N170 ERP. Indeed, a recent study 
revealed that the N170 ERP showed reward-related effects (Marini et al., 2011), suggesting an 
electrophysiological predictor of a successful encoding into long-term memory, which relies on the 
hippocampus. In accordance, it has been shown that the FG was positively correlated with 
hippocampal activation during the successful encoding of faces with high confidence (Tsukiura and 
Cabeza, 2011). Thus, it is conceivable that S-ketamine and psilocybin differentially modulate reward-
related networks, leading to differential N170 ERP responses to happy faces. Noteworthy, rewarding 
signals are conveyed via dopaminergic neurons (Enomoto et al., 2011; Koob and Le Moal, 2001) and 
both S-ketamine and psilocybin exhibit affinity for DA1/2 receptors (Vollenweider and Geyer, 2001). 
Hence, varying modulation of the dopamine system in reward regions induced by S-ketamine and 
psilocybin might also contribute to this dissociable effect on happy face processing. 
 
Yet, the N170 ERP modulation produced by psilocybin and S-ketamine might not only depend on 
alterations in structures related to emotional processing, but also on alterations in the visual system 
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per se. In particular, the parvocellular visual system is specialized for fine-grained analysis of object 
identification by the ventral visual stream, also known as “what pathway” (Foxe et al., 2005; Sehatpour 
et al., 2010). This corresponds well with the configurationally encoding of faces as reflected by the 
N170 ERP generated in the FG, which belongs to the ventral stream (Teipel et al., 2007). Thus, it 
could be hypothesized that the N170 ERP modulation by both drugs is probably followed by alteration 
in the parvocellular stream. Finally and especially because of the valence-specific effects, the N170 
ERP modulation by both drugs is probably an interaction between alterations in structures responsible 
for both visual (ventral stream) and emotional processing. 
 
In conclusion, our findings suggest that glutamate and serotonin differentially contribute to the 
modulation of visual responses to emotional facial expressions in healthy humans. The assessment of 
early visual responses to emotional expressions may provide a useful framework to detect 
pharmacologically induced changes in emotional processing and might also lead to a greater 
understanding of pharmacological mechanisms underlying emotional processing biases and its 
dysfunction in affective disorders. Furthermore, we demonstrated that psilocybin probably offers a 
promising alternative agent to S-ketamine for the treatment of affective disorders insofar that 
psilocybin does not alter the processing of happy faces, and further because psilocybin relative to S-
ketamine produces more bliss, less depersonalization, and also less cognitive deficits (Vollenweider 
and Kometer, 2010).  
To further examine task-specific functional integration following S-ketamine and psilocybin 
administration, we intend to translate a similar emotional paradigm into an fMRI study. We are 
specifically interested in the pharmacologically induced alteration in PFC regions including the anterior 
cingulated cortex (ACC), dorsolateral PFC (DLPFC) and lateral ventral PFC (VPFC), subcortical 
regions subsuming the amygdala and striatal structures, as well as visual regions such as the inferior 
occipital gyrus (IOG), the FG and the superior temporal sulcus (STS). Following this, we will use DCM 
modeling to estimate effective connectivity within the outlined network and its modulation after drug 
administration (see Figure 4). Such analyses allow us to better understand functional integration 
during facial processing per se and the impact of glutamatergic and serotonergic manipulations on it. 
To further prove the plausibility of psilocybin as an agent to reduce specific symptoms of affective 
disorders, further studies are needed to examine, on the one hand, whether repeated doses in healthy 
humans trigger sustained effects in emotional processing, and on the other hand to translate this 
model into studies of patients suffering from mood or anxiety disorders. We would hypothesized that 
patients will reveal an aberrant coupling between prefrontal and limbic brain regions due to an 
attenuated frontal top-down control over limbic structures and that both drugs have the potential to 
restore an adequate balance between these both regions. Thus, on the long-term, the DCM analysis 
might give us the opportunity to detect aberrant coupling indicating dysfunctional emotional processing 
biases, which contribute to vulnerability to mood disorders, and further to examine whether psilocybin 
and S-ketamine can resist this dysfunctional emotional biases. As it has currently been done to predict 
the behavioral antidepressant effect of ketamine with different methodological approaches (Salvadore 
et al., 2009; Salvadore et al., 2010; Salvadore et al., 2011), the use of DCM may serve as promising 
tool to predict not only susceptibility to mood disorders or even the presence of mood disorders, but 
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also to predict the effect of potential therapeutic agents on functional integration. What then remains is 
the relationship to the subjectively perceived mood. 
 
 
 
Figure 4 Alterations in effective connectivity within the face-processing network. Thick gray arrows 
indicate significant endogenous connections and the thick black arrow indicates a significant 
endogenous connection significantly modulated by anger. Dashed arrows indicate backwards 
connections and thin black arrows indicate bidirectional connections. Adapted from Dima et al. (2011). 
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5.3. MMN and N170 Event-related Potentials Under the View of Predictive 
Coding 
 
To bridge the gap between chaper 2/3 and chapter 4, I show in the next section how our N170 ERP 
findings can also be interpreted within the framework of predictive coding models. Roughly reviewed, 
the concept of predictive coding assumes that every neuronal system forms predictions about the 
upcoming input from a lower-level system based on previous experience. The role of PEs has been 
classically investigated in reinforcement learning (stimulus-response learning), but recent studies 
revealed evidence for the processing PEs during stimulus-stimulus learning. In particular, the MMN 
constitutes an empirical example that PEs may be equally important during perceptual learning of 
stimulus-stimulus associations that are behaviorally irrelevant instead of stimulus-response 
relationships, which are of high biological relevance. This entails adjustments to our internal model of 
the environment so that potentially surprising events can be predicted (den Ouden et al., 2009). MMN 
theories, which proposed the MMN as a paradigmatic example of learning based predictive coding 
(Baldeweg, 2006; Friston, 2005), were supported by DCM studies (David et al., 2006; Garrido et al., 
2007b). They revealed that the MMN can be understood as PE signal, which results from deviant-
induced changes in inter-regional connections strength among the hierarchical network, which in turns 
depends on NMDAR functioning. Interestingly, such statistical relationships between different stimuli 
(stimulus-stimulus) to optimize learning are also formed within the visual system. The pioneer work of 
Rao and Ballard (1999) firstly described that visual processing rests upon feedback connections from 
higher- to lower-order visual cortical areas, which again carry predictions from lower-level neural 
activities. Within this hierarchy, representational neurons (R units) form expectations about the 
physical identity of a stimulus and send the expectations further to next lower level (E unit). The 
neurons in the E unit encode the PE when the expected information do not match with the actual 
input, and pass this PE back to the R unit neurons to update their predictions (Figure 7). In other 
words, predictive coding propose that perceptual inference proceeds as an iterative matching process 
of top-down predictions against bottom-up evidence along the visual cortical hierarchy (Friston, 2005; 
Rao and Ballard, 1999). 
 
 
Figure 7 Predictive coding in visual perception. In this scheme, representation units (R) encode 
expectations about next incoming information and error units (E) encode the PE between the 
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prediction and the observed input to update the prediction in the R neurons, i.e. predictions are used 
as priors for the preceding layer. Adapted from Summerfield and Egner (2009). 
 
A very recent study suggests that even early visual activity can be modulated by learning, suggesting 
top-down predictions (Rauss et al., 2011). The authors argued that these early top-down effects on 
visual processing can be regarded as a consequence of predictive coding mechanisms in the visual 
system. Low-level visual areas might adapt their processing to selectively enhance visual stimuli most 
likely to be affected by positive feedback (Serences, 2008), and inhibit stimuli that are least likely to be 
processed further. Thus, in term of predictive coding, neural visual signals are related to internal goals 
and predictions based on previous input (Mumford, 1992). 
 
Neuronal responses elicited by the second and subsequent occurrence of a stimulus are reduced 
compared to the first representation (Grill-Spector et al., 2006), an effect often termed “repetition 
suppression” (RS). Interestingly, RS has been observed within the fusiform face area (FFA) 
(Summerfield and Egner, 2009; Summerfield et al., 2008). In more detail, it was found that RS in the 
FFA reflects a relative reduction in top-down perceptual PE, when processing an expected compared 
with an unexpected stimulus (Summerfield and Egner, 2009; Summerfield et al., 2008). Along this line, 
a recent investigation revealed that activity in the FFA in response to faces and houses was 
indistinguishable under high face expectations and maximally differentiated under low face 
expectation (Egner et al., 2010). The authors explained their findings by predictive coding models. 
Specifically, they argued that neuronal responses in the ventral visual stream (i.e. FFA) appear to be 
determined by feature expectation and surprise rather than by stimulus features per se. In accordance 
to this finding, a previous fMRI study examined the difference between brain regions responsible for 
detecting the physical presence of the stimulus per se and those supporting perceptual set using a 
simple task that required subjects to discriminate between randomly presented images of faces, 
houses and cars. In the “face block” subjects had to judged whether each object was a face or not, 
and in the “house block” whether the object was a house or not etc. Thus, while the perceptual input 
was kept identical across blocks, the task encouraged subjects to employ distinct top-down perceptual 
sets (or templates) in the two block types, one for detecting face stimuli, and one for detecting house 
stimuli. Generally, faces revealed stimulus-driven activation in key regions of the face processing 
network, including the amygdala, IOG, FFA and vMFC. But more interestingly, compared to the 
activation in response to the physical stimulus (i.e. face), face block-related activity was associated 
with an increase in top-down connectivity from the frontal cortex to face-selective visual areas, 
reflected by DCM estimations. These findings suggest that subjects do indeed deploy predictive 
information in the service of face perception. Thus, during perceptual inference, face prediction in the 
vMFC are formed and back propagated via feedback connections to face-sensitive zones of the 
extrastriate cortex, in the service of deciding whether a stimulus is a face or not (Summerfield et al., 
2006) (Figure 8). Important to note, the expectations effects on visual responses i.e. reduced visual 
responses with increasing number of preceding stimuli, reveal the exact opposite pattern of attention 
effects on visual responses, in particular that neural responses are enhanced for attended relative to 
unattended stimuli (Boynton, 2009; Reynolds and Heeger, 2009). 
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Figure 8 Dynamic causal modeling revealed that during face set blocks (as compared with house set 
blocks), the vMFC displayed enhanced  top-down effective connectivity with the amygdala and FFA, 
while both face stimuli and face set affected bottom-up connectivity from the IOG to the FFA and 
amygdala. These data support the notion that ventral frontal regions might provide top-down 
perceptual “priors” to posterior regions, where these predictions are matched against incoming 
sensory information. Adapted from Summerfield et al. (2009). 
 
Consistent with RS effects in the FFA, the N170 ERP shows also RS effects following repeated 
stimulus repetitions (Mercure et al., 2011; Vizioli et al., 2010). This is highly reasonable, given that the 
dipole of the N170 ERP lies in the FFA (Deffke et al., 2007). In line with this, the N170 ERP shows 
rapid adaptation effects (Nemrodov and Itier, 2011), which may reflect the dampening of surprise 
responses in error neurons to the second or subsequent presentation of a stimulus (Friston, 2005). 
The hierarchical structures underlying the N170 ERP in response to faces and houses has been also 
investigated by using DCM (David et al., 2006). Category-selectivity, as indexed by the face-selective 
N170, could be explained by category-specific differences in forward connections from sensory to 
higher areas in the ventral stream. In particular, stronger FFA and STS responses were found for 
faces compared to houses. This selectivity was due to an increase in coupling from IOG to FFA and 
from IOG to STS. This suggests that category-selectivity emerges downstream from IOG. But 
unfortunately, no RS effects were considered to study expectations and surprise effects in this study. 
Therefore, consistent to the roving MMN paradigm, parametric modulation of preceding stimulus 
repetitions should be considered to study visual responses more dynamically. This means that a single 
neuronal response to a specific object is meaningless without controlling for its temporal context. 
Furthermore, the effect of expectation and surprise on neural population should also be investigated 
as a function of stimulus valence, given that visual areas might adapt their processing to selectively 
enhance visual stimuli most likely to be affected by positive feedback (Serences, 2008), and inhibit 
stimuli that are least likely to be processed further. 
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Summarized, auditory (i.e. MMN) and visual (i.e. N170) neuronal responses can be explained within 
the framework of predictive coding models. Already early and rapid neuronal responses are influenced 
by top-down control, depending on the preceding context. Our brain is constantly exposed to a broad 
spectrum of stimuli. Predictive coding may be a general principle of the brain in which statistical 
relationships in the world are monitored, even when they are not attended and not direct relevant for 
ongoing behavior. This ensure to ignore predictable and uninteresting events in the environment, while 
enhancing the salience of unexpected events (den Ouden et al., 2009). 
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